(54) Title

Engineered rabbit antibody variable domains and uses thereof
(51) International Patent Classification(s)

CO7K 16/00 (2006.01)
(21) Application No: 2008246442
(22) Date of Filing: $\quad 2008.04 .30$
(87) WIPO No: WO08/136694
(30) Priority Data
(31) Number

60/916,226
(32) Date
2007.05.04
(33) Country US
(43) Publication Date: 2008.11 .13
(44) Accepted Journal Date: 2014.07 .03
(71) Applicant(s)

Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA
(72) Inventor(s)

Castanheira Aires Da Silva, Frederico Nuno;Braz Goncalves, Joao Manuel
(74) Agent / Attorney

Freehills Patent Attorneys, Level 43101 Collins Street, Melbourne, VIC, 3000
(56) Related Art

US 2005/0048578 A1
US 2006/0216293 A1
WO 2004/016740 A2
WO 2001/030393 A2
WO 2001/031065 A1
ROBBEN J. et al. Gene, vol. 126, pages 109-113 (1993)
ESTEVES P.J. et al. The Journal of Immunology, vol. 172, pages 1044-1053 (2004)
POSPISIL R. et al. Cellular Immunology, vol. 185, pages 93-100 (1998)
SILVA F.A.D. et al. Journal of Molecular Biology, vol. 340, pages 525-542 (2004)
RADER C. et al. The Journal of Biological Chemistry, vol. 275, pages 13668-13676
(2000)

WO 2008/016950 A1
WO 2004/091543 A2
WO 2006/073748 A2
MARCHESINI M.I. et al. Microbial Pathogenesis, vol. 37, pages 95-105 (2004) WO 2008/004834 A1
(19) World Intellectual Property Organization International Bureau
(43) International Publication Date 13 November 2008 (13.11.2008)


PCT
(10) International Publication Number WO 2008/136694 A1
(51) International Patent Classification: C07K 16/00 (2006.01)
(21) International Application Number:

PCT/PT2008/000018
(22) International Filing Date: 30 April 2008 (30.04.2008)
(25) Filing Language:

Portuguese
(26) Publication Language:

English
(30) Priority Data: 60/916,226

4 May 2007 (04.05.2007)
US
(71) Applicant (for all designated States except US): TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA [PT/PT]; Avenida Professor Egas Moniz, Edificio Egas Moniz, piso 2, sala A8, 1649-028 Lisboa (PT).
(72) Inventors; and
(75) Inventors/Applicants (for US only):

BRAZ GONCALVES, João Manuel [PT/PT]; Avenida João XXIII, $321-4^{\circ} \mathrm{F}$, 2870-159 Montijo (PT). CASTANHEIRA AIRES DA SILVA, Frederico Nuno [PT/PT]; Rua Actor Isidoro 26, $3^{\circ}$ Esq., 1900-019 Lisboa (PT).
(74) Agent: VIEIRA PEREIRA FERREIRA, Maria Silvina; CLARKE, MODET \& $\mathrm{C}^{\circ}$, Rua Castilho, 50-9${ }^{\circ}$, 1269-163 LISBOA (PT).
(81) Designated States (unless otherwise indicated, for every kind of national protection available): $\mathrm{AE}, \mathrm{AG}, \mathrm{AL}, \mathrm{AM}$, $\mathrm{AO}, \mathrm{AT}, \mathrm{AU}, \mathrm{AZ}, \mathrm{BA}, \mathrm{BB}, \mathrm{BG}, \mathrm{BH}, \mathrm{BR}, \mathrm{BW}, \mathrm{BY}, \mathrm{BZ}, \mathrm{CA}$, $\mathrm{CH}, \mathrm{CN}, \mathrm{CO}, \mathrm{CR}, \mathrm{CU}, \mathrm{CZ}, \mathrm{DE}, \mathrm{DK}, \mathrm{DM}, \mathrm{DO}, \mathrm{DZ}, \mathrm{EC}, \mathrm{EE}$, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

- of inventorship (Rule 4.17(iv))


## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
with sequence listing part of description published separately in electronic form and available upon request from the International Bureau regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain.


# ENGINEERED RABBIT ANTIBODY VARIABLE DOMAINS AND USES THEREOF 

## 1. FIELD OF THE INVENTION

The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production of research tools and therapeutic polypeptides that exhibit immunospecificity for an antigen of interest, including single binding-domain polypeptides, i.e., single domain antibodies comprising one of a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain.

## 2. BACKGROUND

Antibodies are composed of two chains termed light and heavy chains. The light chain contains an amino-terminal variable domain (VL domain) and a carboxy-terminal constant domain (CL). The heavy chain is composed of an amino-terminal variable domain ( VH ) and three constant domains ( $\mathrm{CH} 1, \mathrm{CH} 2, \mathrm{CH} 3$ ). The antibody binding site is located in the VL and VH domains and is made up by six hypervariable loops that represent the Complementarity-Determining Regions (CDRs). Both VL and VH regions contain three CDR loops (CDR1, CDR2 and CDR3), which are connected to a structurally conserved beta.-sheet framework.

With the development of hybridoma technology, it became possible to produce a single population of antibodies, or monoclonal antibodies (mAbs), that specifically targeted a single epitope opening a revolution in the drug discovery field. However ${ }_{\wedge}$ problems with antibody production and in vivo responses, including immunogenicity and cytokine-associated side-effects, have lead to the investigation of altering antibody structure and/or function while still retaining immunospecific binding. Studies have attempted to reduce the antibody to its smallest functional form, without significantly changing the antigen recognition and affinity. The identification of the smallest
antibody fragment that is capable of binding to antigen has evolved from full antibody molecules or IgG to Fab and recombinant single chain Fv fragments.
Due to the progress in gene recombination in the 80 's, the rapid and easy generation of recombinant variable domains was possible. Using the polymerase chain reaction, diverse repertoires of genes encoding VH and VL domains were cloned from the genomic DNA of immunized animals, allowing the characterization of multiple binding activities and functionalities against several antigens. Nevertheless, the variable domain fragments initially isolated were scarcely soluble and difficult to produce.
Problems in production were addressed with the characterization of camelid antibodies, which are dimeric molecules that comprise only heavy chains. Not only did the discovery of the dimeric molecule address many issues with respect to recombinant antibody production, but the molecule also highlighted the possibility that the heavy chain of immunoglobulin molecules could direct immunospecific binding in the absence of a light chain. It is now widely accepted that Ig heavy chains may retain significant antigen binding ability in the absence of a light chain. There is also evidence from structural studies that the CDR3 region of the $\mathrm{V}_{\mathrm{H}}$ domain is the most significant of the CDR domains with respect to immunospecificity. This is based on the findings that the HCDR3 amino acid residues provide most of the surface contact area and are crucial in the molecular interaction with the antigen. Accordingly, further reduction of antigen binding protein size to single domain binding proteins may be possible based upon immunoglobulin VH domains.

### 2.1 Rabbit Antibodies

The rabbit antibody repertoire, which in the form of polyclonal antibodies has been utilized for decades, is an outstanding source for antibodies that feature strong affinity and high specificity (Mage et al., 2006). In addition, rabbits, which belong to the order Lagomorpha, are evolutionarily distant from mice and rats, which belong to the order Rodentia. As a consequence, epitopes conserved between rodent and human antigens that are invisible to rodent mAbs (and also human mAbs generated from transgenic mice with human immunoglobulin genes) can often be recognized by rabbit polyclonal antibodies.

Rabbit mAbs generated by phage display offer additional advantages due to the fact that phenotype and genotype are selected at the same time. Knowledge of the rabbit mAb
sequence allows the ready generation of a variety of mAb formats, including singledomain antibodies, scFv , Fab, and IgG, and, importantly, humanization and affinity maturation (Rader et al., 2000; Steinberger et al., 2000; Rader, 2001). Consequently, rabbit mAbs generated by phage display have become promising reagents for therapeutic applications in humans.
In normal rabbits, $70-90 \%$ of Ig molecules and B cells carry the VHa allotypes due to the use of the D-proximal VH gene segment, VH1, in VDJ gene rearrangements. Rearrangements of a variety of Vk and VI gene segments appear to occur in rabbits, since a variety of different VL sequences have been found among expressed cDNA sequences.
The B cell repertoire that develops in rabbit bone marrow is limited by the small number of VH gene segments used in VDJ gene rearrangements. Whereas multiple Vk gene segments are rearranged in bone marrow B lineage cells, most B lineage cells rearrange the same VH gene, VH 1 , which encodes the VHa allotypic sequences. The repertoire is also limited by the usage of a small number of JH and $D$ gene segments in VDJ rearrangements. JH4 is found in $80 \%$ of the VDJ gene rearrangements and JH2 in the other $20 \%$; the other three functional JH gene segments are used rarely. Also, from the total of 12 D gene segments, most VDJ gene rearrangements use D2a (D9), D2b (Df), D3 or D5; D4 and D6 are rarely utilized. While limited usage of VH, D and JH gene segments would result in a limited VDJ repertoire, N nucleotides are found in essentially all VD and DJ junctions from the earliest rearrangements during cellular differentiation. The high diversity of N regions among VDJ gene rearrangements results in a much larger repertoire than expected from rearrangement of a limited number of $\mathrm{V}, \mathrm{D}$ and J gene segments. The size of this repertoire has not been estimated. However, given that essentially all VDJ genes are somatically diversified in periphery after B cells leave the bone marrow and other primary sites of $B$ lymphopoiesis, it is conceivable that the repertoire that develops in the primary sites of $B$ cell development is functionally insufficient.
After B-cell Ig gene rearrangements occur in sites such as bone marrow of young rabbits, immature $\operatorname{IgM} B$ cells undergo further $\operatorname{Ig}$ repertoire diversification in appendix and other gut-associated lymphoid tissues. These sites appear to foster development of a primary preimmune repertoire.

Gene conversion of rearranged heavy and light chain sequences is found in rabbit appendix by 3-4 weeks of age. Somatic hypermutation occurs in the D and J regions, which lack known gene conversion donors. The JH region is also diversified by somatic hypermutation and it is therefore likely that somatic hypermutation also occurs in the rearranged VH gene segments.
Gene conversion and somatic hypermutation occur not only in germinal-centers of the young rabbit appendix, but are also used for diversification during immune responses in secondary lymphoid tissues such as spleen and lymph nodes.
When sequences of rearranged heavy and light chain genes in clones from developing appendix and from spleen during specific immune responses are compared, the diversification patterns in the clones from appendix are strikingly different from those found in spleen, where an immunizing antigen was driving the expansion and selection process toward high affinity. Clonally related appendix B cells developed different amino acid sequences in each complementarity-determining region (CDR), including CDR3, whereas dominant clones from spleen underwent few changes in CDR3.
The data also indicate a higher rate of hypermutation in rabbit during immune responses in splenic germinal centers, such that the balance between hypermutation and selection tends more towards mutation and less towards selection in rabbit compared to mouse.
Germinal centers (GCs) in secondary lymphoid organs are specialized structures within which somatic diversification of rearranged V genes occurs that lead to affinity maturation of Abs in immune responses to T-dependent Ags.
Unlike mice and humans, rabbits rearrange only a few heavy chain V region (VH) genes, so that the diversity generated by combinatorial mechanisms is limited. The overall pattern is one of splenic precursor cells whose germline or near germline sequences changed both by gene conversion and point mutations during early divisions and largely by point mutations during later divisions. It is possible that within the same expanding clonal populations, considerable diversification of light chain sequences occurred in parallel with the changes in the VH sequences, these events may produce the diverse sequences that serve as substrates for further affinity maturation by selection either within GCs or later among emigrant cells in sites such as bone marrow.
The limited heavy chain VHDHJH repertoire due to preferential usage of the VH1 gene segment is compensated by a diverse light chain VkJk repertoire in B cells developed in
the bone marrow. This repertoire is greatly expanded both in GALT by gene conversion and somatic hypermutation, and later, in germinal centers of spleen and lymph nodes following immunization.

As discussed above, rabbit antibodies are subject to evolving maturation by somatic hypermutation, and are not dependent on gene conversion for increasing its affinity and binding towards a given antigen. In addition to recognition, another important property of isolated single-domain antibodies is its inherent structure stability. Because rabbit antibodies evolve by somatic hypermutation, VH and VL stability of rabbit antibodies is not dependent on inherent properties of a single VH or VL family but a property that can be subject to evolution. Antibody stability is important not only for promoting a good conformation of CDRs for antigen recognition, but also for downstream applications such as production and serum hali-life. Moreover, since the present invention isolates VH and VL protein domains, it is conceivable that the hydrophobic interface can promote protein aggregation. For that reason, the present method of selecting isolated VH and VL domains that are inherently stable provide the possibility of identifying novel small-domain antibodies with original and different properties than those presently existent.

The present method encompasses the identification of distinctive rabbit singlendomain antibodies, with unique properties compared to human, mouse and camel antibodies, and presenting high affinity, specificity and stability.
As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude other additives, components, integers or steps.
Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment, or any form of suggestion, that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art.

## 3. SUMMARY OF TIE INVENTION

The present invention relates to methody of production of inmunospecific polypeptides comprising sequences derived from tabbit immanoglobulin variable domains, to polypeptides comprising such sequences, and to polypeptides produced by such methods. In particular, the invention encompasses methods for the isolation and ure of rabbit $V_{k}$ andor $V_{i}$ domains and/or novel CDR and framework regions derived therefrom. The invention Hather provides for the identification of novel amino acid soquences (incuding nove amino acid residues at defined mosithons) within isolated rabbit $\mathrm{V}_{\text {a }}$ and $\mathrm{V}_{2}$ domains for use as "scaffold" or structurne sequences in the context of CDR loops andor framework regions in recombinant immunospecific polypeptides. The rabbit scaffold sequences (inchadiag scafiold reidues) or novel CDR/axamework sequences of the inverstion enhance the stability andro affimity of the variable domann(s)
and/or immunospecific polypeptides (e.g., antibodies) that contain them, in particular, relative to rodent antibodies, enabling the production and/or use of highly specific, single domain immunopeptides, e.g., single domain antibodies.

The present invention encompasses the production of novel rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains with specificity for a given antigen, or epitope thereof. In particular, the invention provides for a method of producing rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains said method comprising: (a) selecting from a phage expression library a set of DNA sequences that encode rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to a desired antigen or epitope thereof (also known as phage "panning") and (b) expressing the set of sequences, or a subset thereof, in bacteria as a fusion protein with chloramphenicol acetyltransferase ("CAT") and selecting bacteria that have chloramphenicol resistance by virtue of CAT expression. In alternate embodiments, the present invention provides for a method of producing rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains, said method comprising (a) expressing sequences of DNA or cDNA encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains of rabbit immunoglobulins in bacteria as a fusion protein with CAT, (b) selecting bacteria that have chloramphenicol resistance by virtue of CAT expression and obtaining the set of DNA sequences encoding the rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria, and (c) preparing a phage expression library from the set of DNA sequences obtained in step (b) and selecting DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to a desired antigen or epitope thereof (i.e., panning the library for immunospecific binding to the antigen or epitope). In certain embodiments, the present invention encompasses methods for the production of a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain wherein the phage panning step is repeated one or more times. In related embodiments, the phage panning step may or may not be repeated sequentially. The phage expression library for use in accordance with the present invention may be obtained commercially or prepared by any method described herein and/or known in the art. Expression of DNA or cDNA sequences in bacteria as fusion proteins is well known and may be performed by any method described herein or known in the art, e.g., cloning the DNA or cDNA sequence encoding the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain into an expression vector that comprises a nucleotide sequence encoding CAT and a promoter sequence that drives fusion protein expression. Expression of CAT in bacteria as a fusion protein with insoluble peptides confers significantly lower chloramphenicol resistance than does expression as a fusion protein
with a soluble peptide (e.g., a peptide that is at least partially folded and not aggregated when expressed in bacteria). Accordingly, selection for chloramphenicol resistance in bacteria transformed with nucleotide sequences encoding fusion proteins comprising $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains and CAT will select those sequences that are capable of being recombinantly expressed as properly folded and/or in non-aggregative forms. In certain embodiments, the present invention encompasses methods comprising culturing said transformed bacteria on selective media comprising at least 0.1 mM , at least 0.2 mM , at least 0.4 mM , at least 0.6 mM , at least 0.8 mM , at least 1.0 mM , at least 1.2 mM , at least 1.4 mM , at least 1.6 mM , at least 1.8 mM , at least 2.0 mM , at least 2.5 mM , at least 3.0 mM , at least 5.0 mM , at least 10 mM , at least 15 mM , or at least 20 mM chloramphenicol. Selection of sequences encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains by the CATfusion assay described herein selects for protein stability. The invention further encompasses the use of any other method known in the art or described herein for assessing the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains of the invention, including assays of thermal and/or kinetic stability (e.g., determinations of protein melting temperature ("Tm") or Gibbs free energy of folding ( $\left.\Delta \mathrm{G}_{\mathrm{N}-\mathrm{u}}\right)$ ). In certain embodiments, the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains of the invention have a melting temperature of at least about $40^{\circ} \mathrm{C}$, at least about $45^{\circ} \mathrm{C}$, at least about $50^{\circ} \mathrm{C}$, at least about $54^{\circ} \mathrm{C}$, or about $55^{\circ} \mathrm{C}$ or greater.

The invention relates to polypeptides comprising $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains, or amino acid sequences or residues, derived from and/or identified in rabbit immunoglobulins, which polypeptides immunospecifically bind desired antigens, or epitopes thereof, as determined by any standard method known in the art for assessing antigen/bindingprotein specificities. Assays to determine the binding specificity of an immunospecific polypeptide, e.g., an antibody or antigen binding fragment thereof, for an antigen or epitope include, but are not limited to ELISA, western blot, surface plasmon resonance (e.g., BIAcore) and radioimmunoassay. Any method known in the art for assessing binding polypeptide specificity may be used to identify polypeptides of the invention that exhibit a Kd of greater than 0.001 nM but not greater than 5 nM , not greater than 10 nM , not greater than 15 nM , not greater than 20 nM , not greater than 25 nM , not greater than 30 nM , not greater than 35 nM , not greater than 40 nM , not greater than 45 nM , or not greater than 50 nM . In certain embodiments, the isolated $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains of the invention exhibit a Kd of no greater than 5 nM , no greater than 10 nM , no greater than

15 nM , no greater than 20 nM , no greater than 25 nM , no greater than 30 nM , no greater than 35 nM , no greater than 40 nM , no greater than 45 nM , or no greater than 50 nM as determined by BIAcore assay.

The nucleotide sequences encoding immunoglobulin $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains may be obtained from naïve rabbits or rabbits that have been previously immunized with an antigen. Immunization of rabbits and isolation of nucleotide sequences (e.g., cDNA) encoding rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains may be done by any method known in the art or described herein. In certain embodiments, nucleotide sequences encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains may be obtained from any tissue of the naïve or immunized rabbit, but is preferably obtained from a tissue source rich in plasma cells, e.g., B cells. In certain embodiments, the rabbit tissue comprising nucleotide sequences encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains is bone marrow. In other embodiments, the rabbit tissue comprising nucleotide sequences encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains is appendix tissue. In yet other embodiments, the rabbit tissue comprising nucleotide sequences encoding $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains is lymphoid tissue; in a specific example in accordance with this embodiment the lymphoid tissue is spleen or lymph node tissue.
The present invention further encompasses immunospecific polypeptides, e.g., antibodies, or antigen binding fragments thereof, comprising the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains isolated, identified or constructed by the methods described herein. In alternate embodiments, the invention encompasses immunospecific polypeptides , e.g., antibodies, comprising novel (relative to the amino acid sequences of immunoglobulins of species other than rabbit) scaffold amino acid sequences, novel amino acid residues at certain positions in the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain (e.g., as determined according the position in the rabbit $\mathrm{V}_{\mathrm{H}}$ and $\mathrm{V}_{\mathrm{L}}$ alignment sequence presented in FIG 3A and FIG 4, respectively), or novel sequences of CDR loops identified by the methods of the invention. In certain embodiments, the immunospecific polypeptides of the invention are monoclonal antibodies, multispecific antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, polyclonal antibodies, single-chain Fvs (scFv), single chain antibodies, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-antiId antibodies to antibodies of the invention), diabodies, minibodies, nanobodies, or antigen binding fragments of any of the above, including, but not limited to, Fab fragmènts, $\mathrm{F}\left(\mathrm{ab}^{\prime}\right)$ fragments, disulfide-linked bispecific Fvs ( sdFv ), and intrabodies. In
certain embodiments the immunospecific polypeptides of the invention are bispecific or multispecific. Bi- or multi-specific molecules of the invention may be formed using methods well known in the art, e.g., chemical conjugation of one or more molecule of the invention to each orther and/or to differing epitope binding polypeptides, wherein the binding domains of the bi- or multi-specific molecule exhibit affinity for at least two differein antigens. For example, the immunospecific polypeptide of the invention may comprise a first and a second $\mathrm{V}_{\mathrm{L}}$ domain, or a first and second $\mathrm{V}_{\mathrm{H}}$ domain, wherein said first and second domain have differing binding specificities (i.e., bind to differeing antigens). In other embodiments, the immunospecific polypeptides of the invention comprise one $\mathrm{V}_{\mathrm{L}}$, or one $\mathrm{V}_{\mathrm{H}}$ domain, and one antigen binding polypeptide, wherein the $\mathrm{V}_{\mathrm{L}}$ domain, or $\mathrm{V}_{\mathrm{H}}$ domain, and said polypeptide exhibit differing binding specificities. In certain embodiments of the invention, at least one antigen binding domain of the bior multispecific molecule of the invention immunospecifically binds to albumin. In other embodiments of the invention, at least one antigen binding domain of the bi-or multispecific molecule of the invention immunospecifically binds to fibronectin.
In certain embodiments, the immunospecific polypeptides of the invention, or antigen binding fragments thereof, do not comprise a $\mathrm{CH}_{1}$ domain. In other embodiments, the immunospecific polypeptides of the invention, or epitope binding fragments thereof, do not comprise one or more of a $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{2}$ domain, $\mathrm{C}_{\mathrm{L}}$ domain, $\mathrm{CH}_{3}$ domain, or H domain, or do not comprise any of a $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{2}$ domain, $\mathrm{C}_{\mathrm{L}}$ domain, $\mathrm{CH}_{3}$ domain, or H domain. In still other embodiments, the immunospecific polypoeptides of the invention, or epitope binding fragments thereof, comprise one of a $\mathrm{CH}_{1}$ domain, H domain, $\mathrm{CH}_{2}$ domain, $\mathrm{C}_{\mathrm{L}}$ domain, or $\mathrm{CH}_{3}$ domain, and do not comprise any other constant domain or hinge region derived from an immunoglobulin (for example, in certain embodiments, the immunospecific polypeptide of the invention or fragment thereof comprises a $\mathrm{CH}_{1}$ domain, but does not comprise any of $\mathrm{a}(\mathrm{n}) \mathrm{H}$ domain, a $\mathrm{CH}_{2}$ domain, or a $\mathrm{CH}_{3}$ domain; or comprises a $\mathrm{CH}_{2}$ domain, but does not comprise any of a $\mathrm{CH}_{1}$ domain, H domain, or a $\mathrm{CH}_{3}$ domain, etc.).

In certain embodiments, the immunospecific polypeptide of the invention comprises one or more of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, and/or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain. In certain embodiments, the immunospecific polypeptide of the invention comprises each of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a
$\mathrm{V}_{\mathrm{H}} \mathrm{CDR} 2$ domain, a $\mathrm{V}_{\mathrm{H}} \mathrm{CDR} 3$ domain, a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 1$ domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, and/or a $V_{L}$ CDR3 domain.
In certain embodiments, the immunospecific polypeptide of the invention comprises one of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or $V_{L}$ CDR3 domain, but does not comprise any other CDR domain, wherein said CDR domains have been isolated and/or identified by the methods of the invention, wherein said CDR domains have been isolated and/or identified by the methods of the invention (for example, in certain embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 2$ domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $V_{H}$ CDR2 domain, but does not comprise a $V_{H} C D R 1$ domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $V_{H}$ CDR3 domain, but does not comprise a $V_{H}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $V_{L}$ CDR1 domain, but does not comprise a $V_{H} C D R 1$ domain, a $V_{H} C D R 2$ domain, a $V_{H}$ CDR3 domain, a $V_{L}$ CDR2 domain, or a $V_{L}$ CDR3 domain; or comprises a $V_{L}$ CDR2 domain, but does not comprise a $V_{H}$ CDR1 domain, a $V_{H}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $V_{L}$ CDR1 domain, or a $V_{L}$ CDR2 domain).
In certain embodiments, the immunospecific polypeptide of the invention comprises any two of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, $\mathrm{V}_{\mathrm{L}}$ CDR1 domains, $V_{L}$ CDR2 domain, or $V_{L}$ CDR3 domain, but does not comprise any other CDR domain, wherein said CDR domains have been isolated and/or identified by the methods of the invention, wherein said CDR domains have been isolated and/or identified by the methods of the invention (for example, in certain embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{H}} \mathrm{CDR} 2$ domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain and a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, but does not comprise a $V_{H}$ CDR1 domain, a $V_{L}$ CDR1 domain, a $V_{L}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$

CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain; or comprises a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 2$ domain and a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $V_{H} C D R 3$ domain and a $V_{L}$ CDR2 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $V_{H}$ CDR3 domain and a $V_{L}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain; or comprises two $\mathrm{V}_{\mathrm{H}}$ CDR3 domains, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}} \mathrm{CDR} 2$ domain, a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 1$ domain, a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 2$ domain or a $\mathrm{V}_{\mathrm{L}} \mathrm{CDR} 3$ domain or comprises; or comprises two $\mathrm{V}_{\mathrm{L}}$ CDR3 domains, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, etc.).

In certain embodiments, the immunospecific polypeptide of the invention comprises any three of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, $V_{L} C D R 2$ domain, or $V_{L} C D R 3$ domain, but does not comprise any other CDR
domains, wherein said CDR domains have been isolated and/or identified by the methods of the invention, wherein said CDR domains have been isolated and/or identified by the methods of the invention (for example, in certain embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}} \mathrm{CDR1}$ domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, and $V_{H}$ CDR3 domain, but does not comprise a $V_{L}$ CDR1 domain, a $V_{L}$ CDR2 domain, or a $V_{L}$ CDR3 domain; or comprises a $V_{L}$ CDR1 domain, a $V_{L}$ CDR2 domain, and $V_{L}$ CDR3 domain, but does not comprise a $V_{H}$ CDR1 domain, $a \cdot V_{H}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, and $V_{L}$ CDR1 domain, but does not comprise a $V_{H}$ CDR3 domain, a $V_{L}$ CDR2 domain, or a $V_{L}$ CDR3 domain; or comprises a $V_{H}$ CDR1 domain, a $V_{L}$ CDR1 domain, and $V_{H}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises two $\mathrm{V}_{\mathrm{H}}$ CDR3 domains, and $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}} \mathrm{CDR} 2$ domain, a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; etc.).

In certain embodiments, the immunospecific polypeptide of the invention comprises any four of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise any other CDR domains, wherein said CDR domains have been isolated and/or identified by the methods of the invention, wherein said CDR domains have been isolated and/or identified by the methods of the invention (for example, in certain embodiments; the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, and a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, but does not comprise a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, and a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR32 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $V_{L}$ CDR1 domain, and a $V_{L}$ CDR2 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain; or comprises a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $V_{L}$ CDR2 domain, and a $V_{L}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain; or comprises two $\mathrm{V}_{\mathrm{H}}$ CDR 3 domains, and two $V_{L}$ CDR3 domains, but does not comprise a $V_{H}$ CDR1 domain, a $V_{H}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, or a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain; etc.).

In certain embodiments, the immunospecific polypeptide of the invention comprises any five of a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, $\mathrm{V}_{\mathrm{L}}$ CDR1 domain, $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, or $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, but does not comprise any other CDR domains, wherein said CDR domains have been isolated and/or identified by the methods of the invention, wherein said CDR domains have been isolated and/or identified by the methods of the invention (for example, in certain embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR1 domain and a $\mathrm{V}_{\mathrm{L}}$ CDR2 domain, but does not comprise a $V_{L}$ CDR3 domain; or comprises a $V_{L}$ CDR1 domain, a $V_{L}$ CDR2 domain, a $\mathrm{V}_{\mathrm{L}}$ CDR3 domain, a $\mathrm{V}_{\mathrm{H}}$ CDR2 domain and a $\mathrm{V}_{\mathrm{H}}$ CDR3 domain, but does not comprise a $\mathrm{V}_{\mathrm{H}}$ CDR1 domain; etc.).

In certain embodiments, the immunospecific polypeptide of the invention comprises one or more of the framework domains isolated and/or identified by the methods of the invention. In specific embodiments, the immunospecific polypeptide of the present invention comprises the framework domains identified herein with heterologous CDR sequences grafted therein.
The polypeptides of the invention include immunoglobulin molecules that may derived from any species (e.g., rabbit, mouse, rat), but are preferably human immunoglobulin molecules that can be of any type (e.g., $\operatorname{IgG}, \operatorname{IgE}, \mathrm{IgM}, \mathrm{IgD}, \operatorname{IgA}$ and $\operatorname{IgY}$ ), or class (e.g., $\mathrm{IgG}_{1}, \mathrm{IgG}_{2}, \mathrm{IgG}_{3}, \mathrm{IgG}_{4}, \mathrm{IgA}_{1}$, and $\mathrm{IgA}_{2}$ ) or subclass. The immunospecific polypeptides, e.g., antibodies, of the invention, or antigen binding fragments thereof, can be produced by any method known in the art, for example, chemical synthesis or recombinant techniques.
In certain embodiments, the immunospecific polypeptide of the invention does not comprise a $\mathrm{V}_{\mathrm{H}}$ domain, e.g., a rabbit $\mathrm{V}_{\mathrm{H}}$ domain, and/or does not comprise a $\mathrm{V}_{\mathrm{H}}$ domain derived from any species other than rabbit. In other embodiments, the immunospecific polypeptide of the invention does not comprise a $\mathrm{V}_{\mathrm{L}}$ domain and/or does not comprise a $\mathrm{V}_{\mathrm{L}}$ domain derived from any species other than rabbit. In preferred embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{H}}$ domain, and does not comprise a $\mathrm{V}_{\mathrm{L}}$ domain. In other embodiments, the immunospecific polypeptide of the invention comprises a $\mathrm{V}_{\mathrm{L}}$ domain, and does not comprise a $\mathrm{V}_{\mathrm{H}}$ domain. In specific embodiments, the immunospecific polypeptides of the invention, e.g., antibodies,
comprise one or more of a $\mathrm{V}_{\mathrm{H}} \mathrm{FR1}$ domain having the amino acid sequence QEQLMETESGGGAEGGLVKPGASLTLTCTAS (SEQ ID NO:57); a V $\mathrm{H}_{\mathrm{H}}$ FR2 domain having the amino acid sequence WVRQAPGKGLEWIG (SEQ ID NO:69); a $\mathrm{V}_{\mathrm{H}}$ FR3 domain having the amino acid sequence YATWVNGRFTLSRDIDQSTGC̣LQLNSLTAADTATYYCAR (SEQ ID NO:95); a $\mathrm{V}_{\mathrm{H}}$ FR4 domain having the amino acid sequence WGQGTLVTVSS (SEQ ID NO:139); a $V_{L}$ FR1 domain having the amino acid sequence ELVLTQTPPSLSASVGETVRIRC (SEQ ID NO:150) or ELVLTQTPSSVSAAVGGTVTINC (SEQ ID NO:155); a V ${ }_{\mathrm{L}}$ FR2 domain having the amino acid sequence WYQQKPEKPPTLLIS (SEQ ID NO:174) or WYQQKPGQRPKLLIY (SEQ ID NO:181); a $V_{L}$ FR3 domain having the amino acid sequence GVPPRFSGSGSGTDYTLTIGGVQAEDVATYYC (SEQ ID NO:183) or GVSSRFKGSGSGTQFTLTISGVQCADAATYYC (SEQ ID NO:205); or a V ${ }_{L}$ FR4 domain having the amino acid sequence FGAGTNVEIK (SEQ ID NO:206) or FAFGGGTELEIL (SEQ ID NO:210). In other embodiments, the immunospecific polypeptides of the invention, e.g., antibodies or antigen binding fragments thereof (e.g., single variable domains), comprise one or more of a $\mathrm{V}_{\mathrm{H}}$ FR1 domain from Table 3, a $\mathrm{V}_{\mathrm{H}}$ FR2 domain from Table 4, $\mathrm{V}_{\mathrm{H}}$ FR3 domain from Table 5 at, $\mathrm{a} \mathrm{V}_{\mathrm{H}}$ FR4 domain from Table 6, a $\mathrm{V}_{\mathrm{L}}$ FR1 domain from Table 7, a $\mathrm{V}_{\mathrm{L}}$ FR2 domain from Table 8, a $\mathrm{V}_{\mathrm{L}}$ FR3 domain from Table 9, or a $V_{L}$ FR4 domain from Table 10 in Section 6.1.2.

In further specific embodiments, the immunospecific polypeptides of the invention, e.g., antibodies, comprise one or more scaffold residues that improve stability and/or antigen binding affintity of the peptides. In certain embodiments the immunospecific polypeptides of the invention comprise one or more of a phenylalanine at position 46 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain; a glutamic acid at position 53 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain; an arginine at position 54 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain; a glycine at position 56 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain;an alanine at position 58 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain; a cysteine at position 44in the; $\mathrm{V}_{\mathrm{H}}$ CDR1 domain; a cysteine at position 59 in the $\mathrm{V}_{\mathrm{H}}$ CDR2 domain; an arginine at position 126 in the $\mathrm{V}_{\mathrm{H}} \mathrm{FR} 4$ domain; a phenylalanine or a tyrosine at position 39 in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain; a lysine at position 45 in the $V_{L}$ FR2 domain; or a cysteine at position 91 in the $V_{L}$ FR3 domain, wherein said positions are according to the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain amino acid sequence alignments presented in FIGS. 3 and 4, respectively.

The present invention also encompasses a method for obtaining a DNA sequence encoding a rabbit $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain that immunospecifically binds to an antigen and that shows a desired stability, wherein said method is a first method comprising:
a) selecting from a phage expression library a set of DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to said antigen, said phage expression library prepared from DNA or cDNA sequences that encode $V_{H}$ and/or $V_{L}$ domains and that were obtained from a biological sample of a rabbit containing cells that express immunoglobulins; and
b) expressing said set of DNA sequences, or a subset thereof, in bacteria as a fusion protein with CAT, selecting bacteria that have chloramphenicol resistance by virtue of CAT expression, and obtaining DNA sequences encoding amino acid sequences corresponding to rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria,
whereby said bacterial resistance to chloramphenicol conferred by said CAT-fusion correlates with stability of said amino acid sequence fused to CAT and wherein said selection is at a chloramphenicol concentration sufficient to select for said desired stability;
or a second method comprising:
a) expressing sequences of DNA or cDNA that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains in bacteria as a fusion protein with CAT, wherein said DNA or cDNA sequences were obtained from a biological sample of a rabbit containing cells that express immunoglobulins;
b) selecting bacteria that have chloramphenicol resistance by virtue of CAT expression, and obtaining the set of DNA sequences encoding amino acid sequences corresponding to rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria,
whereby said bacterial resistance to chloramphenicol conferred by said CAT-fusion correlates with stability of said amino acid sequence fused to CAT and wherein said selection is at a chloramphenicol concentration sufficient to select for said desired stability; and
c) selecting from a phage expression library DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to said antigen, wherein said library is prepared from said set of DNA sequences, or subset thereof.

The present invention also encompasses the use of immunospecific polypeptides or fragments thereof comprising the amino acid sequence of any of the variable domains, CDRs, amino acid scaffold sequences (e.g., framework domains such as those listed in Tables 3-10 in Section 6.1.2), or amino acid scaffold residues of the invention with mutations (e.g., one or more amino acid substitutions) in any of the above. In specific examples in accordance with this embodiment, the present invention encompasses immunospecific polypeptides comprising one or more amino acid substitutions, wherein said substitutions result in one or more of, at position 46 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a phenylalanine; at position 53 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glutamic acid; at position 54 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an arginine; at position 56 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glycine; at position 58 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an alanine; at position 44 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 59 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 126 in the $\mathrm{V}_{\mathrm{H}}$ FR4 domain, a cysteine; at position 39 in the $V_{L}$ FR2 domain, a phenylalanine or a tyrosine; at position 45 in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a lysine; or at position 91 in the $\mathrm{V}_{\mathrm{L}}$ FR3 domain, a cysteine. Preferably, mutations in these regions, domains or residues maintain or enhance the avidity and/or affinity of the immunospecific polypeptide for the antigen, i.e. epitope, to which they immunospecifically bind. The recited positions are according to the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain amino acid sequence alignments presented in FIGS. 3 and 4, respectively.
In certain embodiments, the polypeptides of the invention, or antigen binding fragments thereof immunospecifically bind an epitope of an antigen which is immuno-neutral or non-immunogenic in mice and/or rats.

The present invention also encompasses immunospecific polypeptides of the invention that have been modified by any method known in the art and/or described herein known to increase or improve the serum half-life of therapeutic polypeptides. Non-limiting examples of such modifications include pegylation, acetylation and the use of nonnatural amino acids. In certain embodiments the serum half-life of the immunospecific polypeptide may be increased or improved by including in the polypeptide an additional antigen binding domain, which domain immunospecifically binds to albumin or fibronectin.

The methods of the invention also encompass polynucleotides that encode the immunospecific polypeptides of the invention. In one embodiment, the invention
provides an isolated nucleic acid sequence encoding a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain identified or constructed by the methods described herein. The invention further encompasses polynucleotides that encode immunospecific polypeptides, e.g., antibodies or antigen binding fragments thereof, comprising novel (relative to the amino acid sequences of immunoglobulins of species other than rabbit) scaffold amino acid sequences, novel amino acid residues at particular positions of the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ amino acid sequence, or novel amino acid sequences of CDR loops identified by the methods described herein. The invention further relates to a vector comprising said nucleic acid. In specific embodiments wherein the immunospecific polypeptide of the invention comprises both a $\mathrm{V}_{\mathrm{H}}$ and a $\mathrm{V}_{\mathrm{L}}$ domain identified, isolated or constructed by the methods of the invention, the invention provides a vector comprising a first nucleic acid molecule encoding said $\mathrm{V}_{\mathrm{H}}$ domain and a second nucleic acid molecule encoding said $\mathrm{V}_{\mathrm{L}}$ domain, said $\mathrm{V}_{\mathrm{H}}$ and $\mathrm{V}_{\mathrm{L}}$ domains independently or concomitantly selected for immunospecific binding to the same antigen and/or epitope. In one specific embodiment, said vector is an expression vector. The invention further provides host cells containing the vectors of polynucleotides encoding the polypeptides of the invention.

The present invention encompasses immunospecific polypeptides, e.g., antibodies, recombinantly fused or chemically conjugated (including both covalently and noncovalently conjugations) to therapeutic agents or additional antigen binding domains, e.g., heterologous polypeptides (i.e., an unrelated polypeptide; or portion thereof, preferably at least 10 , at least 20 , at least 30 , at least 40 , at least 50 , at least 60 , at least 70 , at least 80 , at least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences or through chemical conjugation. The immunospecific polypeptides of the invention may be used for example to target the therapeutic agent to particular cell types, either in vitro or in vivo, by fusing or conjugating the agent to the immunospecific polypeptides of the present invention that are specific for particular cell surface receptors. In other embodiments, the additional antigen binding domains may be used to bind the immunospecific polypeptides of the invention to albumin or fibronectin, thereby improving serum half-life (see, e.g., Holt et al., 2008, Protein Eng Des Sel 21:283-288 and Stork et al., 2007, Protein Eng Des Sci :20:569-576, each of which is hereby incorporated by reference herein in its entirety). The therapeutic-
agent/immunospecific polypeptide fusions of the invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., PCT publication Number WO 93/2 1232; EP 439,095; Naramura et al., Immunol. Lett., 39:91-99, 1994; U.S. Pat. No. 5,474,981; Gillies et al., PNAS, 89:1428-1432, 1992; and Fell et al., J. Immunol., 146:2446-2452, 1991, which are incorporated herein by reference in their entireties. Therapeutic agents for use in accordance with the methods of the invention are not to be construed as limited to classical chemical therapeutic agents (e.g., chemotherapeutics), but may include peptides that may or may not modify or alter biological responses, drug moieties, radioactive materials, macrocýclic chelators, and siRNA. In non-limiting examples, such polypeptides as therapeutic agents may include albumin, protamine, albumin interacting proteins (e.g., gp60, gp30, gp 18 ), protein A, a G protein, protein transduction domains (see e.g., Bogoyevitch et al., 2002, DNA Cell Biol 12:879-894, hereby incorporated by reference in its entirety), toxins, cytotoxins, or portions of antibody molecules: (e.g., Fc domain, $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{1}$ domain, CL domain, etc.); such radionuclides may include radionuclides (e.g., alpha-, beta-, gamma-emitters, etc.) known in the art for labeling (i.e., producing a detectable signal in vivo or in vitro) and/or producing a therapeutic effect (e.g., ${ }^{125} \mathrm{I},{ }^{131} \mathrm{I},{ }^{14} \mathrm{C}$, etc.); such macrocyclic chelators include those known in the art for conjugating radiometal ions (e.g., DOTA).

In a certain embodiments, the CDR and/or framework regions of the immunospecific polypeptides of the invention are derived from rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ regions identified or isolated by the methods described herein. In other embodiments, the CDR and /or framework regions of the immunospecific polypeptides of the invention are not derived from rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ regions identified or isolated by the methods described herein, but comprise novel scaffold amino acid sequences and/or novel amino acid residues at certain positions of the amino acid sequence of the $V_{H}$ or $V_{L}$ domains identified by the methods of the invention. In some embodiments, the immunospecific polypeptides of the invention described herein comprise additional alterations, including, but not limited to, amino acid deletions, insertions, and modifications, of the $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ sequences isolated and identified herein.

Preferably, the immunospecific polypeptides, e.g. antibodies, of the invention, or antigen binding fragments thereof, are monoclonal (i.e., bind the same epitope of an antigen), and in certain embodiments may be humanized.
The invention further provides a pharmaceutical composition comprising (i), and (ii) a pharmaceutically acceptable carrier
In certain embodiments of the invention, pharmaceutical compositions are provided for use in accordance with the methods of the invention, said pharmaceutical compositions comprising a therapeutically effective amount of an immunospecific polypeptide of the invention, or antigen binding fragment thereof, and a pharmaceutically acceptable carrier.

### 3.1 Definitions

As used herein, the term "analog" in the context of proteinaceous agents (e.g., proteins, polypeptides, and antibodies) refers to a proteinaceous agent that possesses a similar or identical function as a second proteinaceous agent but does not necessarily comprise a similar or identical amino acid sequence of the second proteinaceous agent, or possess a similar or identical structure of the second proteinaceous agent. A proteinaceous agent that has a similar amino acid sequence refers to a second proteinaceous agent that satisfies at least one of the following: (a) a proteinaceous agent having an amino acid sequence that is at least $30 \%$, at least $35 \%$, at least $40 \%$, at least $45 \%$, at least $50 \%$, at least $55 \%$, at least $60 \%$, at least $65 \%$, at least $70 \%$, at least $75 \%$, at least $80 \%$, at least $85 \%$, at least $90 \%$, at least $95 \%$ or at least $99 \%$ identical to the amino acid sequence of a
second proteinaceous agent; (b) a proteinaceous agent encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a second proteinaceous agent of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous, amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, or at least 150 contiguous amino acid residues; and (c) a proteinaceous agent encoded by a nucleotide sequence that is at least $30 \%$, at least $35 \%$, at least $40 \%$, at least $45 \%$, at least $50 \%$, at least $55 \%$, at least $60 \%$, at least $65 \%$, at least $70 \%$, at least $75 \%$, at least $80 \%$, at least $85 \%$, at least $90 \%$, at least $95 \%$ or at least $99 \%$ identical to the nucleotide sequence encoding a second proteinaceous agent. A proteinaceous agent with similar structure to a second proteinaceous agent refers to a proteinaceous agent that has a similar secondary, tertiary or quaternary structure to the second proteinaceous agent. The structure of a polypeptide can be determined by methods known to those skilled in the art, including but not limited to, peptide sequencing, X-ray crystallography, nuclear magnetic resonance, circular dichroism, and crystallographic electron microscopy. To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence; see, e.g. FIGS. 3-4). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., \% identity=number of identical overlapping positions/total number of positions.times. $100 \%$ ). In one embodiment, the two sequences are the same length.
The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical
algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score $=100$, wordlength $=12$ to obtain nucleotide sequences homologous to a nucleic acid molecules of the present invention. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score-50, wordlength $=3$ to obtain amino acid sequences homologous to a protein molecule of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., the NCBI website). Another preferred non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12 , and a gap penalty of 4 can be used.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

As used herein, the term "analog" in the context of a non-proteinaceous agent refers to a second organic or inorganic molecule which possess a similar or identical function as a first organic or inorganic molecule and is structurally similar to the first organic or inorganic molecule.

As used herein, the term "derivative" in the context of polypeptides or proteins, including immunospecific polypeptides (e.g., antibodies), refers to a polypeptide or protein that comprises an amino acid sequence which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The term
"derivative" as used herein also refers to a polypeptide or protein which has been modified, i.e., by the covalent attachment of any type of molecule to the polypeptide or protein. For example, but not by way of limitation, an immunospecific polypeptide of the invention may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. A derivative polypeptide or protein may be produced by chemical modifications using techniques known to those of skill in the art, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Further, a derivative polypeptide or protein derivative possesses a similar or identical function as the polypeptide or protein from which it was derived.
As used herein, the term "epitope" refers to a region on an antigen molecule to which an antibody specifically binds. Antigen molecules can comprise single or multiple epitopes.
As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 centiguous amino residues, at least 70 contiguous amino acid residues, at least contiguous 80 amino acid residues, at least contiguous 90 amino acid residues, at least contiguous 100 amino acid residues, at least contiguous 125 amino acid residues, at least 150 contiguous amino acid residues, at least contiguous 175 amino acid residues, at least contiguous 200 amino acid residues, or at least contiguous 250 amino acid residues of the amino acid sequence of another polypeptide. In a specific embodiment, a fragment of a polypeptide retains at least one function of the polypeptide. Preferably, fragments of the immunospecific polypeptides of the invention are antigen binding fragments (in particular, epitope binding fragments).
As used herein, the terms "heavy chain," "light chain," "variable region," "framework region," "constant domain," and the like, have their ordinary meaning in the immunology art and refer to domains in naturally occurring immunoglobulins and the corresponding domains of synthetic (e.g., recombinant) binding proteins (e.g.,
humanized antibodies, single chain antibodies, chimeric antibodies, etc.). The basic structural unit of naturally occurring immunoglobulins (e.g., $\operatorname{IgG}$ ) is a tetramer having two light chains and two heavy chains, usually expressed as a glycoprotein of about $150,000 \mathrm{Da}$. The amino-terminal ("N") portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal (" $\mathrm{C}^{\prime \prime}$ ) portion of each chain defines a constant region, with light chains having a single constant domain and heavy chains usually having three constant domains and a hinge region. Thus, the structure of the light chains of an immunoglobulin molecule, e.g., IgG, is $n-V_{L}--C_{L}-c$ and the structure of heavy chains of an immunoglobulin molecule, e.g., IgG , is $\mathrm{n}-\mathrm{V}_{\mathrm{H}}-\mathrm{C}_{\mathrm{H} 1}--\mathrm{H}-\mathrm{C}_{\mathrm{H} 2}-\mathrm{C}_{\mathrm{H} 3}-\mathrm{C}$ (where H is the hinge region). The variable regions of the immunospecific polypeptides of the invention, e.g., antibodies, consist of the complementarity determining regions (CDRs), which contain the residues in contact with antigen and non-CDR segments, referred to as framework segments, which in general maintain the structure and determine the positioning of the CDR loops (although certain framework residues may also contact antigen). Thus, the $\mathrm{V}_{\mathrm{L}}$ and $\mathrm{V}_{\mathrm{H}}$ domains have the structure $\mathrm{n}-\mathrm{FR} 1, \mathrm{CDR} 1, \mathrm{FR} 2, \mathrm{CDR} 2$, FR3, CDR3, FR4-c.
As used herein, the terms "humanized antibody" or "humanized immunospecific polypeptide" refer to a polypeptide comprising at least one immunoglobulin variable comprising a human framework region and one or more CDRs identified by the methods of the invention. In some embodiments, the immunospecific polypeptide of the invention does not comprise an entire immunoglobulin, or may comprise a single immunoglobulin variable domain (e.g., a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain) and but not comprise any other immunoglobulin domain or region (e.g., $\mathrm{Fc}, \mathrm{CH}_{1}, \mathrm{CH}_{2}, \mathrm{CH}_{3}, \mathrm{CL}$, etc.). The immunospecific polypeptide (e.g., antibody or variable domain) providing the CDRs is called the "donor" and the human immunoglobulin, or fragment thereof (e.g., variable domain) providing the framework is called the "acceptor". Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about $85-90 \%$, preferably about $95 \%$ or more identical. Hence, in accordance with embodiments wherein the immunospecific polypeptide of the invention comprises a humanized immunoglobulin, all parts of a said immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural
human immunoglobulin sequences. In the context of immunospecific polypeptides as used herein, i.e., polypeptides comprising at least a variable domain (or epitope binding fragment thereof), humanized molecules of the invention, e.g., antibodies, do not encompass chimeric molecules of the invention because, e.g., the entire variable region of the chimeric molecule would non-human. One says that the donor molecule has been "humanized", by the process of "humanization", because the resultant humanized molecule is expected to bind to the same antigen as the donor antibody that provides the CDRs. Generally, humanized immunospecific molecules are human immunoglobulins (or variable domains and/or fragments thereof ), the recipient molecule, in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody; e.g., donor CDRs from a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain) having the desired specificity, affinity, and capacity. In some instances, Framework Region (FR) residues of the human immunoglobulin, or fragment thereof, are replaced by corresponding non-human residues. Furthermore, humanized molecules may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine functionality, e.g., immunospecificity. In general, the humanized molecule, e.g., antibody, will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin or variable domain and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized molecule optionally also will comprise at a CL and/or a $\mathrm{CH}_{1}$ domain and/or least a portion of an immunoglobulin constant region ( Fc ). In some embodiments, a humanized molecule of the invention is a derivative. Such a humanized molecule comprises amino acid residue substitutions, deletions or additions in one or more of the non-human, e.g., rabbit, CDRs. The derivative of the humanized molecule of the invention may have substantially the same binding, better binding, or worse binding when compared to a non-derivative humanized molecule of the invention. In specific embodiments, one, two, three, four, or five amino acid residues of the CDRs identified and/or constructed in accordance with the methods of the invention have been substituted, deleted or added (i.e., mutated). For further details in humanizing antibodies, see European Patent Nos. EP 239,400, EP 592,106, and EP 519,596; International Publication Nos. WO $91 / 09967$ and WO

93/17105; U.S. Pat. Nos. 5,225,539, 5,530,101, 5,565,332, 5,585,089, 5,766,886, and 6,407;213; and Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; Roguska et al., 1994, Proc Natl Acad Sci USA 91:969-973; Tan et al., 2002, J. Immunol. 169:1119-25; Caldas et al., 2000, Protein Eng. 13:353-60; Morea et al., 2000, Methods 20:267-79; Baca et al., 1997, J. Biol. Chem. 272:10678-84; Roguska et al., 1996, Protein Eng. 9:895-904; Couto et al., 1995, Cancer Res. 55 (23 Supp):5973s-5977s; Couto et al., 1995, Cancer Res. 55:1717-22; Sandhu, 1994, Gene 150:409-10; Pedersen et al., 1994, J. Mol. Biol. 235:959-73; Jones et al., 1986, Nature 321:522-525; Reichmann et al., 1988, Nature 332:323-329; and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596 (each of which is hereby incorporated by reference herein in its entirety). The term "humanization" also includes methods of protein and/or antibody resurfacing such as those disclosed in U.S. patents 5,770,196; $5,776,866 ; 5,821,123$; and $5,896,619$, each to Studnicka et al. (each of which is incorporated herein by reference in its entirety).
As used herein, the terms "immunospecifically binds," :"immunospecifically recognizes," "specifically binds," "specifically recognizes" and analogous terms refer to molecules that specifically bind to an antigen (e.g., epitope or immune complex) and do not specifically bind to another molecule. A molecule that specifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., immunoassays, BIAcore, or other assays known in the art. Preferably, molecules that specifically bind an antigen do not cross-react with other proteins. Molecules that specifically bind an antigen can be identified, for example, by immunoassays, BIAcore, or other techniques known to those of skill in the art.

As used herein, the terms "immunospecific polypeptides" and "immunospecific polypeptide" refer to polypeptides, peptides, and/or proteins that comprise at least one of a $\mathrm{V}_{\mathrm{H}}$ or a $\mathrm{V}_{\mathrm{L}}$ domain and exhibit immunospecific binding as determined by any method known in the art for assessing antigen/antibody specificity (e.g., BIAcore). The terms may refer to polyclonal antibodies, monoclonal antibodies, multispecific antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, polyclonal antibodies, single-chain Fvs (scFv), single chain antibodies, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-anti-Id antibodies to antibodies of the invention), diabodies (see e.g., U.S. Patent Application Publication Nos. 2007/0004909
and 2006/0210564, each of which is hereby incorporated by reference herein in its entirety), minibodies (see, e.g., U.S. Patent 5,837,821 and U.S. Patent Application Publication No. 2007/0003556, each of which is hereby incorporated by reference herein in its entirety), nanobodies (see, e.g., Revets et al., 2005, Expert Opin Biol Ther 5:111-124, hereby incorporated by reference in its entirety), or antigen binding fragments of any of the above, including, but not limited to, Fab fragments, $F(a b$ ') fragments, disulfide-linked bispecific Fvs (sdFv), and intrabodies. The terms also include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antigen binding site, and may be of any type (e.g., $\operatorname{IgG}, \mathrm{IgE}, \mathrm{IgM}, \mathrm{IgD}, \mathrm{IgA}$ and $\operatorname{IgY}$ ), class (e.g., $\mathrm{IgG}_{1}, \mathrm{IgG}_{2}, \mathrm{IgG}_{3}$, $\operatorname{IgG}_{4}, \operatorname{IgA}_{1}$, and $\operatorname{IgA}_{2}$ ) or subclass. The terms may also refer to bispecific or multispecific molecules comprising two or more antigen binding molecules, at least one of which is a $\mathrm{V}_{\mathrm{H}}$ or a $\mathrm{V}_{\mathrm{L}}$ domain determined by the methods of the invention, or at least one of which comprises a variable domain framework region determined by the methods of the invention.

When referring to immunospecific polypeptides of the invention, e.g., antibodies, (as broadly defined herein), the assignment of amino acids to each domain is in accordance with methods well known in the art for the characterization of antibody variable domains, including, e.g., variable domains of human, murine and rabbit variable domains. Amino acids from the rabbit variable domain of mature heavy and light chains as isolated and identified by the methods of the present invention are designated by their position in the alignment sequences presented in FIG. 3 for the $\mathrm{V}_{\mathrm{H}}$ domain and in FIG 4 for the $V_{L}$ domain. For example, the FR1 domain of a rabbit $V_{H}$ domain isolated and/or identified by the methods of the invention typically comprises from 24 to 31 amino acid residues, each of which is designated by their position in an alignment sequence based on the longest amino acid sequence for each domain (see, e.g., FIG. 4). Accordingly, a specific variable domain may or may not comprise a residue at a particular position of the alignment sequence. The alignments presented in FIGS. 3-4 and specific domain determiniations of the polypeptides of the invention were determined according to methods known in the art for characterizing and aligning sequences based on immunoglobulin molecules (e.g., aligned according to Kabat et al., Sequences of Proteins of Immunological Interest, $5^{\text {th }}$ Ed. Public Health Service, NH1,

MD (1991), expressly incorporated herein by references). Thus, as presented in FIG. 3, in the alignment sequnce of the $\mathrm{V}_{\mathrm{H}}$ domain, the FR1 consists of positions 1-31, the CDR1 of positions 32-44, the FR2 of positions 45-58, the CDR2 of positions 59-69, the FR3 of postions 70-110, the CDR3 of positions 111-125, and the FR4 of positions 126136; and as presented in FIG. 4, in the alignment sequence of the $\mathrm{V}_{\mathrm{L}}$ domain the FR1 consists of positions 1 to 23 , the CDR1 of positions 24 to 37, the FR2 of positions 3852 , the CDR2 of positions 53 to 59 , the FR3 of positions 60 to 91 , the FR4 of positions 92-105, and the FR4 of positions 106-116B.

As used herein, the terms "nucleic acids" and "nucleotide sequènces" include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), combinations of DNA and RNA molecules or hybrid DNA/RNA molecules, and analogs of DNA or RNA molecules. Such analogs can be generated using, for example, nucleotide analogs, which include, but are not limited to, inosine or tritylated bases. Such analogs can also comprise DNA or RNA molecules comprising modified backbones that lend beneficial attributes to the molecules such as, for example, nuclease resistance or an increased ability to cross cellular membranes. The nucleic acids or nucleotide sequences can be single-stranded, double-stranded, may contain both single-stranded and double-stranded portions, and may contain triple-stranded portions, but preferably is double-stranded DNA.

As used herein, the terms "prophylactic agent" and "prophylactic agents" refer to any agent(s) which can be used in the prevention of a disorder, or prevention of recurrence or spread of a disorder. A prophylactically effective amount may refer to the amount of prophylactic agent sufficient to prevent the recurrence or spread of a disease, the recurrence or exacerbation of symptoms of a disease, or the occurrence of such in a subject. A prophylactically effective amount may also refer to the amount of the prophylactic agent that provides a prophylactic benefit in the prevention of disease. Further, a prophylactically effective amount with respect to a prophylactic agent of the invention means that amount of prophylactic agent alone, or in combination with other agents, that provides a prophylactic benefit in the prevention of disease.

As used herein, the terms "single-chain Fv " or "scFv" refer to antibody fragments that comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide
linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994). In specific embodiments, scFvs include bi-specific scFvs and humanized scFvs.

As used herein, the term "stable" in the context of a formulation comprising an immunospecific polypeptide of the invention refers to a formulation in which the protein therein essentially retains its physical and chemical stability and integrity upon storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993) (each of which is hereby incorporated by reference in its entirety). Stability can be measured at a selected temperature for a selected time period. For rapid screening, the formulation may be kept at $40^{\circ} \mathrm{C}$. for 2 weeks to 1 month, at which time stability is measured. Where the formulation is to be stored at $2-8^{\circ} \mathrm{C}$., generally the formulation should be stable at $30^{\circ} \mathrm{C}$. or $40^{\circ} \mathrm{C}$. for at least 1 month and/or stable at $2-8^{\circ} \mathrm{C}$. for at least 2 years. Where the formulation is to be stored at $30^{\circ}$ C., generally the formulation should be stable for at least 2 years at $30^{\circ} \mathrm{C}$. and/or stable at $40^{\circ} \mathrm{C}$. for at least 6 months. For example, the extent of aggregation following lyophilization and storage can be used as an indicator of protein stability. For example, a "stable" formulation may be one wherein less than about $10 \%$ and preferably less than about $5 \%$ of the protein is present as an aggregate in the formulation. In other embodiments, any increase in aggregate formation following lyophilization and storage of the lyophilized formulation can be determined. For example, a "stable" lyophilized formulation may be one wherein the increase in aggregate in the lyophilized formulation is less than about $5 \%$ and preferably less than about $3 \%$, when the lyophilized formulation is stored at $2-8{ }^{\circ} \mathrm{C}$. for at least one year. In other embodiments, stability of the protein formulation may be measured using a biological activity assay.
As used herein, the term "stable" in the context of an immunospecific polypeptide of the invention may refer to the kinetic stability of a protein, or the resistance of a protein to unfolding. Kinetic stability can be best explained by illustrating the unfolding process as a simple equilibrium reaction between two protein conformations, the native folded
state ( N ) and the unfolded state ( U ), which is normally separated by a higher energy transition state (TS). Since the height of the TS barrier determines the rate of folding and unfolding, kinetically stable proteins possess an unusually high energy TS, which results in extremely slow unfolding rates that virtually trap the protein in its native state. Even though the overall change in Gibbs free energy ( $\Delta \mathrm{G}$ ) may be favorable for unfolding under extreme solvent conditions, such as high concentrations of denaturant, the high activation energy of the TS significantly slows the unfolding rate of kinetically stable proteins. Methods to asses the stability of polypeptides are well known in the art and include, e.g., single molecule force spectroscopy, assessment of thermal denaturation, e.g., monitored by dynamic light scattering ("DLS"), and resistance to SDS denaturation (see, e.g., U.S. Patent Application publication 2006/0099647, hereby incorporated by reference in its entirety). Stability may also be assessed by the characteristics of protein expression in recombinant expression systems. Polypeptides that readily fold, and which are resistant to unfolding, will be expressed as soluble protein in such systems, while improperly or only partially folded proteins interact via their hydrophobic regions to form inclusion bodies. The inventors have additionally implemented a stability assay based on the solubility of recombinant protein, wherein said protein is expressed as a fusion with CAT and the CAT activity of the fusion is evaluated (see, infra).

As used herein, the terms "subject" and "patient" are used interchangeably. As used herein, a subject is preferably a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) or a primate (e.g., monkey and human), most preferably a human. As used herein, a "therapeutically effective amount" refers to that amount of the therapeutic agent of the invention sufficient to treat or manage a disease or disorder. A therapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease. A therapeutically effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease. Further, a therapeutically effective amount with respect to a therapeutic agent of the invention means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of a disease, e.g., sufficient to enhance the therapeutic
efficacy of an amount of therapeutic agent of the invention sufficient to treat or manage a disease

## 4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 Schematic representation of primer position in the nucleotide sequence of the heavy chain variable domain

FIG. 2A-2B Schematic representation of primer position in the nucleotide sequence of the light chain variable domain; (A) $\kappa$ chain; (B) $\lambda$ chain.

FIG 3 Exemplary alignment of amino acid sequences of heavy chain variable domains ( $\mathrm{V}_{\mathrm{H}}$ domains) selected by the methods of the invention.

FIG. 4 Exemplary alignment of amino acid sequences of light chain variable domains ( $\mathrm{V}_{\mathrm{L}}$ domains) selected by methods of the invention.

FIG. 5 Schematic representation of expression vector allowing expression of SDVL and/or SDVH domains as fusion proteins with CAT.

FIG. 6A-B Intrinsic fluorescence of the unfolding transition curves of a representatinve SDVL domain of the invention. (A) Heat induced unfolding; (B) GdmCl induced unfolding.

## 5. DETAILED DESCRIPTION

### 5.1 Immunospecific Polypeptides

The present invention relates to modified, engineered immunospecific polypeptides, e.g., antibodies, having $\mathrm{V}_{\mathrm{H}}$ and or $\mathrm{V}_{\mathrm{L}}$ domains, or portions thereof (e.g., CDR domains, framework domains, etc.) derived from rabbits. In preferred embodiments, the present invention encompasses single domain antibodies derived from rabbit immunoglobulin variable domains and/or epitope binding fragments thereof. The present inventors have discovered that rabbit variable domains maintain unique stability, and retain high binding affinity when recombinantly expressed as single domains.

The present invention encompasses methods for the isolation and use of rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains and/or novel CDR and framework regions derived therefrom. The invention further provides for the identification of novel amino acid sequences (including novel amino acid residues at defined positions) within isolated rabbit $\mathrm{V}_{\mathrm{H}}$ and $V_{L}$ domains for usc as "scaffold" or structural sequences in the context of CDR loops
and/or framework regions in recombinant immunospecific polypeptides. The rabbit scaffold sequences (including scaffold residues) or novel CDR/framework sequences of the invention enhance the stability and/or affinity of the variable domain(s) and/or immunospecific polypeptides (e.g., antibodies) that contain them, in particular, relative to rodent antibodies, enabling the production and/or use of highly specific, single domain immunopeptides, e.g., single domain antibodies.

The present invention encompasses the production of novel rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains with specificity for a given antigen, or epitope thereof. In particular, the invention provides for a method of producing rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains said method comprising: (a) selecting from a phage expression library a set of DNA sequences that encode rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to a desired antigen or epitope thereof (also known as phage "panning") and (b) expressing the set of sequences, or a subset thereof, in bacteria as a fusion protein with chloramphenicol acetyltransferase ("CAT") and selecting bacteria that have chloramphenicol resistance by virtue of CAT expression. In alternate embodiments, the present invention provides for a method of producing rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains, said method comprising (a) expressing sequences of DNA or cDNA encoding $V_{H}$ or $V_{L}$ domains of rabbit immunoglobulins in bacteria as a fusion protein with CAT, (b) selecting bacteria that have chloramphenicol resistance by virtue of CAT expression and obtaining the set of DNA sequences encoding the rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria, and (c) preparing a phage expression library from the set of DNA sequences obtained in step (b) and selecting DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to a desired antigen or epitope thereof (i.e., panning the library for immunospecific binding to the antigen or epitope). In certain embodiments, the present invention encompasses methods for the production of a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain wherein the phage panning step is repeated one or more times. In related embodiments, the phage panning step may or may not be repeated sequentially. The phage expression library for use in accordance with the present invention may be obtained commercially or prepared by any method described herein and/or known in the art. Expression of DNA or cDNA sequences in bacteria as fusion proteins is well known and may be performed by any method described herein or known in the art, e.g., cloning the DNA or cDNA sequence encoding the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain into an expression vector that comprises a nucleotide
sequence encoding CAT and a promoter sequence that drives fusion protein expression. The invention further encompasses the $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domain, or fragments thereof, produced by the methods described herein. The invention also encompasses the novel scaffold amino acid sequences or scaffold amino acid residues (at defined positions of the variable domain of the invention) isolated and/or identified by these methods.

In one embodiment, the present invention provides single domain antibodies comprising two $\mathrm{V}_{\mathrm{H}}$ domains. In another embodiment, the present invention provides a fragment of a single domain antibody comprising one VH domain. In still other embodiments, the invention provides an immunospecific polypeptide comprising a single $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain and not comprising any other immunoglobulin derived domain (e.g., CL domain, $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{2}$ domain, $\mathrm{CH}_{3}$ domain, Fc domain, etc.). Prior to the instant invention, single domain antibodies were based primarily on the antibodies of the genus Camelus, i.e., camelized single domain antibodies (See e.g., Muyldermans et al., 2001, Trends Biochem. Sci. 26:230; Nuttall et al., 2000, Cur. Pharm. Biotech. 1:253; Reichmann and Muyldermans, 1999, J. Immunol. Meth. 231:25; International Publication Nos. WO 94/04678 and WO 94/25591; U.S. Pat. No. 6,005,079; which are incorporated herein by reference in their entireties). In certain embodiments the immunospecific polypeptides of the invention are bispecific or multispecific. Bi- or multi-specific molecules of the invention may be formed using any method known in the art and/or described herein, e.g., formed by the creation of a fusion or conjugate peptide. The bispecific or multispecifc molecules of the invention çomprise at least one $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain, or at least one framework region of a variable domain, identified, isolated or constructed according to the methods of the invention. In certain embodiments, a certain embodiments, the bispecific or multispecific molecule of the invention comprises more than one $\mathrm{V}_{\mathrm{L}}$ and/or more than one $\mathrm{V}_{\mathrm{L}}$ domain, which domains were isolated, identified and/or constructed by the methods of the invention. Immunospecific polypeptides, e.g., antibodies, of the invention include, but are not limited to single domain antibodies, monoclonal antibodies, multispecific antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, polyclonal antibodies, single-chain Fvs (scFv), single chain antibodies, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-anti-Id antibodies to antibodies of the invention), diabodies, minibodies, nanobodies, or antigen binding fragments of any of the above,
including, but not limited to, Fab fragments, $F(a b ')$ fragments, disulfide-linked bispecific Fvs (sdFv), and intrabodies, and epitope binding fragments thereof. In particular, the immunospecific polypeptides, e.g., antibodies, of the present invention include single domain antibodies or immunoglobulin molecules and immunologically active portions of immunoglobulin molecules.

The CDRs, scaffold amino acid sequences and/or scaffold amino acid residues of the immunospecific polypeptides, e.g., antibodies, of the present invention may be derived from any member of the Leporidae family (e.g., rabbits and hares) and are preferably derived from rabbits (e.g., New Zealand White rabbits). In certain embodiments, the polypeptides of the invention are humanized monoclonal antibodies.
The present invention also encompasses immunospecific polypeptides or fragments thereof comprising an amino acid sequence of a framework domain that is at least $45 \%$, at least $50 \%$, at least $55 \%$, at least $60 \%$, at least $65 \%$, at least $70 \%$, at least $75 \%$, at least $80 \%$, at least $85 \%$, at least $90 \%$, at least $95 \%$, or at least $99 \%$ identical to the amino acid sequence of a framework domain of the invention. In certain embodiments, the invention encompasses framework domains that comprise $1,2,3,4,5,6,7,8,9$, or 10 amino acid modifications (e.g., insertion, substitution, deletion, etc.) relative to a framework domain of the invention. The present invention further encompasses immunospecific polypeptides or fragments thereof comprising an amino acid sequence of one or more CDRs that is at least $45 \%$, at least $50 \%$, at least $55 \%$, at least $60 \%$, at least $65 \%$, at least $70 \%$, at least $75 \%$, at least $80 \%$, at least $85 \%$, at least $90 \%$, at least $95 \%$, or at least $99 \%$ identical to the amino acid sequence of one or more CDRs of the invention. In certain embodiments, the invention encompasses CDRs that comprise 1 , $2,3,4$, or 5 amino acid modifications (e.g., insertion, substitution, deletion, etc.) relative to a CDR of the invention. The determination of percent identity of two amino acid sequences can be determined by any method known to one skilled in the art.
The present invention also encompasses the use of immunospecific polypeptides or fragments thereof comprising the amino acid sequence of any of the variable domains, CDRs, amino acid scaffold sequences, or amino acid scaffold residues (e.g., in the heavy chain variable domain FR2 positions $46,53,54,56$ and 58 , in the heavy chain domain CDR1 positions 44 and 59, in the heavy chain variable domain FR4 position 126, in the light chain variable domain FR2 positions 39 and 45, and in the light chain
variable domain FR3 position 91) of the invention with mutations (e.g., one or more amino acid substitutions) in any of the above. In specific examples in accordance with this embodiment, the present invention encompasses immunospecific polypeptides comprising one or more amino acid substitutions, wherein said substations result in one or more of, at position 46 in the $V_{H}$ FR2 domain, a phenylalanine; at position 53 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glutamic acid; at position 54 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an arginine; at position 46 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glycine; at position 58 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an alanine; at position 44 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 59 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 126 in the $\mathrm{V}_{\mathrm{H}}$ FR4 domain, a cysteine; at position 39 in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a phenylalanine or a tyrosine; at position 45 in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a lysine; or at position 91 of the $\mathrm{V}_{\mathrm{L}}$ FR3 domain, a cysteine. Preferably, mutations in these regions, domains or residues maintain or enhance the avidity and/or affinity of the immunospecific polypeptide for the antigen, i.e. epitope, to which they immunospecifically bind. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an immunospecific polypeptide, e.g., antibody, for a particular antigen.
In other embodiments, the present invention encompasses the use of immunospecific polypeptides or fragments thereof comprising amino acid sequences of any of the variable domains, CDRs, amino acid scaffold sequences, or comprising the amino acid scaffold residues (e.g., in the heavy chain variable domain FR2 positions $46,53,54,56$ and 58, in the heavy chain domain CDR1 positions 44 and 59, in the heavy chain variable domain FR4 position 126, in the light chain variable domain FR2 positions 39 and 45, and in the light chain variable domain FR3 position 91) identified herein. In certain embodiments, the present invention encompasses immunospecific polypeptides having one or more of, at position 46 in the $V_{H}$ FR2 domain, a phenylalanine; at position 53 in the $\mathrm{V}_{\mathrm{H}} \mathrm{FR} 2$ domain, a glutamic acid; at position 54 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an arginine; at position 46 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glycine; at position 58 in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an alanine; at position 44 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 59 in the $\mathrm{V}_{\mathrm{H}}$ CDR1 domain, a cysteine; at position 126 in the $\mathrm{V}_{\mathrm{H}}$ FR4 domain, a cysteine; at position 39 in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a phenylalanine or a tyrosine; at position 45 in the $V_{L}$ FR2 domain, a lysine; or at position 91 of the $V_{\mathrm{L}}$ FR3 domain, a cysteine. The scaffold residues identified herein may maintain or enhance the avidity
and/or affinity of the immunospecific polypeptide for the antigen, i.e. epitope, to which they immunospecifically bind, in particular, for embodiments of the invention comprising single domain binding proteins, i.e., a polypeptide comprising only a single $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain and not comprising any other immunoglobulin variable domain. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an immunospecific polypeptide, e.g., antibody, for a particular antigen.

The polypeptides used in the methods of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the immunospecific polypeptide of the present invention. For example, but not by way of limitation, derivatives include immunospecific polypeptides that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

In certain embodiments, the immunospecific molecules of the invention are modified to increase serum half-life in vivo. Methods well known in the art to increase serum halflife include conjugation or fusion to antibody domains including, but not limited to, antibody constant regions including Fc and/or hinge regions (see for example, U.S. Patent Nos. $5,565,335$, and $6,277,375$, each hereby incorporated by reference in its entirety, including all references cited therein), and/or other known elements such as interferon and/or thymosin targeting peptides, and permeability increasing proteins (see, e.g., U.S. Patent Nos. 6,319,691 and 5,643,570, respectively, each of which is incorporated herein by reference in its entirety, including all references cited within each respective patent). Where the immunospecific molecule of the invention comprises an IgG constant domain, such modifications can also include introduction of one or more amino acid modifications (i.e., substitutions, insertions or deletions) into said constant domain, or, preferably into an FcRn binding fragment thereof (preferably a Fc or hinge- Fc domain fragment). See, e.g., International Publication No. WO 98/23289; International Publication No. WO 97/34631; and U.S. Patent No. 6,277,375,
each of which is incorporated herein by reference in its entirety. Other modifications known in the art to extend the life of the molecules of the invention, include the use non-natural amino acids, for example in the D form, or, alternatively or additionally, the use of amino acid analogs, such as sulfur-containing forms of amino acids. Alternatively, the polynucleotides and genes of the invention can be recombinantly fused to elements that are useful in the preparation of immunogenic constructs for the purposes of vaccine formulation or elements useful for the isolation of the polypeptides provided.

The molecules of the invention may contain modifications to the C -and/or N -terminus which include, but are not limited to amidation or acetylation. In certain embodiments, the amino acid residues contain reactive side chains, for example carboxy side chain in glutamic acid, that can be capped by capping groups known in the art. Acetylation refers to the introduction of a $\mathrm{COCH}_{3}$ group either at the amino terminus or on the side chain(s) of at least one lysine in the peptide(s) or peptide fragment(s). Importantly, acetylation can regulate protein stability. For example, analysis of in vivo acetylated E2F1 shows that the acetylated version has a longer half-life (Martinez-Balbás et al., (2000): EMBO J. 19(4):662-71; see also Takemura et al. (1992) J Cell Sci. 103 ( Pt 4):953-64; each of which reference is hereby incorporated in its entirety). Accordingly, in certain embodiments, the amino-terminal of the immunospecific molecules of the invention are modified by acetylation. In certain embodiments, a lysine side chain in the immunospecific molecule is modified. In yet other embodiments, the immunospecific molecule of the invention is acetylated both at the amino terminus and on a lysine side chain.

The present invention also encompasses the use of immunospecific polypeptides comprising the amino acid sequence of any of the immunospecific polypeptides of the invention with mutations (e.g., one or more amino acid substitutions) in the framework or variable regions. Preferably, mutations in these regions maintain or enhance the avidity and/or affinity of the antibodies for the particular antigen(s), and/or epitope, to which they immunospecifically bind. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an antibody for a particular antigen.

Standard techniques known to those skilled in the art can be used to introduce mutations in the nucleotide sequence encoding an immunospecific polypeptide of the invention, or fragment thereof, including, e.g., site-directed mutagenesis and PCR-mediated mutagenesis, which results in amino acid substitutions. In certain embodiments, the derivatives have conservative amino acid substitutions made at one or more predicted non-essential amino acid residues.

The present invention also encompasses the use of immunospecific polypoeptides comprising the amino acid sequence of any of the immunospecific polypeptides of the invention with mutations (e.g., one or more amino acid substitutions) in the framework or variable regions. Preferably, mutations in these regions maintain or enhance the avidity and/or affinity of the antibodies for the particular antigen(s), and/or epitope, to which they immunospecifically bind. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an antibody for a particular antigen.

Immunospecific polypeptides of the invention, or fragments thereof, with increased in vivo half-lives can be generated by attaching to said polypeptides or fragments to polymer molecules such as high molecular weight polyethyleneglycol (PEG). PEG can be attached to said polypeptides or fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N - or C -terminus of said polypeptides or fragments or via epsilon-amino groups present on lysine residues Linear or branched polymer derivatization that results in minimal loss of biological activity can be used. The degree of conjugation can be closely monitored by SDSPAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the immunospecific polypeptides or fragments of the invention. Unreacted PEG can be separated from polypeptide-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.

For some uses, including in vivo use in humans and in vitro detection assays, it may be preferable to use chimeric or humanized molecules.

Nucleic acid sequences encoding rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to an antigen and/or an epitope are selected for both affinity and stability using sequential screening methods for each characteristic. Using the methods of the invention, initial pools encoding rabbit variable domains will become enriched in
sequences encoding immunospecific polypeptides, e.g., rabbit variable domains, that exhibit high affinity for an antigen of interest as well as high stability (e.g., the capacity to be properly expressed and folded in recombinant systems, the capacity to resist degradation or aggregation in these systems, an to retain its functional characteristic of immunospecific binding). In certain embodiments, the polypeptides encoded by the sequences are selected for immunospecific binding to an antigen prior to being selected for stability. In other embodiments, the polypeptides encodes by the sequences are selected for stability prior to being selected for immunospecific binding to an antigen. The invention encompasses methods wherein the either or both of the binding selection and/or stability selection step(s) is repeated one or more times. The invention further encompasses methods wherein the binding selection and stability selection steps, and/or repeats thereof, are performed in any order one or more times.

### 5.1.1 Affinity Selection Using Phage Display

Rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to an antigen and/or an epitope are selected using the various phage display and panning methods known in the art. Using phage display methods, functional rabbit variable domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. The phage particles are then contacted with an antigen and/or epitope of interest and the particles exhibiting immunospecific binding to said antigen and/or epitope are selected or identified using methods well known in the art, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Examples of phage display methods that can be used in accordance with the methods of the invention include those disclosed in Brinkman et al., J. Immunol. Methods, 182:41-50, 1995; Ames et al., J. Immunol. Methods, 184:177-186, 1995; Kettleborough et al., Eur. J. Immunol., 24:952-958, 1994; Persic et al., Gene, 187:9-18, 1997; Burton et al., Advances in Immunology, 57:191280, 1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; $5,750,753 ; 5,821,047 ; 5,571,698 ; 5,427,908 ; 5,516,637 ; 5,780,225 ; 5,658,727$; $5,733,743$ and $5,969,108$; each of which is incorporated herein by reference in its entirety.

The phage display libraries for use in the methods of the invention may be obtained commercially or derived from the antibody repertoires of naïve or immunized rabbits as described herein and/or known in the art. As is known in the art, the polypeptide encoded by the nucleic acid in the phagemid vector, and thus expressed on the surface of the phage, may be a single rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain, may be a single chain antibody, may be a scFv or may be any fragment of the rabbit heavy or light chain. In certain embodiments, each phage particle expresses a single variable domain on its surface. In alternate embodiments, the phage particle expresses a $\mathrm{V}_{\mathrm{H}}$ and a $\mathrm{V}_{\mathrm{L}}$ domain on its surface, such that the $\mathrm{V}_{\mathrm{H}}$ and $\mathrm{V}_{\mathrm{L}}$ domains interact to form binding pair.

The phage particles used in phage display and panning methods are filamentous phage and may be selected from class I phages (e.g., fd, M13, fl, Ifl, ke, ZJ/Z, Ff, etc.) or class II phages (e.g., Xf, Pfl, Pf3, etc.), or derivatives thereof. The nucleotide sequences encoding the portions of the rabbit heavy and/or light chains, e.g., rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains, are expressed from a phagemid vector, which drives expression of the sequence in the host cell (i.e., bacteria) as a fusion with the gene III capsid protein (pIII) of phage fd or its counterpart in another filamentous phage. Phage display technology encompasses the use of a helper phage, or a plasmid encoding complementing phage genes, to help package the phagemid genome, wherein the pIII fusion protein is a capsid protein therefor.
Individual phage particles expressing the portions of the rabbit heavy or light chains, and thus comprising the nucleotide sequence encoding said portions, that exhibit specificity for a desired antigen can be isolated from the library using screening methods known in the art (see, e.g., Gherardi et al., 1990, J Immunol Meth 126:61-68, hereby incorporated by reference herein in its entirety). Selection may be accomplished by anchoring the antigen and/or epitope of interest to a solid surface (e.g., culture dish, microtitre plate, chromatography beads, magnetic beads, etc.) and passing the library of phage particles over the bound antigen ad/or epitope. Those individual phage that bind are retained after washing and optionally detected by any detection system known in the art (e.g., anti-fd antibody-enzyme conjugates). In specific embodiments, the pIII fusion protein further comprises a target amino acid sequence to facilitate detection by antitarget antibody-enzyme conjugates. Bound phage particles may be removed under increasingly stringent wash conditions to select for increasing binding affinity. The
stringency of the wash condition can be increased by any method known in the art, e.g., by alteration of the wash pH , by increasing the time of the wash, by adding detergent to the wash solution, etc. In specific embodiments, the set of bound phage particles is collected and re-selected for immunospecific binding to target antigen and/or epitope one or more times. Phage display selection may be performed before or after or both before and after selection of polypeptides of the invention by stability analysis.
Phage display technology can be used to increase the affinity of an immunospecific polypeptide of the invention for a target antigen and/or epitope. The technology, referred to as affinity maturation, employs mutagenesis or CDR walking and reselection using target antigen and/or an epitope thereof to identify amino acid sequences of the invention that bind with higher affinity to the antigen when compared with the initial pool of selected sequences. Mutagenizing entire codons rather than single nucleotides results in a semi-randomized repertoire of amino acid mutations. Libraries can be constructed consisting of a pool of variant clones each of which differs by a single amino acid alteration in a single CDR and which contain variants representing each possible amino acid substitution for each CDR residue. Mutants with increased binding affinity for the antigen can be screened by contacting the immobilized mutants with labeled antigen. Any screening method known in the art can be used to identify mutant antibodies with increased avidity to the antigen (e.g., ELISA) (See Wu et al., 1998, Proc Natl. Acad. Sci. USA 95:6037; Yelton et al., 1995, J. Immunology 155:1994, each of which is hereby incorporated by reference herein in its entirety).
The binding specificity of the polypeptides of the invention may be evaluated by any method known in the art for determining binding-pair interactions, including, but not limited to ELISA, western blot, surface plasmon resonance (e.g., BIAcore) and radioimmunoassay. Any method known in the art for assessing binding polypeptide specificity may be used to identify polypeptides of the invention that exhibit a Kd of greater than 0.001 nM but not greater than 5 nM , not greater than 10 nM , not greater than 15 nM , not greater than 20 nM , not greater than 25 nM , not greater than 30 nM , not greater than 35 nM , not greater than 40 nM , not greater than 45 nM , or not greater than 50 nM . In certain embodiments, the isolated $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains of the invention exhibit a Kd of no greater than 5 nM , no greater than 10 nM , no greater than 15 nM , no greater than 20 nM , no greater than 25 nM , no greater than 30 nM , no greater than 35 nM , no
greater than 40 nM , no greater than 45 nM , or no greater than 50 nM as determined by BIAcore assay.

The present invention also provides for immunospecific polypeptides of the invention, or fragments thereof, that have a high binding affinity for the antigen of interest. In a specific embodiment, an immunospecific polypeptide of the present invention or fragment thereof has an association rate constant or $\mathrm{k}_{\text {on }}$ rate (antibody (Ab)+antigen ( Ag ) $\mathrm{Ab}-\mathrm{Ag}$ ) of at least $10^{5} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $5 \times 10^{5} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $10^{6} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $5 \times 10^{6} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $10^{7} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $5 \times 10^{7} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, or at least $10^{8} \mathrm{M}^{-1} \mathrm{~s}^{-1}$. In a preferred embodiment, an immunospecific polypeptide of the present invention or fragment thereof has a $\mathrm{k}_{\text {on }}$ of at least $2 \times 10^{5} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $5 \times 10^{5} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $10^{6} \mathrm{M}^{-1}$ $\mathrm{s}^{-1}$, at least $5 \times 10^{6} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $10^{7} \mathrm{M} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, at least $5 \times 10^{7} \mathrm{M}^{-1} \mathrm{~s}^{-1}$, or at least $10^{8} \mathrm{M}^{-1}$ $\mathrm{s}^{-1}$.

In another embodiment, an immunospecific polypeptide of the present invention or fragment thereof has a $\mathrm{k}_{\text {off }}$ rate (antibody ( Ab ) +antigen ( Ag ) $\mathrm{Ab}-\mathrm{Ag}$ ) of less than $10^{-1} \mathrm{~s}^{-}$ ${ }^{1}$, less than $5 \times 10^{-1} \mathrm{~s}^{-1}$, less than $10^{-2} \mathrm{~s}^{-1}$, less than $5 \times 10^{-2} \mathrm{~s}^{-1}$, less than $10^{-3} \mathrm{~s}^{-1}$, less than $5 \times 10^{-3} \mathrm{~s}^{-1}$, less than $10^{-4} \mathrm{~s}^{-1}$, less than $5 \times 10^{-4} \mathrm{~s}^{-1}$, less than $10^{-5} \mathrm{~s}^{-1}$, less than $5 \times 10^{-5} \mathrm{~s}^{-1}$, less than $10^{-6} \mathrm{~s}^{-1}$, less than $5 \times 10^{-6} \mathrm{~s}^{-1}$, less than $10^{-7} \mathrm{~s}^{-1}$, less than $5 \times 10^{-7} \mathrm{~s}^{-1}$, less than $10^{-8}$ $\mathrm{s}^{-1}$, less than $5 \times 10^{-8} \mathrm{~s}^{-1}$, less than $10^{-9} \mathrm{~s}^{-1}$, less than $5 \times 10^{-9} \mathrm{~s}^{-1}$, or less than $10^{-10} \mathrm{~s}^{-1}$. In a preferred embodiment, an immunospecific polypeptide of the present invention or fragment thereof has a $k_{\text {off }}$ of less than $5 \times 10^{-4} \mathrm{~s}^{-1}$, less than $10^{-5} \mathrm{~s}^{-1}$, less than $5 \times 10^{-5} \mathrm{~s}^{-1}$, less than $10^{-6} \mathrm{~s}^{-1}$, less than $5 \times 10^{-6} \mathrm{~s}^{-1}$, less than $10^{-7} \mathrm{~s}^{-1}$, less than $5 \times 10^{-7} \mathrm{~s}^{-1}$, less than $10^{-8}$ $\mathrm{s}^{-1}$, leșs than $5 \times 10^{-8} \mathrm{~s}^{-1}$, less than $10^{-9} \mathrm{~s}^{-1}$, less than $5 \times 10^{-9} \mathrm{~s}^{-1}$, or less than $10^{-10} \mathrm{~s}^{-1}$.
In still other embodiments, an immunospecific polypeptide of the present invention or fragment thereof has an affinity constant or $\mathrm{K}_{\mathrm{a}}\left(\mathrm{k}_{\text {on }} / \mathrm{K}_{\text {off }}\right)$ of at least $10^{2} \mathrm{M}^{-1}$, at least $5 \times 10^{2} \mathrm{M}^{-1}$, at least $10^{3} \mathrm{M}^{-1}$, at least $5 \times 10^{3} \mathrm{M}^{-1}$, at least $10^{4} \mathrm{M}^{-1}$, at least $5 \times 10^{4} \mathrm{M}^{-1}$, at least $10^{5} \mathrm{M}^{-1}$, at least $5 \times 10^{5} \mathrm{M}^{-1}$, at least $10^{6} \mathrm{M}^{-1}$, at least $5 \times 10^{6} \mathrm{M}^{-1}$, at least $10^{7} \mathrm{M}^{-1}$, at least $5 \times 10^{7} \mathrm{M}^{-1}$, at least $10^{8} \mathrm{M}^{-1}$, at least $5 \times 10^{8} \mathrm{M}^{-1}$, at least $10^{9} \mathrm{M}^{-1}$, at least $5 \times 10^{9} \mathrm{M}^{-1}$, at least $10^{10} \mathrm{M}^{-1}$, at least $5 \times 10^{10} \mathrm{M}^{-1}$, at least $10^{11} \mathrm{M}^{-1}$, at least $5 \times 10^{11} \mathrm{M}^{-1}$, at least $10^{12}$ $\mathrm{M}^{-1}$, at least $5 \times 10^{12} \mathrm{M}^{-1}$, at least $10^{13} \mathrm{M}^{-1}$, at least $5 \times 10^{13} \mathrm{M}^{-1}$, at least $10^{14} \mathrm{M}^{-1}$, at least $5 \times 10^{14} \mathrm{M}^{-1}$, at least $10^{15} \mathrm{M}^{-1}$, or at least $5 \times 10^{15} \mathrm{M}^{-1}$. In yet another embodiment, an immunospecific polypeptide of the present invention or fragment thereof has a dissociation constant or $\mathrm{K}_{\mathrm{d}}\left(\mathrm{k}_{\mathrm{off}} / \mathrm{k}_{\mathrm{on}}\right)$ of less than $10^{-2} \mathrm{M}$, less than $5 \times 10^{-2} \mathrm{M}$, less than
$10^{-3} \mathrm{M}$, less than $5 \times 10^{-3} \mathrm{M}$, less than $10^{-4} \mathrm{M}$, less than $5 \times 10^{-4} \mathrm{M}$, less than $10^{-5} \mathrm{M}$, less than $5 \times 10^{-5} \mathrm{M}$, less than $10^{-6} \mathrm{M}$, less than $5 \times 10^{-6} \mathrm{M}$, less than $10^{-7} \mathrm{M}$, less than $5 \times 10^{-7}$ M , less than $10^{-8} \mathrm{M}$, less than $5 \times 10^{-8} \mathrm{M}$, less than $10^{-9} \mathrm{M}$, less than $5 \times 10^{-9} \mathrm{M}$, less than $10^{-10} \mathrm{M}$, less than $5 \times 10^{-10} \mathrm{M}$, less than $10^{-11} \mathrm{M}$, less than $5 \times 10^{-11} \mathrm{M}$, less than $10^{-12} \mathrm{M}$, less than $5 \times 10^{-12} \mathrm{M}$, less than $10^{-13} \mathrm{M}$, less than $5 \times 10^{-13} \mathrm{M}$, less than $10^{-14} \mathrm{M}$, less than $5 \times 10^{-14} \mathrm{M}$, less than $10^{-15} \mathrm{M}$, or less than $5 \times 10^{-15} \mathrm{M}$..

### 5.1.2 Solubility/Stability Selection of Immunospecific Polypeptides

Nucleotide sequences encoding rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domains that exhibit high stability are selected using a modified chloramphenicol resistance assay. The assay selects for polypeptides that exhibit remain soluble, are properly folded, and resist aggregation during recombinant expression.
The method of stability selection is based on assessing solubility of the recombinant protein as expressed in $E$. coli as a fusion with chloramphenicol acetyltransferase ("CAT"), the enzyme responsible for conferring bacterial resistance to the antibiotic chloramphenicol. CAT is a highly soluble homotrimeric protein of 25 kDa molecular weight that has been shown to maintain activity when fused to a variety of other proteins (Robben et al., 1993, Gene 126:109-113). The level of activity of CAT in fusion proteins (and thus resistance to chloramphenicol), however, is significantly lower when the gene is expressed in a fusion protein with insoluble protein than when expressed as a construct with soluble protein. Accordingly, soluble forms of the polypeptides of the invention (e.g., rabbit $\mathrm{V}_{\mathrm{H}}$ and $\mathrm{V}_{\mathrm{L}}$ domains) can be selected out of a large pool of potential proteins by selection with chloramphenicol. Bacteria comprising the nucleotide sequences of the invention may be selected using liquid media or bacterial plates. The present invention encompasses methods comprising culturing said transformed bacteria on selective media comprising at least 0.1 mM , at least 0.2 mM , at least 0.4 mM , at least 0.6 mM , at least 0.8 mM , at least 1.0 mM , at least 1.2 mM , at least 1.4 mM , at least 1.6 mM , at least 1.8 mM , at least 2.0 mM , at least 2.5 mM , at least 3.0 mM , at least 5.0 mM , at least 10 mM , at least 15 mM , or at least 20 mM chloramphenicol. The bacteria may be transformed, and the DNA extracted from the selected bacteria, by any method known in the art.
The invention also encompasses other assays known in the art for evaluation of protein stability. Nonlimiting examples of such assays are single molecule force spectroscopy,
assessment of alterations in intrinsic fluorescence, assessment of thermal denaturation, e.g., monitored by dynamic light scattering ("DLS"), and resistancè to SDS denaturation (see, e.g., U.S. Patent Application publication 2006/0099647, hereby incorporated by reference in its entirety). The methods of the present invention further encompass determination of the Gibbs free energy of folding ( $\Delta \mathrm{G}_{\mathrm{N}-\mathrm{U}}$ ) as a method of determining stability. In certain embodiments $\Delta \mathrm{G}_{\mathrm{N}-\mathrm{U}}$ of the molecules of the invention is about 1 $\mathrm{kJ} / \mathrm{mol}$, about $2 \mathrm{~kJ} / \mathrm{mol}$, about $\cdot 4 \mathrm{~kJ} / \mathrm{mol}$, about $6 \mathrm{~kJ} / \mathrm{mol}$, about $8 \mathrm{~kJ} / \mathrm{mol}$, about 10 $\mathrm{kJ} / \mathrm{mol}$, about $12 \mathrm{~kJ} / \mathrm{mol}$, about $14 \mathrm{~kJ} / \mathrm{mol}$, about $16 \mathrm{~kJ} / \mathrm{mol}$, about $18 \mathrm{~kJ} / \mathrm{mol}$, about 20 $\mathrm{kJ} / \mathrm{mol}$, about $21 \mathrm{~kJ} / \mathrm{mol}$, about $22 \mathrm{~kJ} / \mathrm{mol}$, about $23 \mathrm{~kJ} / \mathrm{mol}$, about $24 \mathrm{~kJ} / \mathrm{mol}$, about 25 $\mathrm{kJ} / \mathrm{mol}$, about $26 \mathrm{~kJ} / \mathrm{mol}$, about $27 \mathrm{~kJ} / \mathrm{mol}$, about $28 \mathrm{~kJ} / \mathrm{mol}$, about $29 \mathrm{~kJ} / \mathrm{mol}$, about 30 $\mathrm{kJ} / \mathrm{mol}$, about $32 \mathrm{~kJ} / \mathrm{mol}$, about $34 \mathrm{~kJ} / \mathrm{mol}$, about $36 \mathrm{~kJ} / \mathrm{mol}$, about $38 \mathrm{~kJ} / \mathrm{mol}$, about 40 $\mathrm{kJ} / \mathrm{mol}$, about $45 \mathrm{~kJ} / \mathrm{mol}$, or about $50 \mathrm{~kJ} / \mathrm{mol}$.

Any other method known in the art for monitoring protein folding/unfolding may also be used in accordance with the methods of the invention.

### 5.2 Humanized Molecules

In preferred embodiments, the immunospecific polypeptides of the invention and/or fragments thereof are humanized. A humanized molecule of the present invention is a polypeptide comprising at least one immunoglobulin variable domain (or a variant or fragment thereof) that is capable of immunospecifically binding to a predetermined antigen and that comprises a framework region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a rabbit immunoglobulin isolated and/or identified by the methods described herein. A humanized immunospecific polypeptide of the invention may comprise substantially all of at least one, or, in certain embodiments, two, variable domains in which all or substantially all of the CDR regions correspond to those of a rabbit variable domain isolated/identified by the methods of the present invention (i.e., donor domain/regions) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. In certain embodiments, a humanized molecule of the invention also comprises at least a portion of an immunoglobulin constant region $(\mathrm{Fc})$, typically that of a human immunoglobulin. The constant domains of the humanized molecules of the invention may be selected with respect to the proposed function of the immunospecific polypeptide, e.g., antibody, in particular the
effector function which may be required. In some embodiments, the constant domains of the humanized molecules of the invention are human $\operatorname{IgA}, \operatorname{IgE}, \operatorname{IgG}$ or $\operatorname{IgM}$ domains. In a specific embodiment, human IgG constant domains, especially of the IgG1 and IgG3 isotypes are used, when the humanized molecules of the invention are intended for therapeutic uses and antibody effector functions are desired. In alternative embodiments, IgG2 and IgG4 isotypes are used when the humanized molecule of the invention is intended for therapeutic purposes and antibody effector function is not required.
In some embodiments, the immunospecific polypeptides of the invention comprise only a heavy chain, only a light chain, only a $\mathrm{V}_{\mathrm{H}}$ domain, only a $\mathrm{V}_{\mathrm{L}}$ domain, or any combination of the above fragments and/or domains. In other embodiments, the immunospecific polypeptide, or fragment, of the invention may further comprise none, one, or one or more of the CH 1 , hinge, $\mathrm{CH} 2, \mathrm{CH} 3$, and CH 4 regions of the heavy chain. In other embodiments, the immunospecific polypeptide, or fragment, of the invention does not comprise a CL domain. The immunospecific polypeptide, or fragment, of the invention may comprise a receptor antibody selected from any class of immunoglobulins, including $\operatorname{IgM}, \operatorname{IgG}, \operatorname{IgD}, \operatorname{IgA}$ and $\operatorname{IgE}$, and any isotype, including $\mathrm{IgG}_{1}, \mathrm{IgG}_{2}, \mathrm{IgG}_{3}$ and $\mathrm{IgG}_{4}$. In some embodiments, the constant domain is a complement fixing constant domain where it is desired that the humanized molecule, e.g., antibody, exhibit cytotoxic activity, and the class is typically $\operatorname{IgG}_{1}$. In other embodiments, where such cytotoxic activity is not desirable, the constant domain may be of the $\mathrm{IgG}_{2}$ class. The humanized molecule of the invention may comprise sequences from more than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
The framework and CDR regions of a humanized molecule of the invention need not correspond precisely to the parental sequences, e.g., the donor rabbit CDR or the consensus framework may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or framework residue at that site does not correspond to either the consensus or the donor molecule. Such mutations, however, are preferably not extensive. Usually, at least $75 \%$ of the humanized residues will correspond to those of the parental framework region (FR) and CDR sequences, more often $90 \%$, and most preferably greater than $95 \%$. Humanized molecules, in particular, antibodies, can be
produced using variety of techniques known in the art, including but not limited to, CDR-grafting (European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; and Roguska et al., 1994, Proc Natl Acad Sci USA 91:969-973), chain shuffling (U.S. Pat. No. 5,565,332), and techniques disclosed in, e.g., U.S. Pat. Nos. 6,407,213, 5,766,886, 5,585,089, International Publication No. WO 9317105, Tan et al., 2002, J. Immunol. 169:1119-25, Caldas et al., 2000, Protein Eng. 13:353-60, Morea et al., 2000, Methods 20:267-79, Baca et al., 1997, J. Biol. Chem. 272:10678-84, Roguska et al., 1996, Protein Eng. 9:895-904, Couto et al., 1995, Cancer Res. 55 (23 Supp):5973s-5977s, Couto et al., 1995, Cancer Res. 55:1717-22, Sandhu, 1994, Gene 150:409-10, Pedersen et al., 1994, J. Mol. Biol. 235:959-73, Jones et al., 1986, Nature 321:522-525, Riechmann et al., 1988, Nature 332:323, and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR or the donor rabbit variable domain to alter, preferably improve, antigen binding (i.e., substitution the scaffold amino acid sequences and/or residues identified by the methods of the present invention). These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; U.S. Publication Nos. 2004/0049014 and 2003/0229208; U.S. Pat. Nos. $6,350,861 ; 6,180,370 ; 5,693,762 ; 5,693,761 ; 5,585,089$; and $5,530,101$ and Riechmann et al., 1988, Nature 332:323, all of which are incorporated herein by reference in their entireties). ). The term "humanization" also includes methods of protein and/or antibody resurfacing such as those disclosed in U.S. patents $5,770,196 ; 5,776,866 ; 5$, 821,123 ; and $5,896,619$, each to Studnicka et al. (each of which is incorporated herein by reference in its entirety).

In some embodiments, the immunospecific polypeptides, or fragments thereof, of the invention comprise a humanized molecule wherein at least one CDR from the donor rabbit variable domain is grafted onto the recipient framework region. In other
embodiments, at least two and preferably all three CDRs of the donor rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains are grafted onto the recipient framework regions.

### 5.3 Chimeric Molecules

A chimeric molecule of the invention is a molecule in which different portions of the immunospecific polypeptide are derived from different immunoglobulin molecules such as molecules having a variable region derived from a rabbit heavy chain or light chain and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, 1985, Science 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J. Immunol. Methods 125:191-202; and U.S. Pat. Nos. $6,311,415,5,807,715,4,816,567$, and $4,816,397$, which are incorporated herein by reference in their entirety. Chimeric molecules of the invention comprising one or more CDRs from the rabbit donor molecules of the invention and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7:805; and Roguska et al., 1994, PNAS 91:969), and chain shuffling (U.S. Pat. No. $5,565,332$ ). Each of the above-identified references is incorporated herein by reference in its entirety.
Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR rabbit donor variable domains to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, Nature 332:323, which are incorporated herein by reference in their entireties.).

### 5.4 Conjugate Molecules

The present invention encompasses immunospecific polypeptides, e.g., antibodies, recombinantly fused or chemically conjugated (including both covalently and noncovalently conjugations) to heterologous polypeptides (i.e., an unrelated polypeptide; or
portion thereof, preferably at least 10 , at least 20 , at least 30 , at least 40 , at least 50 , at least 60 , at least 70 , at least 80 , at least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The immunospecific polypeptides of the invention may be used for example to target heterologous polypeptides to particular cell types, either in vitro or in vivo, by fusing or conjugating the heterologous polypeptides to molecules of the invention that exhibit immunospecificity for particular cell surface receptors. Alternatively or additionally, the heterologous polypeptides, in particular antigen binding heterologous polypeptides, may be used for example to target the immunospecific polypeptides of the invention to particular serum proteins or protein targets, either in vitro or in vivo, by fusing or conjugating the molecules of the invention to heterologous polypeptides that exhibit immunospecificity for particular c serum proteins or target proteins. Such fusions or conjugations result in bispecific or multispecific polypeptides of the invention. The immunospecific polypeptides of the invention fused or conjugated to heterologous polypeptides may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., PCT Publication No. WO 93/21232; EP 439,095; Naramura et al., 1994, Immunol. Lett., 39:91-99; U.S. Pat. No. 5,474,981; Gillies et al., 1992, Proc Natl Acad Sci, 89:14281432; and Fell et al., 1991, J. Immunol., 146:2446-2452, each of which is incorporated herein by reference in its entirety.
Further, an immunospecific polypeptide of the invention may be conjugated to a therapeutic agent or drug moiety that modifies a given biological response. Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin (i.e., PE-40), or diphtheria toxin, ricin, gelonin, and pokeweed antiviral protein, a protein such as tumor necrosis factor, interferons including, but not limited to, .alpha.-interferon (IFN-.alpha.), .beta.interferon (IFN-.beta.), nerve growth factor (NGF), platelet derived growth factor (PDGF), tissue plasminogen activator (TPA); an apoptotic agent (e.g., TNF-.alpha., TNF-.beta., AIM I as disclosed in PCT Publication No. WO 97/33899), AIM II (see, e.g., PCT Publication No. WO 97/34911), Fas Ligand (Takahashi et al., 1994, J.

Immunol., 6:1567-1574), and VEGI (PCT Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent (e.g., angiostatin or endostatin), or a biological response modifier such as, for example, a lymphokine (e.g., interleukin-1, ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), and granulocyte colony stimulating factor ("G-CSF")), macrophage colony stimulating factor, ("M-CSF"), or a growth factor (e.g.; growth hormone (" GH "); a protease, or a ribonuclease.
Immunospecific polypeptides of the invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. As described in Gentz et al., 1989, Proc. Natl. Acad. Sci. USA, 86:821-824. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., 1984,Cell, 37:767, hereby incorporated by reference in its entirety) and the "flag" tag (Knappik et al., 1994, Biotechniques, 17(4):754-761, hereby incorporated by reference in its entirety).
The present invention further includes the use of compositions comprising heterologous polypeptides fused or conjugated to fragments of the molecules of the invention. For example, the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fc fragment, Fv fragment, $\mathrm{F}(\mathrm{ab})_{2}$ fragment, scFv , minibody, nanobody or portion thereof. Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See, e.g., U.S. Pat. Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, and 5,112,946; EP 307,434; EP 367,166; International Publication Nos. WO 96/04388 and WO 91/06570; Ashkenazi et al., 1991, Proc. Natl. Acad. Sci. USA 88: 10535-10539; Zheng et al., 1995, J. Immunol. 154:5590-5600; and Vil et al., 1992, Proc. Natl. Acad. Sci. USA 89:11337-11341 (said references incorporated by reference in their entireties).
Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to alter the activities of the immunospecific polypeptides of the invention, e.g., antibodies, or fragments thereof
(e.g., antibodies or fragments thereof with higher affinities and lower dissociation rates). See, generally, U.S. Pat. Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., 1997, Curr. Opinion Biotechnol. 8:724-33; Harayama, 1998, Trends Biotechnol. 16:76; Hansson, et al., 1999, J. Mol. Biol. 287:265; and Lorenzo and Blasco, 1998, BioTechniques 24:308 (each of these patents and publications are hereby incorporated by reference in its entirety). Nucleic acids of the invention or fragments thereof, or the encoded polypeptides or fragments thereof, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination.

The present invention also encompasses immunospecific polypeptides conjugated to a diagnostic or a therapeutic agent. Such molecules can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the polypeptide of the invention to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the immunospecific polypeptide of the invention or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 (hereby incorporated by reference in its entirety) for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Such diagnosis and detection can be accomplished by coupling the polypeptide of the invention to detectable substances including, but not limited to, various enzymes, enzymes including, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic group complexes such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials such as, but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent material such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, and aequorin; radioactive material such as, but not limited to, bismuth $\left({ }^{213} \mathrm{Bi}\right)$, carbon $\left({ }^{14} \mathrm{C}\right)$, chromium $\left({ }^{51} \mathrm{Cr}\right)$,
cobalt $\left({ }^{57} \mathrm{Co}\right)$, fluorine ( $\left.{ }^{18} \mathrm{~F}\right)$, gadolinium $\left({ }^{153} \mathrm{Gd}\right.$, $\left.{ }^{159} \mathrm{Gd}\right)$, gallium ( $\left({ }^{68} \mathrm{Ga},{ }^{67} \mathrm{Ga}\right)$, germanium $\left({ }^{68} \mathrm{Ge}\right)$, holmium $\left({ }^{166} \mathrm{Ho}\right)$, indium $\left({ }^{115} \mathrm{In},{ }^{113} \mathrm{In},{ }^{112} \mathrm{In},{ }^{111} \mathrm{In}\right)$, iodine $\left({ }^{131} \mathrm{I},{ }^{125} \mathrm{I}\right.$, $\left.{ }^{123} \mathrm{I},{ }^{121} \mathrm{I}\right)$, lanthanium $\left({ }^{140} \mathrm{La}\right)$, lutetium $\left({ }^{177} \mathrm{Lu}\right)$, manganese $\left({ }^{54} \mathrm{Mn}\right)$, molybdenum $\left({ }^{99} \mathrm{Mo}\right)$, palladium ( ${ }^{103} \mathrm{Pd}$ ), phosphorous ( ${ }^{32} \mathrm{P}$ ), praseodymium ( ${ }^{142} \mathrm{Pr}$ ), promethium ( ${ }^{149} \mathrm{Pm}$ ), rhenium ( ${ }^{186} \mathrm{Re},{ }^{188} \mathrm{Re}$ ), rhodium $\left({ }^{105} \mathrm{Rh}\right)$, ruthemium $\left({ }^{97} \mathrm{Ru}\right)$, samarium ( ${ }^{153} \mathrm{Sm}$ ), scandium ( $\left({ }^{47} \mathrm{Sc}\right)$, selenium ( ${ }^{75} \mathrm{Se}$ ), strontium $\left({ }^{85} \mathrm{Sr}\right)$, sulfur $\left({ }^{35} \mathrm{~S}\right)$, technetium $\left({ }^{99} \mathrm{Tc}\right)$, thallium $\left({ }^{20} 1 \mathrm{Ti}\right)$, tin $\left({ }^{113} \mathrm{Sn},{ }^{117} \mathrm{Sn}\right)$, tritium $\left({ }^{3} \mathrm{H}\right)$, xenon $\left({ }^{133} \mathrm{Xe}\right)$, ytterbium $\left({ }^{169} \mathrm{Yb},{ }^{175} \mathrm{Yb}\right)$, yttrium ( ${ }^{90} \mathrm{Y}$ ), zinc $\left({ }^{65} \mathrm{Zn}\right)$; positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. Additionally, any of the above tracer radio metals may exhibit therapeutic effect when conjugated to an immunospecific polypeptide in accordance with the methods of the invention.

An immunospecific polypeptide of the invention may be conjugated to a therapeutic moiety such as a cytotoxin (e.g., a cytostatic or cytocidal agent), a therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.). Cytotoxins or cytotoxic agents include any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B , gramicidin D , ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin $\mathrm{D}, 1$-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6 -mercaptopurine, 6 -thioguanine, cytarabine, 5 -fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C , and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

In certain embodiments, the immunospecific polypeptide of the invention can be conjugated to a therapeutic moiety such as siRNA useful for the treatment or prevention of diseases that are caused by over-expression or misexpression of gencs and diseases brought about by expression of genes that contain mutations. The mechanisms of
siRNA activity and it mode of use are well known in the art, see, e.g., Provost et al., 2002, EMBO J., 21: 5864-5874; Tabara et al., 2002, Cell 109:861-71; Ketting et al., 2002, Cell 110:563; and Hutvagner \& Zamore, 2002, Science 297:2056, each of which is hereby incorporated by reference herein in its entirety.

Moreover, an immunospecific polypeptide of the invention can be conjugated to therapeutic moieties such as a radioactive materials or macrocyclic chelators useful for conjugating radiometal ions (see above for examples of radioactive materials). In certain embodiments, the macrocyclic chelator is $1,4,7,10$-tetraazacyclododecane- $\mathrm{N}, \mathrm{N}, \mathrm{N}$ ", N "tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule. Such linker molecules are commonly known in the art and described in Denardo et al., 1998, Clin Cancer Res. 4:2483-90; Peterson et al., 1999, Bioconjug. Chem. 10:553; and Zimmerman et al., 1999, Nucl. Med. Biol. 26:943-50 each incorporated by reference in their entireties.

The immunospecific polypeptide of the invention may be conjugated to a therapeutic moiety that does not alter or modify biological response, but instead functions in targeting and/or transport of the immunospecific polypeptide or fragment thereof. Nonlimiting examples of such moieties include protein A, G proteins, albumin, albumin interacting peptides (e.g., gp60, gp30, gp18; see, e.g., Schnitzer et al., 1992, J Biol Chem 34:24544-24553); and protein transduction domains (see, e.g., Bogoyevitch et al, 2002, DNA Cell Biol 12:879-894) (each of the references cited above hereby incorporated by reference herein in its entirety). Such moieties also include moties that improve or increase the serum half-life of the immunospecific polypeptides of the invention. Nonlimiting examples of moieties that increase or improve the serum halflife of polypeptides include albumin and fibronenctin, or active fragments thereof, as well as albumin and/or fibronectine binding proteins, e.g., albumin and/or fibronectin binding antibodies, or antigen binding fragments thereof (see, e.g., Holt et al., 2008, Protein Eng Des Sel 21:238-288; Weimer et al., 2008, Thromb Haemost 99:659-667; Yazaki et al., 2008, Nucl Med Biol 35:151-158; Huang et al., 2007, J Pept Sci 12:588595; and Stork et al., 2007, Protein Eng Des Sel 20:569-576, each of which is hereby incorporated by reference in its entirety).

Techniques for conjugating such therapeutic moieties to polypeptides are well known; see, e.g., Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In

Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), 1985, pp. 243-56, Alan R. Liss, Inc.); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), 1987, pp. 623-53, Marcel Dekker, Inc.); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), 1985, pp. 475-506); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), 1985, pp. 303-16, Academic Press; and Thorpe et al., Immunol. Rev., 62:119-58, 1982 (each of which reference is hereby incorporated herein by reference in its entirety).

The immunospecific polypeptide of the invention, or an epitope binding fragment thereof, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a prophylactic or therapeutic.

Alternatively, an immunospecific polypeptide of the invention can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. $4,676,980$, which is incorporated herein by reference in its entirety.

Molecules of the invention may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

The invention also encompasses the use of liposomes for prolonging or increasing the serum half-life of molecules of the invention. In certain embodiments an immunospecific molecule of the inention of the invention, e.g., comprising a $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain, may be conjugated to liposomes using previously described methods, see, e.g., Martin et al., 1982, J. Biol. Chem. 257: 286-288, which is incorporated herein by reference in its entirety. The invention thus encompasses methods of preparing liposomes with a prolonged serum half-life, i.e., enhanced circulation time, such as those disclosed in U.S. Patent No. 5,013,556. Preferred liposomes used in the methods of the invention are not rapidly cleared from circulation, i.e., are not taken up into the mononuclear phagocyte system (MPS). The invention encompasses sterically stabilized liposomes which are prepared using common methods known to one skilled in the art.

Although not intending to be bound by a particular mechanism of action, sterically stabilized liposomes contain lipid components with bulky and highly flexible hydrophilic moieties, which reduces the unwanted reaction of liposomes with serum proteins, reduces oposonization with serum components and reduces recognition by MPS. Sterically stabilized liposomes are preferably prepared using polyethylene glycol. For preparation of liposomes and sterically stabilized liposome see, e.g., Bendas et al., 2001 BioDrugs, 15(4): 215-224; Allen et al., 1987 FEBS Lett. 223: 42-6; Klibanov' et al., 1990 FEBS Lett., 268: 235-7; Blum et al., 1990, Biochim. Biophys. Acta., 1029: 917; Torchilin .et al., 1996, J. Liposome Res. 6: 99-116; Litzinger et al., 1994, Biochim. Biophys. Acta, 1190: 99-107; Maruyama et al., 1991, Chem. Pharm. Bull., 39: 1620-2; Klibanov et al., 1991, Biochim Biophys Acta, 1062; 142-8; Allen et al., 1994, Adv. Drug Deliv. Rev, 13: 285-309; all of which are incorporated herein by reference in their entirety. The invention also encompasses liposomes that are adapted for specific organ targeting, see, e.g., U.S. Patent No. 4,544,545, or specific cell targeting, see, e.g., U.S. Patent Application Publication No. 2005/0074403. Particularly useful liposomes for use in the compositions and methods of the invention can be generated by reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter

### 5.5 Preparation and Characterization of Polypeptides of the Invention

 The immunospecific polypeptides, or fragments thereof, of the invention may be characterized for specific binding to an antigen and/or epitope using any immunological or biochemical based method known in the art for characterizing binding pair interactions. Specific binding of an immunospecific polypeptide of the invention to an antigen and/or epitope may be determined for example using immunological or biochemical based methods including, but not limited to, an ELISA assay, surface plasmon resonance assays, immunoprecipitation assay, affinity chromatography, and equilibrium dialysis. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity of the molecules of the invention include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay),"sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley \& Sons, Inc., New York, which is incorporated by reference herein in its entirety).
Immunospecific polypeptides, or fragments thereof, of the invention may also be assayed using any surface plasmon resonance based assays known in the art for characterizing the kinetic parameters of the interaction of the immunospecific protein with an antigen and/or epitope of interest. Any SPR instrument commercially available including, but not limited to, BIAcore Instruments, available from Biacore AB (Uppsala, Sweden); IAsys instruments available from Affinity Sensors (Franklin, Mass.); IBIS system available from Windsor Scientific Limited (Berks, UK), SPRCELLIA systems available from Nippon Laser and Electronics Lab (Hokkaido, Japan), and SPR Detector Spreeta available from Texas Instruments (Dallas, Tex.) can be used in the instant invention. For a review of SPR-based technology see Mullet et al., 2000, Methods 22: 77-91; Dong et al., 2002, Review in Mol. Biotech., 82: 303-23; Fivash et al., 1998, Current Opinion in Biotechnology 9: 97-101; Rich et al., 2000, Current Opinion in Biotechnology 11: 54-61; all of which are incorporated herein by reference in their entirety. Additionally, any of the SPR instruments and SPR based methods for measuring protein-protein interactions described in U.S. Pat. Nos. 6,373,577; 6,289,286; $5,322,798 ; 5,341,215 ; 6,268,125$ are contemplated in the methods of the invention, all of which are incorporated herein by reference in their entirety.
Briefly, SPR based assays involve immobilizing a member of a binding pair on a surface, and monitoring its interaction with the other member of the binding pair in solution in real time. SPR is based on measuring the change in refractive index of the solvent near the surface that occurs upon complex formation or dissociation. The surface onto which the immobilization occur is the sensor chip, which is at the heart of the SPR technology; it consists of a glass surface coated with a thin layer of gold and forms the basis for a range of specialized surfaces designed to optimize the binding of a molecule to the surface. A variety of sensor chips are commercially available especially
from the companies listed supra, all of which may be used in the methods of the invention. Nonlimiting examples of sensor chips include those available from BIAcore AB, Inc., e.g., Sensor Chip CM5, SA, NTA, and HPA. A molecule of the invention may be immobilized onto the surface of a sensor chip using any of the immobilization methods and chemistries known in the art, including but not limited to, direct covalent coupling via amine groups, direct covalent coupling via sulfhydryl groups, biotin attachment to avidin coated surface, aldehyde coupling to carbohydrate groups, and attachment through the histidine tag with NTA chips

### 5.5.1 Polynucleotides Encoding the Immunospecific Polypeptides of the Invention

The present invention also includes polynucleotides that encode the immunospecific polypeptides of the invention (e.g., polypeptides comprising a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain, comprising one or more CDRs identified by the methods of the invention, comprising amino acid scaffold sequences or amino acid scaffold residues, etc.) or other immunospecific polypeptides or fragments thereof produced by the methods of the invention, and humanized versions thereof, and methods for producing same.

The methods of the invention also encompass polynucleotides that hybridize under various stringency, e.g., high stringency, intermediate or lower stringency conditions, to polynucleotides that encode an immunospecific polypeptide of the invention. The hybridization can be performed under various conditions of stringency. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 67896792). Filters containing DNA are pretreated for 6 h at $40^{\circ} \mathrm{C}$. in a solution containing $35 \%$ formamide, 5 X SSC, 50 mM Tris- HCl ( pH 7.5 ), 5 mM EDTA, $0.1 \%$ PVP, $0.1 \%$ Ficoll, $1 \%$ BSA, and $500 \mu \mathrm{~g} / \mathrm{ml}$ denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: $0.02 \% \mathrm{PVP}, 0.02 \%$ Ficoll, $0.2 \%$ BSA, $100 \mu \mathrm{~g} / \mathrm{ml}$ salmon sperm DNA, $10 \%$ ( $\mathrm{wt} / \mathrm{vol}$ ) dextran sulfate, and 5$20 \times 10^{6} \mathrm{cpm}{ }^{32} \mathrm{P}$-labeled probe is used. Filters are incubated in hybridization mixture for $18-20 \mathrm{~h}$ at $40^{\circ}$. C., and then washed for 1.5 h at $55^{\circ} \mathrm{C}$. in a solution containing 2 X SSC, 25 mM Tris- HCl ( pH 7.4 ), 5 mM EDTA, and $0.1 \%$ SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at $60^{\circ} \mathrm{C}$. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third
time at $65-68^{\circ} \mathrm{C}$. and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations). By way of example and not limitation, procedures using conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at $65^{\circ} \mathrm{C}$. in buffer composed of $6 \mathrm{X} \mathrm{SSC}, 50 \mathrm{mM}$ Tris- $\mathrm{HCl}(\mathrm{pH}$ 7.5 ), 1 mM EDTA, $0.02 \%$ PVP, $0.02 \%$ Ficoll, $0.02 \%$ BSA, and $500 \mu \mathrm{~g} / \mathrm{ml}$ denatured salmon sperm DNA. Filters are hybridized for 48 h at $65^{\circ} \mathrm{C}$. in prehybridization mixture containing $100 \mu \mathrm{~g} / \mathrm{ml}$ denatured salmon sperm DNA and 5-20 $\times 10^{6} \mathrm{cpm}$ of ${ }^{32} \mathrm{P}$-labeled probe. Washing of filters is done at $37^{\circ}$. C . for 1 h in a solution containing 2 X SSC, $0.01 \%$ PVP, $0.01 \%$ Ficoll, and $0.01 \%$ BSA. This is followed by a wash in 0.1 X SSC at $50^{\circ} \mathrm{C}$ for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. Selection of appropriate conditions for such stringencies is well known in the art (see e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; see also, Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manuals, .COPYRGT. 1987-1997, Current Protocols, .COPYRGT. 1994-1997 John Wiley and Sons, Inc.; see especially, Dyson, 1991, "Immobilization of nucleic acids and hybridization analysis," In: Essential Molecular Biology: A Practical Approach, Vol. 2, T. A. Brown, ed., pp. 111-156, IRL Press at Oxford University Press; Oxford, UK) (each of which is hereby incorporated by reference herein in its entirety).

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art.
A polynucleotide encoding an immunospecific polypeptide of the invention may be generated from nucleic acid from a suitable source (e.g., a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the rabbit antibodies, in particular, rabbit variable domains, such as plasma cells) by hybridization with immunoglobulin specific probes and/or PCR amplification using synthetic primers hybridizable to the $3^{\prime}$ and $5^{\prime}$ ends of the variable domain sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the
antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.
Once the nucleotide sequence of the immunospecific polypeptide of the invention is determined, it may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley \& Sons, NY, which are both incorporated by reference herein in their entireties), to generate molecules of the invention having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.
In a specific embodiment, one or more of the rabbit CDRs identified by the methods of the invention are inserted within heterologous framework regions using routine recombinant DNA techniques. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., 1998, J. Mol. Biol. 278: 457-479 for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an immunospecific polypeptide, e.g., antibody, that specifically binds to the antigen and/or epitope of interest. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibodies of the invention to said antigen and/or epitope.
In another embodiment, libraries or rabbit immunoglobulins or immunoglobulin variable domains or any other rabbit libraries available in the art, can be screened by standard techniques known in the art, to clone the nucleic acids encoding the immunospecific polypeptides of the invention.

### 5.5.2 Recombinant Expression of Immunospecific Polypeptides of the Invention.

Once a nucleic acid sequence encoding an molecule of the invention has been obtained, the vector for the production of the immunospecific polypeptide may be produced by recombinant DNA technology using techniques well known in the art. Methods which
are well known to those skilled in the art can be used to construct expression vectors containing the coding sequences of the polypeptides of the invention and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and Ausubel et al. eds., 1998, Current Protocols in Molecular Biology, John Wiley \& Sons, NY).
An expression vector comprising the nucleotide sequence of an immunospecific polypeptide of the invention can be transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation) and the transfected cells are then cultured by conventional techniques to produce the polypeptide of the invention. In specific embodiments, the expression of the polypeptide is regulated by a constitutive, an inducible or a tissue, specific promoter.
The host cells used to express the recombinant immunospecific polypeptides of the invention may be either bacterial cells such as Escherichia coli, or, preferably, eukaryotic cells, especially for the expression of whole recombinant immunoglobulin molecule. In particular, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for immunoglobulins (Foecking et al., 1998, Gene 45:101; Cockett et al., 1990, Bio/Technology 8:2).
A variety of host-expression vector systems may be utilized to express the immunospecific polypeptides of the invention. Such host-expression systems represent vehicles by which the coding sequences of the polypeptides may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express the polypeptides of the invention in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., E. coli and B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing polypeptide coding sequences; yeast (e.g., Saccharomyces Pichia) transformed with recombinant yeast expression vectors containing polypeptide coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the
polypeptide coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing polypeptide coding sequences; or mammalian cell systems (e.g., $\mathrm{COS}, \mathrm{CHO}$, BHK, 293, 293T, 3 T3 cells, lymphotic cells (see U.S. Pat. No. 5,807,715), Per C. 6 cells (rat retinal cells developed by Crucell)) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5 K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the immunospecific polypeptide being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an immunospecific polypeptide of the invention, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the $E$. coli expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the immunospecific polypeptide coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye \& Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke \& Schuster, 1989, J. Biol. Chem. 24:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free gluta-thione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The immunospecific polypeptide coding sequence may be cloned individually into nonessential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV. promoter (e.g., the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the immunospecific polypeptide coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the immunospecific polypeptide molecule in infected hosts. (e.g., see Logan \& Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:355-359). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., 1987, Methods in Enzymol. 153:51-544).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 293T, 3T3, W138, BT483, Hs578T, HTB2, BT20 and T47D, CRL7030 and Hs578Bst.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express an immunospecific polypeptide of the invention may be engineered. Rather than using expression vectors which
contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the immunospecific polypeptide of the invention. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the immunospecific polypeptide of the invention.
A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthineguanine phosphoribosyltransferase (Szybalska \& Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can be employed in tk-, hgprt- or aprt-cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan \& Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, 1991, 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley \& Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley \& Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150: 1; and hygro, which confers
resistance to hygromycin (Santerre et al., 1984, Gene 30:147) (each of the above references hereby incorporated in their entireties).
The expression levels of an immunospecific polypeptide of the invention can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an immunospecific polypeptide is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the immunospecific polypeptide of the invention, production of the immunospecific polypeptide will also increase (Crouse et al., 1983, Mol. Cell. Biol. 3:257) (each of the above references hereby incorporated in their entireties).
The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52; Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.
Once the immunospecific polypeptide of the invention has been recombinantly expressed, it may be purified by any method known in the art for purification of an immunospecific polypeptide, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

### 5.6 Prophylactic and Therapeutic Methods

Immunospecific polypeptides of the present invention that function as a prophylactic and or therapeutic agents against a disease, disorder, or infection can be administered to an animal, preferably a mammal, and most preferably a human, to treat, prevent or ameliorate one or more symptoms associated with the disease, disorder, or infection.

Immunospecific polypeptides of the invention can be administered in combination with one or more other prophylactic and/or therapeutic agents useful in the treatment, prevention or management of a disease, disorder, or infection. In certain embodiments, one or more immunospecific polypeptides of the invention are administered to a mammal, preferably a human, concurrently with one or more other therapeutic agents useful for the treatment of a disease. The term "concurrently" is not limited to the administration of prophylactic or therapeutic agents at exactly the same time, but rather it is meant that immunospecific polypeptides of the invention and the other agent are administered to a subject in a sequence and within a time interval such that the immunospecific polypeptides of the invention can act together with the other agent to provide an increased benefit than if they were administered otherwise. For example, each prophylactic or therapeutic agent may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. Each therapeutic agent can be administered separately, in any appropriate form and by any suitable route.

In various embodiments, the prophylactic or therapeutic agents are administered less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In preferred embodiments, two or more components are administered within the same patient visit.
The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The dosage and frequency further will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity and type of disease, the route of administration, as well as age, body weight, response, and the past medical history of the patient. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example,
dosages reported in the literature and recommended in the Physician 's Desk Reference ( $56^{\text {th }}$ ed., 2002).

### 5.7 Compositions and Methods of Administering

The invention provides methods and pharmaceutical compositions comprising the immunospecific polypeptides of the invention. The invention also provides methods of treatment, prophylaxis, and amelioration of one or more symptoms associated with a disease, disorder or infection by administering to a subject an effective amount of a fusion protein or a conjugated molecule of the invention, or a pharmaceutical composition comprising a fusion protein or conjugated molecules of the invention. In a preferred aspect, an immunospecific polypeptide or fusion protein or conjugated molecule, is substantially purified (i.e., substantially free from substances that limit its effect or produce undesired side-effects). In a specific embodiment, the subject is an animal, preferably a mammal such as non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey such as, a cynomolgous monkey and a human). In a preferred embodiment, the subject is a human.

Various delivery systems are known and can be used to administer a composition comprising immunospecific polypeptides of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the immunospecific polypeptide or fusion protein, receptor-mediated endocytosis (See, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc.

Methods of administering an immunospecific polypeptide of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). In a specific embodiment, the immunospecific polypeptides of the invention are administered intramuscularly, intravenously, or subcutaneously. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968; 5,985,

20; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903, each of which is incorporated herein by reference in its entirety.
The immunospecific molecules of the invention may be delivered in a sustained release formulation. The formulations provide extended release and extended half-life of administered therapeutic polypeptides. Controlled release systems suitable for use include, without limitation, diffusion-controlled, solvent-controlled and chemicallycontrolled systems. Diffusion controlled systems include, for example reservoir devices, in which the immunospecific molecules of the invention are enclosed within a device such that release of the molecules is controlled by permeation through a difussion barrier. Common reservoir devices include, for example, membranes, capsules, microcapsules, liposomes, and hollow fibers. Monolithic (matrix) device are a second type of diffusion controlled system, wherein the immunospecific molecules are dispersed or dissolved in an rate-controlling matrix (e.g., a polymer matrix). The immunospecific molecules of the invention are homogeneously dispersed throughout a rate-controlling matrix and the rate of release is controlled by diffusion through the matrix. Polymers suitable for use in the monolithic matrix device include naturally occurring polymers, synthetic polymers and synthetically modified natural polymers, as well as polymer derivatives.
The amount of the composition of the invention which will be effective in the treatment, prevention or amelioration of one or more symptoms associated with a disorder can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
Generally, humanized immunospecific polypeptides, e.g., antibodies, have a longer half-life within the human body than immunospecific polypeptides, e.g., antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of humanized immunospecific polypeptides, e.g., antibodies, and less frequent administration is often possible. Further, the dosage and frequency of administration of immunospecific polypeptides of the invention or fragments thereof may be reduced by
enhancing uptake and tissue penetration of the antibodies by modifications such as, for example conjugation to $G$ proteins.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion, by injection, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering an immunospecific polypeptide of the invention, care must be taken to use materials to which the immunospecific polypeptide or the fusion protein does not absorb.

Treatment of a subject with a therapeutically or prophylactically effective amount of the immunospecific polypeptides of the invention can include a single treatment or, preferably, can include a series of treatments. The pharmaceutical compositions of the invention may be administered once a day, twice a day, or three times a day. In other embodiments, the pharmaceutical compositions may be administered once a week, twice a week, once every two weeks, once a month, once every six weeks, once every two months, twice a year or once per year. It will also be appreciated that the effective dosage of the antibodies used for treatment may increase or decrease over the course of a particular treatment.

### 5.7.1 Pharmaceutical Compositions

The compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g., impure or non-sterile compositions) and pharmaceutical compositions (i.e., compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms. Such compositions comprise a prophylactically or therapeutically effective amount of a prophylactic and/or therapeutic agent disclosed herein or a combination of those agents and a pharmaceutically acceptable carrier. Preferably, compositions of the invention comprise a prophylactically or therapeutically effective amount of the immunospecific polypeptides of the invention and a pharmaceutically acceptable carrier.
In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more
particularly in humans. The term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include, but are not limited to those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2ethylamino ethanol, histidine, procaine, etc.

### 5.7.2 Kits

The invention provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the immunospecific polypeptides of the invention. Additionally, one or more other prophylactic or therapeutic agents useful for the
treatment of a disease can also be included in the pharmaceutical pack or kit. The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises one or more immunospecific polypeptides of the invention. In another embodiment, a kit further comprises one or more other prophylactic or therapeutic agents useful for the treatment of a disease, in one or more containers. In other embodiments, the prophylactic or therapeutic agent is a biological or hormonal therapeutic.

### 5.8 Characterization and Demonstration of Therapeutic Utility

Combinations of prophylactic and/or therapeutic agents can be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not limited to, rats, mice, chicken, cows, monkeys, pigs, dogs, rabbits, etc. Any animal system well-known in the art may be used. In a specific embodiment of the invention, combinations of prophylactic and/or therapeutic agents are tested in a mouse model system. Such model systems are widely used and well-known to the skilled artisan. Prophylactic and/or therapeutic agents can be administered repeatedly. Several aspects of the procedure may vary such as the temporal regime of administering the prophylactic and/or therapeutic agents, and whether such agents are administered separately or as an admixture.

Once the prophylactic and/or therapeutic agents of the invention have been tested in an animal model they can be tested in clinical trials to establish their efficacy. Establishing clinical trials will be done in accordance with common methodologies known to one skilled in the art, and the optimal dosages and routes of administration as well as toxicity profiles of the compositions of the invention can be established using routine experimentation.

Toxicity and efficacy of the prophylactic and/or therapeutic protocols of the instant invention can be determined by standard pharmaceutical procedures in cell cultures or
experimental animals, e.g., for determining the $\mathrm{LD}_{50}$ (the dose lethal to $50 \%$ of the population) and the $\mathrm{ED}_{50}$ (the dose therapeutically effective in $50 \%$ of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio $\mathrm{LD}_{50} / \mathrm{ED}_{50}$. Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans. The dosage of such agents lies preferably within a range of circulating concentrations that include the $\mathrm{ED}_{50}$ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any agent used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the $\mathrm{IC}_{50}$ (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

## 6. EXAMPLES

The following methods can be used with naïve or immunized rabbits

### 6.1 Isolation and Characterization of Immunospecific, Stable $\mathbf{V}_{\mathbf{H}}$ and $\mathbf{V}_{\mathbf{L}}$ Domains

The following method provides for the identification and isolation of distinctive rabbit variable domains which exhibit unique properties compared to human, mouse, or camel antibodies, presenting high affinity, specificity and stability

### 6.1.1 Materials and Methods

## Rabbit Immunization (Optional)

New Zealand White rabbits were immunized with purified Vif, HIV GP41, HIV integrase, TNF-alpha, vWF, or Delta4 over the course of twelve week. The rabbits were
administered four subcutaneous injections at 2-3 week intervals of $50 \mu \mathrm{~g}$ purified protein prepared in 1 ml adjuvant according to the manufacturer's directions (Ribi Immunochem Research, Hamilton, MT). Five days after the final boost, spleen and bone marrow were harvested and used for total RNA preparation

## RNA Isolation and Library Construction

Tissue Samples were harvested and prepared for total RNA isolation using TRI reagent (Molecular Research Centre) according to the manufacturer's protocol. Isolated total RNA was dissolved in $500 \mu 1$ of RNase-free water and concentration and purity were determined by spectrophotometry. First strand cDNA was synthesized from total RNA using an oligo (dT) primer and reverse transcriptase (Superscript; Invitrogen) using the manufacturer's protocol.

Primary amplification of the genes coding for the variable regions of the heavy chains and light chains was performed using the sense primers presented in table 1 ( $5^{\prime}$ part of the variable region; FIG. 1) and the antisense primers presented in table 2 ( 3 ' part of the constant region of the heavy and light chains; FIGS. 2A-B)

Table 1. Sense Primers for Isolation of Rabbit VH or VL domains From cDNA

## Preparation

| Domain | Primer | Sequence |
| :---: | :---: | :---: |
| VH | SDVH1-F | 5'GGG CCC AGG CGG CC CAG TCG GTG GAG GAG TCC TGG 3' (SEQ ID NO:10) |
|  | SDVH2-F | $\begin{aligned} & \text { 5' GGG CCC AGG CGG CC CAG TCG GTG AAG GAG } \\ & \text { TCC GAG 3' (SEQ ID NO:11) } \\ & \hline \end{aligned}$ |
|  | SDVH3-F | 5' GGG CCC AGG CGG CC CAG TCG YTG GAG GAG TCC GGG 3' (SEQ ID NO:12) |
|  | SDVH4-F | 5' GGG CCC AGG CGG CC CAG SAG CAG CTG RTG GAG TCC GG 3' (SEQ ID NO:13) |
| VL | SDVK1-F | 5' GGG CCC AGG CGG CC GAGC TCG TGM TGA CCC AGA CTC CA 3' (SEQ ID NO:14) |
|  | SDVK2-F | 5' GGG CCC AGG CGG CC GAGC TCG ATM TGA CCC AGA CTC CA 3' (SEQ ID NO:15) |
|  | SDVK3-F | 5' GGG CCC AGG CGG CC GAGC TCG TGA TGA CCC AGA CTG AA 3' (SEQ ID NO:16) |
|  | SDVA-F | 5' GGG CCC AGG CGG CC GAGC TCG TGC TGA CTC AGT CGC CCT C 3' (SEQ ID NO:17) |

Table 2. Antisense Primers for Isolation of Rabbit VH or VL domains from cDNA Preparation

| Domain | Primer | Sequence |
| :---: | :---: | :---: |
| VH | SDG-R | 5' CCT GGC CGG CCT GGC CAC TAG TGA CTG AYG GAG CCT TAG GTT GCC C 3' (SEQ ID NO:18) |
| VL | SDVKj10-R | 5' CCT GGC CGG CCT GGCC TTT GAT TTC CAC <br> ATT GGT GCC 3' (SEQ ID NO:19) |
|  | SDVKj0-R | 5' CCT GGC CGG CCT GGCC TAG GAT CTC CAG CTC GGT CCC 3' (SEQ ID NO:20) |
|  | SDVK42j0-R | 5' CCT GGC CGG CCT GGCC TTT GAC SAC CAC CTC GGT CCC 3' (SEQ ID NO:21) |
|  | SDVA-R | 5' CCT $\quad$ GGC $\quad$ CGG CCT GGC C   <br> GCCTGTGACGGTCAGCTGGGTCCC 3, (SEQ ID  <br> NO:22)     |

The primary PCR was performed in $50 \mu 1$ reaction volume using 25 pmol of each primer. $2.5 \mu \mathrm{l}$ random primed or oligo-dT cDNA was used as template (equivalent of 5 $\mu \mathrm{g}$ mRNA). The reaction conditions for the primary PCR were 11 min at $94^{\circ} \mathrm{C}$, followed by $30 / 60 / 120 \mathrm{sec}$ at $54 / 55 / 72^{\circ} \mathrm{C}$ for 30 cycles, and 5 min at $72^{\circ} \mathrm{C}$. All reactions were performed with $2.5 \mathrm{mM} \mathrm{MgCl2}, 200 \mu \mathrm{M} \mathrm{dNTP}$ (Roche Diagnostics, Brussels, Belgium) and 1.25 U AmpliTaq Gold DNA polymerase (Roche).
PCR products were separated ón a $1 \%$ agarose gel and the DNA eluted using the QIAquick gel extraction kit or QIAEXII (Qiagen)
All primers have the Sfil site. DNA fragments were Sfi-cut, purified, and cloned into phagemid vector. The phagemid contained a suppressor stop codon and sequences encoding peptide tags for purification $\left(\mathrm{His}_{6}\right)$ and detection (HA).

## Library Ligation and transformation

Approximately 50ng of linearized vector DNA (as determined by gel electrophoresis against known amounts) were ligated with approximately a 1-3 fold excess of insert in $20 \mu \mathrm{l}$ reactions containing 1 X ligase buffer ( 50 mM Tris $\mathrm{pH} 7.5,5 \mathrm{mM} \mathrm{MgCl}, 1 \mathrm{mM}$ dithioerythritol, 1 mM ATP, pH 7.5 ) and 1 U T4 DNA ligase (Roche), for ligation of cohesive-end ligations. Ligations were incubated $16-18 \mathrm{~h}$ at $12-14^{\circ} \mathrm{C}$.

Results of the ligations and a corresponding number of cuvettes were incubated on ice for 10 min . Simultaneously, electrocompetent E.coli were thawed on ice. $2 \mu \mathrm{l}$ of each ligation reaction were added to the electrocompetent bacteria, transferred to a cuvette and stored on ice for 1 min . Electroporation was performed at $2.5 \mathrm{kV}, 25 \mu \mathrm{~F}$, and $200 \Omega$. Cuvettes were immediately flushed with 1 ml of SOC medium at room temperature and the cultures shaken at 250 rpm for 1 h at $37^{\circ} \mathrm{C}$ or $30^{\circ} \mathrm{C}$. Cultures were then spread on LB agar plates containing $100 \mu \mathrm{~g} / \mathrm{ml}$ ampicilin, $30 \mu \mathrm{~g} / \mathrm{ml}$ kanamycin, and $17 \mu \mathrm{~g} / \mathrm{ml}$ chloramphenicol and incubated overnight at $37^{\circ} \mathrm{C}$ or $30^{\circ} \mathrm{C}$.

Phagemid vector was isolated and electorporated into host cells according to manufacturer's protocols. After electroporation, 5 ml of SOC was added and cultures were shaken for 1 h at $37^{\circ} \mathrm{C}$. 10 ml of SB medium $/ \mathrm{carb}$ was then added for 1 h at $37^{\circ} \mathrm{C}$. $4.5 \mu \mathrm{l}$ of $100 \mathrm{mg} / \mathrm{ml}$ carbenicillin was next added and cultures were shaken for another 1 h at $37^{\circ} \mathrm{C}$ before adding 1 ml of VSCM13 (helper phage; $10^{13} \mathrm{pfu} / \mathrm{ml}$ ) to each 15 ml culture. A total of 170 ml SB medium/carb added to the cultures, which were shaken for 2 h at $37^{\circ} \mathrm{C}$. $280 \mu \mathrm{l}$ of $50 \mathrm{mg} / \mathrm{ml}$ kanamycin was added and the cultures continued shaking $\mathrm{O} / \mathrm{N}$ at $37^{\circ} \mathrm{C}$. On the following morning, the cultures were centrifuged and the phage supernatants precipitated by adding 25 ml of PEG-8000 (polyethylene glycol) $/ \mathrm{NaCl}$ and incubation on ice for 30 min . Phage was centrifuged from the supernatant and pellets were resuspended in 2 ml of TBS/BSA $1 \%$, spun down and filtered through a $0.2 \mu \mathrm{~m}$ filter into a sterile tube.

## Library Panning

Immobilized antigens (Vif, Gp41, Integrase, TNF-alpha, vWF, Delta4) were used to pan the phage expression library for immunospecific binding. Antigen was bound to a microtitre plate by incubation overnight $\mathrm{O} / \mathrm{N}$ at $4^{\circ} \mathrm{C}$. Plates were then washed and blocked with TBS/BSA $3 \%$ for 1 lh at $37^{\circ} \mathrm{C}$. $50 \mu \mathrm{l}$ of freshly prepared phage library was added to each well and incubated for 2 h at $37^{\circ} \mathrm{C}$. Panning consisted of several rounds of binding phage to an antigen immobilized to the well of an ELISA plate, washing, elution by trypsinization (cleaves the antibody fragment off the phage surface), and reamplification. During each round, specific binding clones were selected and amplified. These clones predominated after 3 or 4 rounds.

Wells were washed with $150 \mu \mathrm{TBS} / 0.5 \%$ Tween 20 . Washing steps were increased from 5 in the first round to 10 in the second round and 15 in the third and fourth round.

If further rounds of panning were desired, phage eluates were transferred to 2 ml E.coli cultures that had been prepared by inoculation with $2 \mu \mathrm{l}$ of ER2537 and incubated while shaking for 2 h at $37^{\circ} \mathrm{C}$ until $\mathrm{O} . \mathrm{D}=1$. The elutate exposed cultures were incubated for 15 min at RT. 6 ml of prewarmed SB medium/carb was added and shaken 1 h at $37^{\circ} \mathrm{C}$ followed by the addition of 1 ml of VCSM13 (helper phage) and 91 ml of prewarmed SB medium $/ \mathrm{carb}$. Cultures were shaken for 2 h at $37^{\circ} \mathrm{C}$, followed by the addition of $140 \mu \mathrm{l}$ of $50 \mathrm{mg} / \mathrm{ml}$ kanamycin and then shaken $\mathrm{O} / \mathrm{N}$ at $37^{\circ} \mathrm{C}$. Antigen coated plates were prepared as described for the next round of panning. Panning of second round was then repeated following the same protocol.
After panning, the pooled phage were tested by binding to antigen coated plates (prepared as described) and detected by HRP-conjugated anti-HA (1:2000) to assess whether it was worthwhile to continue with the analysis of single clones.

## Construction of CAT-fusion Single-Domain Antibody Libraries

The CAT gene was amplified from pCAT (Stratagene) by PCR and inserted into pETderived plasmid using EcoRI and SphI restriction sites to create the pE-CAT. The $5^{\prime} \mathrm{PCR}$ primer originally used to clone the variable domains was also designed to contain two sequential and different SfiI cloning sites, and an amber codon (TAG) just before the beginning of the CAT gene. To clone our single-domain antibody libraries fused into the CAT gene, SDVH and SDVL fragments were generated by PCR from each p-SDVH (plasmid expressing VH domains) and pSDVL (plasmid expressing VL domains) library vectors or from phagemid vectors selected by panning. The resulting SDVH and SDVL PCR fragments were gel-purified, digested with the restriction endonuclease SfiI, and cloned independently into the appropriately Sfil cut vector pE CAT. The pSDVH-CAT and pSDVL-CAT constructs are under the control of the strong Lac promoter that also includes an N-terminal Hist ${ }_{6}$ affinity tag and the ampicillin resistance gene. Altenatively, SDVH or SDVL fragments may be cloned into readily available vectors designed to express cloned sequences as fusion proteins with CAT, e.g., the PCFN1 vector (see Maxwell, et al., 1999, J Prot Sci 8:1908-1911, incorporated herein by reference in its entirety; FIG. 5).

## Chloramphenicol resistance analysis

Chloramphenicol resistance assays were performed by transforming ER2738 cells (New England Biolabs, Inc) with each single-domain CAT-fusion library. The
transformation mixtures were inoculated into 5 mL of SOC and incubated at $37^{\circ} \mathrm{C}$ for 1 hour. Next, 10 ml of SB medium with $3 \mu 1$ of $100 \mathrm{mg} / \mathrm{ml}$ ampicillin was added to each library. A total of 15 ml of each culture was shaken for 1 hour at $37^{\circ} \mathrm{C}$. Subsequently $4.5 \mu \mathrm{l}$ of $100 \mathrm{mg} / \mathrm{ml}$ ampicillin was added and cultures shaken for one hour at $37^{\circ} \mathrm{C}$. Then, 85 ml of SB medium with $85 \mu \mathrm{l}$ of $100 \mathrm{mg} / \mathrm{ml}$ ampicillin was added and cultures grown overnight at $37^{\circ} \mathrm{C}$. The following day, $600 \mu \mathrm{l}$ of each culture was used to inoculate 20 ml of SB medium containing $100 \mu \mathrm{~g} / \mathrm{ml}$ of ampicillin. Expression of CATfusion single-domain proteins was induced by addition of 0.5 mM IPTG when the optical density of cultures reached $0.9($ at 600 nM$)$. After 2 hours of incubation at $37^{\circ} \mathrm{C}$, $100 \mu \mathrm{l}$ aliquots of each library were plated on agar plates with IPTG $(200 \mu \mathrm{~g} / \mathrm{ml})$ and various concentrations of chloramphenicol. Plates were incubated at $37^{\circ} \mathrm{C}$ for $16-20$ hours. The level of resistance was quantified as the highest level of chloramphenicol at which colonies appeared after the $37^{\circ} \mathrm{C}$ incubation period.

## Stability Analysis

Confirmation of the stability of clones selected by panning and/or chloramphenicol resistance assays (or combinations of both) was performed by monitoring the unfolding transition in response to heat or increasing concentration of guanidium chloride ( GdmCl ) by intrinsic fluorescence. Expressed and isolated clones were diluted to a concentration of $6 \mu \mathrm{M}$. Intrinsic fluorescencewas determined at a wavelength of 280 or 295nm, with emission spectra recoded from 310 to 440 nm . Fluorescence spectra were corrected for background fluorescence of the solution. FIG. 6A depectis the representative unfolding transition curve of a $\mathrm{V}_{\mathrm{L}}$ domain of the invention in response to increasing heat. FIG. 6B depectis the representative unfolding transition curve of a $\mathrm{V}_{\mathrm{L}}$ domain of the invention in response to increasing concentrations of GdmCl ; prior to fluorescence measurement, $6 \mu \mathrm{M}$ samples of protein were incubated overnight at $25^{\circ} \mathrm{C}$ for each concentration of GdmCl .

## Sequence Analysis

Vector clones selected by panning and/or chloramphenicol resistance, or combinations of both, were inoculated into culture, and the cultures were induced with 1 mM IPTG (isopropyl- $\beta$-D-thiogalactopyranoside) and tested for binding. DNA fingerprinting (analysis of different sizes of fragments after amplification by PCR), and AluI analysis (enzyme which digests DNA in scveral sequences) of antibody fragments encoding

PCR products were performed in parallel to test for diversity among the clones. Selected clones were then subjected to DNA sequence analysis and expressed without gene III product for further analysis.

### 6.1.2 Results

## Heavy Chain Variable Domain

Tables 3-6 present representative framework sequences of rabbit heavy chain variable domains selected by the stability assay and/or the stability assay with phage panning. Sequence analysis of selected clones relative to initial pools indicated that the following sequences provide enhanced stability and/or affinity: for the VH FR1 domain, QEQLMETESGGGAEGGLVKPGASLTLTCTAS (SEQ ID NO:57); for the VH FR2 domain, WVRQAPGKGLEWIG (SEQ ID NO:69); for the VH FR3 domain, YATWVNGRFTLSRDIDQSTGCLQLNSLTAADTATYYCAR (SEQ ID NO:95); and for the VH FR4 domain, WGQGTLVTVSS (SEQ ID NO:139).

Additional point mutation studies indicated that the presence of one or more of the following amino acid residues conferred enhanced stability and/or affinity to the $\mathrm{V}_{\mathrm{H}}$ domain: a phenylalanine at position 46 (within the FR2 domain), a glutamic acid at position 53 (within the FR2 domain), an arginine at position 54 (within the FR2 domain), a glycine at position 56 (within the FR2 domain), an alanine at position 58 (within the FR2 domain), and an arginine at position 126 (within the FR4 domain). Analysis and point mutation studies within the CDR domains also indicated that the presence of a cysteine at position 44 (the final CDR1 residue) and/or a cysteine at position 59 (the first residue in CDR2) conferred enhanced stability and/or affinity. It is believed that these cysteines act to stabilize the three-dimensional structure of the domain, Amino acid positions are according to the positions within the sequence alignments presented in FIG3.

Table 3. Amino Acid Sequences of $\mathbf{V}_{\mathbf{H}}$ FR1 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 1-31 |
| :--- | :--- |
| 23 | QQQLV--ESGGR----LVKPDETLTITCTVS |
| 24 | -QSVE--ESGGG----LVTPGTPLTLTCTVS |
| 25 | -QSLE--ESGGG----LVQPGGSLKVSCKAS |
| 26 | -QSLE--ESGGR----LVTPGTPLTLTCTVS |
| 27 | QQQLM--KSGGG----LVQPGGSLTLSCKAS |


| 28 | -QSLE--ESGGR----LVTPGGSLTPTCTVS |
| :---: | :---: |
| 29 | -QSVE--ESGGR----LVKPDETLTLTCTVS |
| 30 | -QSVE--ESRGR----LVTPGTPLTLTCTVS |
| 31 | QEQLV--ESGGG----LVQPGGSLKLSCKAS |
| 32 | QQQLV--ESGGG----LVQPGGSLKLSCKAS |
| 33 | -QSMK--ESEGR----LVTPGGSLTLTCTVS |
| 34 | -QSVE--ESRGR----LVTPGGSLTLTCTVS |
| 35 | -QSVE--ESGGG----LVQPGGSLKVSCKAP |
| 36 | -QSLE--ESGGR----LVTPGGSLTLTCTVS |
| 37 | -QSVE--ESGGR----LVTPGGSLTLTCTVS |
| 38 | QEQLM--ESGGG----LVQPGGSLTLSCKAS |
| 39 | -QSLE--ESGGR----LVTPGTPLTLTCTAS |
| 40 | QQQLV--ESGGG----LVQPGGSLTLSCKAS |
| 41 | -QSVE--ESGGR----LVTPGTPLTLTCTVS |
| 42 | -QSVE--ESRGG----LVQPGGSLKVSCKAS |
| 43 | -QSVE--ESRGG----LFKPTDTLTLTCTVS |
| 44 | -QSVE--ESGGR----LISPGGSLTLTCTVS |
| 45 | -QSLE--ESGGR----LVKPDETLTLTCTVS |
| 46 | -QSVE--ESRGR----LVTPGTPLTLTCTAS |
| 47 | -QSVE--ESRGR----LVKPDETLTLTCTVS |
| 48 | -QSVE--ESRGD----LVKPEGSLTLTCTAS |
| 49 | -QSLE--ESGGR----LVTPGTPLTLTCTIS |
| 50 | -QSLE--ESGGR----LVTLGTPLTLTCTVS |
| 51 | -QSLE--ESWGR----LVKPDETLTITCTVS |
| 52 | -QSVE--ESGGG----LVQPGGSLKLSCKAS |
| 53 | QEQLV--ESGGG----LVKPEGSLTLTCKAS |
| 54 | -QSVE--ESGGN----LVTPGTPLTLTCTVS |
| 55 | QQQLM--ESGGG----LVQPGGSLKLSCKAS |
| 56 | QEQLMETESGGGAEGGLVKPGGSLELCCKAS |
| 57 | QEQLMETESGGGAEGGLVKPGASLTLTCTAS |
| 58 | --QSLE-ESGGR----LVTPGTPLTLTCTVS |
| 59 | --QSVE-ESRGD----LVKPGASLTLTCTAS |
| 60 | --QSVE-ESGGR----LITPGGSLTLTCTVS |
| 61 | --QSLE-ESGGD----LVKPGASLTLTCTAS |
| 62 | --QSVE-ESRGR----LVTPGTPLTLTCTVS |
| 63 | QEQLMETESGGG----LVKPGASLTLTCTAS |
| 64 | --QSLE-ESGGD----LVQPGASLTLTCTAS |
| 65 | -QQQLV-ESGGD----LVKPEGSLTLTCTAS |
| 66 | --QSLE-ESGGD----LVKPEGSLTLTCTAS |

Table 4. Amino Acid Sequences of $\mathbf{V}_{\mathbf{H}}$ FR2 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 45-58 |
| :---: | :---: |
| 67 | WVRQAPGEGLEWIG |
| 68 | WVRQAPGKGLQYIG |
| 69 | WVRQAPGKGLEWIG |
| 70 | WVRQAPGKGLDWIG |
| 71 | WVRQAPGEGLDWIG |
| 72 | WVRQAPGKGLEYIG |
| 73 | WGRQAPREGLEWIG |
| 74 | WVRQAPGKRLEWIG |
| 75 | WVRQAPGKGLEWVA |
| 76 | WVRQAPEKGLEWIG |
| 77 | WVRQAPGKGLEWIA |
| 78 | WFRQAPGKGLEWIA |
| 79 | WFRQAPGKGLEWIG |
| 80 | WFRQAPGKELEWIG |
| 81 | WFRQAPGKGREWIG |
| 82 | WFRQAPGKGLEGIG |
| 83 | WVRQAPGKEIEWIG |
| 84 | WVRQAPGKEREWIG |
| 85 | WVRQAPGKELEGIG |
| 86 | WVRQAPGKGREWIG |
| 87 | WVRQAPGKGREGIG |
| 88 | WVRQAPGKGLEGIG |
| 89 | WFRQAPGKEREWIG |
| 90 | WFRQAPGKELEGIG |
| 91 | WFRQAPGKGREGIG |
| 92 | WVRQAPGKEREGIG |
| 93 | WFRQAPGKEREGIG |

Table 5. Amino Acid Sequences of $\mathbf{V}_{\mathrm{H}}$ FR3 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION $\mathbf{7 0 - 1 1 0}$ |
| :--- | :--- |
| 94 | YASWAKGRFTIS-KTSSTTVDLKITSP-- <br> TTEDTATYFCAR |
| 95 | YATWVNGRFTLSRDIDQSTGCLQLNSL-- <br> TAADTATYYCAR |
| 96 | YATWAKGRFTIS-KTS- <br> TTVNLQMETTSLTTEDTATFFCAR |


| 97 | YATWAKGRFTIS- <br> KTSSTTVTLQMETTSLTAADTATYFCAR |
| :---: | :---: |
| 98 | YASWAKGRFTIS-KTS-TTVDLKITSP-TTEDTATYFCAS |
| 99 | YASWAEGRFSISKASSTTVTLQMETTSLTAADTATYFCAR |
| 100 | YANWAKGRFTIS-KTS-TTVDIKITSP-TTEDTATYFCVR |
| 101 | YASWPQGRFTIS VTSSTTVTLQMETTSLTAADTATYFCAK |
| 102 | YASWAKGRFTIS-QTS-TTVDLKITSP-TTEDTATYFCAR |
| 103 | YATWAKGRFTISKPSSTTVTLQMETTSLTAADTATYFCAR |
| 104 | YANWAKGRFTIAKTSSTTVTLQMETTSLTAADTATYFCAR |
| 105 | YASWAKGRFTIS-KTS-TTVDIKITSP-TTEDTATYFCAR |
| 106 | YPSWVDGRFTIS-KTS-TTVDLKITSP-TTEDTATYFCAR |
| 107 | YADWVTGRFTISSHNAQNTLYLQLNSL-TAADTATYFCAR |
| 108 | YANWAKGRCTIS-KTS-TTVDLKITSP-TTEDTATYFCAP |
| 109 | YATWVNGRLTISSHNAQNTLYLQLNSL-TAADTATYFCAR |
| 110 | YANWAKGRFTIS-KTP-TTVDIKINSP-TTEDTATYFCAR |
| 111 | YADWAKGRFTIS-KTS-TTVDLKITSP-TTEDTATYFCAR |
| 112 | YADWAKGRFTIS-KTS-TTMDLKITSP'-TTEDTATYFCGR |
| 113 | YASWVNGRFTISSRNAQNTLYLQLNSL-TAADTATYFCAR |
| 114 | YASWVNGRFTISSDNAQNTVDLQLNSL-TAADTATYFCAR |
| 115 | YANWAKGRFTSS-KTS-TTVDIKITSP-TTEDTATYFCAR |
| 116 | YANWAKGRFTIS-KTS-TTVDIEIASP-TTEDTATYFCVR |
| 117 | YASWAEGRFTIS-KASSTTVDLKMTSL-- |


|  | TTEDTATYFCAR |
| :---: | :---: |
| 118 | YANWAKGRFTIS-RTS-TTVDLKMTSL-TTEDTATYFCAR |
| 119 | YASWAKGRFTIS-KTSSTTVDLEMTSL-TTEDTATYFCAR |
| 120 | YANWAKGRFTIS-KASSTTVELKMTGL-TTEDTATYFCAR |
| 121 | YASWVNGRFTISSHNAQNTLYLQLNSL-TAADTATYECAR |
| 122 | YANWARGRFTIS-RTS-TTVDLEITSP-TTEDTATYFCGR |
| 123 | YASWVNGRFTISRTS--TTVDLKMTSL-TTEDTATYECIR |
| 124 | YARWAKDRVTISKTS--TTVDIKITSP-TTEDTATYFCAR |
| 125 | YANWAKGRETISKTS--TTVDIEIISP-TKEDTATYFCAT |
| 126 | YANWAKGRFTISKAS--TTVDLKITSP-TTEDTATYFCVR |
| 127 | YANWARGRFTISKTS--TTVDLKMTSP-TTEDTAIYFCAR |
| 128 | YATWAKGRFTISKTS--TTVDLKVTSP-TTEDTATYFCAS |
| 129 | YPSWAEGRFTISKTS--TTVDLKIASP-ATEDTATYFCAR |
| 130 | YASWAKGRFTISRTS--TTADLRITSP-TIEDTATYFCAR |
| 131 | YANWAKGRFTISKTS--TTVDLKMTSL-TAADTATYECAR |
| 132 | YATWAKGRETISKTSS-TTVDLKMTSL-TTEDTATYFCTR |
| 133 | YANWAKGRFTIS-RTS-TTVDLKMTSP-TTEDTATYFCIR |
| 134 | YASWAEGRFTIS-RTS-TTVDLKMTSP-TTEDTATYFCAR |
| 135 | YASWAKGPFTIS-KTS-TTVDLKMTSP-TTEDMATYFCAR |
| 136 | YASWAKGRFTIS-KTS-TTVDLKITSP-ITEDTATYFCIR |
| 137 | YASWVNGRFTISSDNAQNTVDLQMNSL-TAADTATYFCAR |


| 138 | YANWVNGRFTISLDNAQNTVFLQMTSL-- <br> TAADTATYFCAR |
| :--- | :--- |

Table 6. Amino Acid Sequences of $V_{H}$ FR4 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 126-136 |
| :--- | :--- |
| 139 | WGQGTLVTVSS |
| 140 | WGPGTLVTVSS |
| 141 | WGQGILVTVSS |
| 142 | WGQGALVTVSS |
| 143 | WGPGTLVTISS |
| 144 | WGQGTLVTASS |
| 145 | WGPGTLVAVSS |
| 146 | WGQGTRVTVSS |
| 147 | WGPGTLVTGSS |
| 148 | WGQGSLVTISS |
| 149 | RGQGSLVTISS |

## Light Chain Variable Domain

Tables 7-10 present representative sequences of rabbit light chain variable framework domains selected by stability assay and phage panning. Sequence analysis of selected clones relative to initial pools indicated that the following sequences provide enhanced stability and/or affinity, for the VL FR1 domain, ELVLTQTPPSLSASVGETVRIRC (SEQ ID NO:150) or ELVLTQTPSSVSAAVGGTVTINC (SEQ ID NO:155); for the VL FR2 domain, WYQQKPEKPPTLLIS (SEQ ID NO:174) or WYQQKPGQRPKLLIY(SEQ ID NO:181); for the VL FR3 domain, GVPPRFSGSGSGTDYTLTIGGVQAEDVATYYC (SEQ ID NO:183) or GVSSRFKGSGSGTQFTLTISGVQCADAATYYC (SEQ ID NO:205); and for the VL FR4 domain, FGAGTNVEIK (SEQ ID NO:206) or FAFGGGTELEIL (SEQ ID NO:210).

Additional point mutation studies indicated that the presence of a phenylalanine at position 39 (within the FR2 domain) and/or the presence of a lysine at position 42 (within the FR2 domain) and/or the presence of a cysteine at position 91 (the final FR3 residue) conferred enhanced stability and/or affinity to the $V_{L}$ domain. Amino acid positions are according to the positions within the sequence alignments presented in FIG. 4.

Table 7. Amino Acid Sequences of $\mathrm{V}_{\mathrm{L}}$ FR1 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 1-23 |
| :--- | :--- |
| $\mathbf{1 5 0}$ | ELVLTQTPPSLSASVGETVRIRC |
| 151 | ELDMTQTPASVSEPVGGTVTIKC |
| 152 | ELVLTQTPSPVSAAVGGTVTIKC |
| 153 | ELDLTQTPASVSEPVGGTVTIKC |
| 154 | ELVLTQTPSSASEPVGGTATIKC |
| 155 | ELVLTQTPSSVSAAVGGTVTINC |
| 156 | ELDMTQTPASVSAAVGGTVTINC |
| 157 | ELDLTQTPASVEVAVGGTVTINC |
| 158 | ELDMTQTPSSVSAAVGGTVTINC |
| 159 | ELVMTQTPASVSAAVGGTVTINC |
| 160 | ELVMTQTPASVEAAVGDSVTINC |
| 161 | ELVLTQTPASVSEPVGGTVTIKC |
| 162 | ELVLTQTPSPVSAAVGGTVTISC |
| 163 | ELVMTQTESPVSAPVGGTVTIKC |
| 164 | ELVLTQTPSSKSVPVGETVTINC |
| 165 | ELDMTQTPSSKSVPVRGTVSISC |
| 166 | ELVLTQSPSSKSVPVGDTVTINC |
| 167 | ELDLTQTPPSLSASVGETVRIRC |
| 168 | ELDLTQTPASVEAAVGGTVTIKC |
| 169 | ELVMTQTPSPVSAAVGGTVTISC |
| 170 | ELVLTQTPSSKSVPVGDTVIINC |
| 171 | ELVLTQSPS-VSGAVGGTVIINC |
| 172 | ELVLTQTPSSVEAAVGGTVTIKC |
| 173 | ELVLTQTPASVEAAVGGTVTIKC |

Table 8. Amino Acid Sequences of $\mathbf{V}_{\mathrm{L}}$ FR2 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 38-52 |
| :--- | :--- |
| 174 | WYQQKPEKPPTLIIS |
| 175 | WYQQKPGQPPKILIY |
| 176 | WYQQKPGQPPKRLIY |
| 177 | WYQLKPGQPPKILIY |
| 178 | WYQQKPGQPPKPLIY |
| 179 | WFQQKPGQPPKLIIY |
| 180 | WYQQKPGKPPTLLIS |
| 181 | WYQQKPGQRPKLLIY |
| 182 | WYQQKAGKPPTLLIY |

Table 9. Amino Acid Sequences of $V_{L}$ FR3 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 60-91 |
| :--- | :--- |
| 183 | GVPPRFSGSGSGTDYTLTIGGVQAEDVATYYC |
| 184 | GVSSRFKGSGSGTEFTLTISGVQCDDAATYYC |
| 185 | GVSSRFKGSRSGTEYTLTISDIECADAATYYC |
| 186 | GVSSRFKGSGSGTEFTLTISDVQCDDAATYYC |
| 187 | GVPSRFKGSGSGTEFTLTISDLECADAATYYC |
| 188 | GVPSRFRGSGSGTEFTLTISGMKAEDAATYYC |
| 189 | GVSSRFKGSGSGTQFTLTISDLECDDAATYYC |
| 190 | GVPSRFKGSGSGTEYTLTISGVECDDAATYYC |
| 191 | GVPPRFSGSGAGTQFTLTISDLECDDAATYYC |
| 192 | GVPSRFKGSGSGAQFTLTISDIECDDAATYYC |
| 193 | GVPSRFKGSGSGTQFTLTISDLECDDAATYYC |
| 194 | GVPSRFKGSGSGTEFTLTISGVQCDDAATYFC |
| 195 | GVPSRFKGSGSGTQFTLTISDVVCDDAATYYC |
| 196 | GVPSRFKGSGSGTDFTLTISSVECDDAATYYC |
| 197 | GVPSRFSGSGSGTQFTLTISDLECDDAATYYC |
| 198 | GVPPRFSGSGSGADYTLTIGGVQAEDAATYYC |
| 199 | GVPSRFKGSGSGTQFTLTISDVQCDDAATYYC |
| 200 | GVSSRFKGSGSGTQFTLTINDLECDDAATYYC |
| 201 | GVPSRFKGSGSGTQFTLTISDVVCDDAATYGC |
| 202 | GVPSRFKGSGSGTQFTLTISGVQCDDAATYYC |
| 203 | GVPSRFSGSGSGTEFTLTINDLDCDDAATYYC |
| 204 | GVPSRFKGSGSGTQFTLTISDIECADAATYYC |
| 205 | GVSSRFKGSGSGTQFTITISGVQCADAATYYC |

Table 10. Amino Acid Sequences of $\mathbf{V}_{\mathbf{L}}$ FR4 domains selected by methods of the invention

| SEQ ID NO | ALIGNMENT POSITION 106-116B |
| :--- | :--- |
| 206 | F--GAGTNVEIK- |
| 207 | F--GGGTEVVVK- |
| 208 | F--GGGTELEIL- |
| 209 | F--GGGTQLTVTG |
| 210 | FAFGGGTELEIL- |

## THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for obtaining a DNA sequence encoding a rabbit $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain that immunospecifically binds to an antigen and that shows a desired stability, wherein said method is a first method comprising:
a) selecting from a phage expression library a set of DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to said antigen, said phage expression library prepared from DNA or cDNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains and that were obtained from a biological sample of a rabbit containing cells that express immunoglobulins; and
b) expressing said set of DNA sequences, or a subset thereof, in bacteria as a fusion protein with CAT, selecting bacteria that have chloramphenicol resistance by virtue of CAT expression, and obtaining DNA sequences encoding amino acid sequences corresponding to rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria,
whereby said bacterial resistance to chloramphenicol conferred by said CATfusion correlates with stability of said amino acid sequence fused to CAT and wherein said selection is at a chloramphenicol concentration sufficient to select for said desired stability;
or a second method comprising:
a) expressing sequences of DNA or cDNA that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains in bacteria as a fusion protein with CAT, wherein said DNA or cDNA sequences were obtained from a biological sample of a rabbit containing cells that express immunoglobulins;
b) selecting bacteria that have chloramphenicol resistance by virtue of CAT expression, and obtaining the set of DNA sequences encoding amino acid sequences corresponding to rabbit $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains from the selected bacteria,
whereby said bacterial resistance to chloramphenicol conferred by said CATfusion correlates with stability of said amino acid sequence fused to CAT and
wherein said selection is at a chloramphenicol concentration sufficient to select for said desired stability; and
c) selecting from a phage expression library DNA sequences that encode $\mathrm{V}_{\mathrm{H}}$ and/or $\mathrm{V}_{\mathrm{L}}$ domains that immunospecifically bind to said antigen, wherein said library is prepared from said set of DNA sequences, or subset thereof.
2. The method of claim 1, wherein said rabbit biological sample is from a rabbit that has been immunized with said antigen.
3. The method of claim 1 or 2 , wherein, in said first method, step a) is repeated one or more times or wherein, in said second method, step c) is repeated one or more times.
4. The method of any one of claims 1 to 3 , wherein said biological sample comprises plasma cells, lymphoid, bone marrow, or appendix tissue.
5. The method of claim 4, wherein said sample comprises lymphoid tissue and said lymphoid tissue is spleen tissue or lymph node tissue.
6. The method of any one of claims 1 to 5 , wherein said antigen is not immunogenic in mice or rats.
7. The method of any one of claims 1 to 6 , wherein said selection is at a chloramphenicol concentration of at least 1.8 mM ; said recombinant $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain has a protein Tm of at least $54^{\circ} \mathrm{C}$; and/or said recombinant $\mathrm{V}_{\mathrm{L}}$ or $\mathrm{V}_{\mathrm{H}}$ domain exhibits a Kd for said antigen of no greater than 50 nM .
8. The method of claim 7, wherein said recombinant $V_{L}$ or $V_{H}$ domain exhibits a Kd for said antigen of no greater than 50 nM .
9. A polypeptide that immunospecifically binds an antigen, wherein said polypeptide comprises one or both of a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain, and at least one of
(a) $\quad$ a $V_{H}$ FR1 domain having the amino acid sequence QEQLMETESGGGAEGGLVKPGASLTLTCTAS (SEQ ID NO: 57);
(b) $\quad$ a $V_{H}$ FR3 domain having the amino acid sequence YATWVNGRFTLSRDIDQSTGCLQLNSLTAADTATYYCAR (SEQ ID NO: 95);
(c) $\quad$ a $V_{L}$ FR1 domain having the amino acid sequence ELVLTQTPPSLSASVGETVRIRC (SEQ ID NO: 150);
(d) $\quad a V_{L}$ FR3 domain having the amino acid sequence GVSSRFKGSGSGTQFTLTISGVQCADAATYYC; (SEQ ID NO: 205); or
(e) $a V_{L}$ FR4 domain having the amino acid sequence FAFGGGTELEIL (SEQ ID NO:210).
10. The polypeptide of claim 9 further comprising at least one of
(f) $\quad \mathrm{a} \mathrm{V}_{\mathrm{H}} \mathrm{FR} 2$ domain having the amino acid sequence WVRQAPGKGLEWIG (SEQ ID NO: 69);
(g) $\quad a V_{H}$ FR4 domain having the amino acid sequence WGQGTLVTVSS (SEQ ID NO:139);
(h) $\quad a V_{L}$ FR1 domain having the amino acid sequence ELVLTQTPSSVSAAVGGTVTINC (SEQ ID NO: 155);
(i) $\mathrm{a} \mathrm{V}_{\mathrm{L}} \mathrm{FR} 2$ domain having the amino acid sequence WYQQKPEKPPTLLIS (SEQ ID NO: 174) or WYQQKPGQRPKLLIY (SEQ ID NO:181);
(j) $\quad a V_{L}$ FR3 domain having the amino acid sequence GVPPRFSGSGSGTDYTLTIGGVQAEDVATYYC (SEQ ID NO: 183); or
(k) $\quad a V_{L}$ FR4 domain having the amino acid sequence FGAGTNVEIK (SEQ ID NO:206).
11. The polypeptide of claim 9 or 10 , wherein said polypeptide further comprises at least one of
(a) in the $V_{H}$ FR2 domain, a phenylalanine at position 46;
(b) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glutamic acid at position 53;
(c) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an arginine at position 54;
(d) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glycine at position 56;
(e) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an alanine at position 58;
(f) in the $\mathrm{V}_{\mathrm{H}} \mathrm{CDR1}$ domain, a cysteine at position 44;
(g) in the $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a cysteine at position 59;
(h) in the $\mathrm{V}_{\mathrm{H}}$ FR4 domain, an arginine at position 126;
(i) in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a phenylalanine or a tyrosine at position 39;
(j) in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a lysine at position 45; or
(k) in the $\mathrm{V}_{\mathrm{L}}$ FR3 domain; a cysteine at position 91
wherein said positions are according to the positions of the $\mathrm{V}_{\mathrm{H}}$ domain or $\mathrm{V}_{\mathrm{L}}$ domain sequence alignments in FIGS. 3 and 4, respectively.
12. A polypeptide that immunospecifically binds an antigen, wherein said polypeptide comprises one or both of a rabbit $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain, and at least one of
(f) $\quad \mathrm{a} \mathrm{V}_{\mathrm{H}} \mathrm{FR} 2$ domain having the amino acid sequence WVRQAPGKGLEWIG (SEQ ID NO: 69);
(g) $\quad a V_{H}$ FR4 domain having the amino acid sequence WGQGTLVTVSS (SEQ ID NO:139);
(h) a $\mathrm{V}_{\mathrm{L}}$ FR1 domain having the amino acid sequence ELVLTQTPSSVSAAVGGTVTINC (SEQ ID NO: 155);
(i) $\quad a V_{L}$ FR2 domain having the amino acid sequence WYQQKPEKPPTLLIS (SEQ ID NO: 174) or WYQQKPGQRPKLLIY (SEQ ID NO:181);
(j) a $\mathrm{V}_{\mathrm{L}}$ FR3 domain having the amino acid sequence GVPPRFSGSGSGTDYTLTIGGVQAEDVATYYC (SEQ ID NO: 183); or
(k) $\quad a V_{L}$ FR4 domain having the amino acid sequence FGAGTNVEIK (SEQ ID NO:206); and
wherein said polypeptide further comprises at least one of
(a) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a phenylalanine at position 46;
(b) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, a glutamic acid at position 53;
(c) in the $\mathrm{V}_{\mathrm{H}}$ FR2 domain, an arginine at position 54;
(d) in the $V_{H}$ FR2 domain, a glycine at position 56;
(e) in the $V_{H}$ FR2 domain, an alanine at position 58;
(f) in the $\mathrm{V}_{\mathrm{H}}$ CDRI domain, a cysteine at position 44;
(g) in the $\mathrm{V}_{\mathrm{H}}$ CDR2 domain, a cysteine at position 59;
(h) in the $\mathrm{V}_{\mathrm{H}}$ FR4 domain, an arginine at position 126;
(i) in the $\mathrm{V}_{\mathrm{L}}$ FR2 domain, a phenylalanine or a tyrosine at position 39;
(j) in the $V_{L}$ FR2 domain, a lysine at position 45; or
(k) in the $\mathrm{V}_{\mathrm{L}}$ FR3 domain; a cysteine at position 91
wherein said positions are according to the positions of the $\mathrm{V}_{\mathrm{H}}$ domain or $\mathrm{V}_{\mathrm{L}}$ domain sequence alignments in FIGS. 3 and 4, respectively.
13. The polypeptide according to claim $9,10,11$, or 12 , wherein said polypeptide does not have one or more of a $\mathrm{CH}_{1}$ domain, $\mathrm{CH}_{2}$ domain, $\mathrm{CH}_{3}$ domain or CL domain; or does not have one of a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain; and/or
wherein a $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain of said polypeptide folds to form a soluble, non-aggregative polypeptide that allows selection at a chloramphenicol concentration of at least 1.8 mM when fused to CAT; and/or
wherein the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain has a protein Tm of at least $54^{\circ} \mathrm{C}$.
14. The polypeptide of claim 13 which does not comprise a rabbit $\mathrm{V}_{\mathrm{H}}$ domain, which does not comprise a $\mathrm{V}_{\mathrm{H}}$ domain of a species other than rabbit, which does not comprise a rabbit $\mathrm{V}_{\mathrm{L}}$ domain or which does not comprise a $\mathrm{V}_{\mathrm{L}}$ domain of a species other than rabbit.
15. The polypeptide of claim 13 or 14 which does not comprise a $\mathrm{CH}_{1}$ domain, which does not comprise a $\mathrm{CH}_{2}$ domain or which does not comprise a $\mathrm{CH}_{3}$ domain.
16. The polypeptide of claim 13, wherein said antigen is not immunogenic in mice or rats.
17. The polypeptide of any one of claims 13 to 16 , wherein said polypeptide is further conjugated to a therapeutic agent, an albumin-interacting peptide, a fibronectin interacting peptide, fibronectin, albumin, protein A , or protein G .
18. An antibody comprising the polypeptide according to claim $9,10,11$, or 12 or an antigen binding fragment thereof;
wherein a $V_{H}$ or $V_{L}$ domain of said polypeptide folds to form a soluble, non-aggregative polypeptide that allows selection at a chloramphenicol concentration of at least 1.8 mM when fused to CAT ; or wherein the $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain has a protein Tm of at least $54^{\circ} \mathrm{C}$.
19. The antibody or antigen binding fragment thereof of claim 18 , wherein said antibody is a single chain antibody, a single domain antibody, a minibody, a diabody, a bispecific antibody, or a nanobody; or wherein said fragment is a Fab, Fab', $\mathrm{F}\left(\mathrm{ab}^{\prime}\right) 2$ or Fv fragment.
20. The antibody or antigen binding fragment thereof of claim 18 , wherein said antibody or said antigen binding fragment does not comprise a $\mathrm{CH}_{1}$ domain.
21. A chimeric or humanized version of the antibody or antigen binding fragment thereof of any one of claims 18 to 20 .
22. The antibody or antigen binding fragment thereof of any one of claims 18 to 21 , wherein said antigen is not immunogenic in mice or rats.
23. The antibody or antigen binding fragment thereof of any one of claims 18 to 22 , wherein said antibody or antigen binding fragment is further conjugated to a therapeutic agent, an albumin-interacting peptide, a fibronectin interacting peptide, fibronectin, albumin, protein $A$, or protein $G$.
24. A fusion polypeptide comprising CAT fused to a rabbit $V_{H}$ or $V_{L}$ domain, said $V_{H}$ or $V_{L}$ domain comprising the polypeptide according to claim $9,10,11$, or 12 .
25. The fusion polypeptide according to claim 24 , wherein said $V_{H}$ or $V_{L}$ domain folds to form a soluble, non-aggregative polypeptide that allows selection at a chloramphenicol concentration of at least 1.8 mM when fused to the CAT; and/or wherein said $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain has a protein Tm of at least $54^{\circ} \mathrm{C}$; and/or wherein said $\mathrm{V}_{\mathrm{H}}$ or $\mathrm{V}_{\mathrm{L}}$ domain exhibits a Kd for said antigen of no greater than 50 nM .
26. The fusion polypeptide according to claim 24 , wherein said polypeptide lacks one or more of a $\mathrm{CH}_{1}$ domain, a $\mathrm{CH}_{2}$ domain, a $\mathrm{CH}_{3}$ domain, or a CL domain, or lacks one of a $\mathrm{V}_{\mathrm{H}}$ domain or a $\mathrm{V}_{\mathrm{L}}$ domain.
27. A fusion polypeptide comprising CAT fused to the antibody or antigen binding fragment thereof according to any one of claims 18 to 23.
28. A fusion polypeptide comprising CAT fused to the polypeptide according to any one of claims 13 to 17.
29. A polynucleotide encoding a fusion polypeptide according to any one of claims 24 to 28 .
30. An expression vector comprising the polynucleotide according to claim 29.
31. A host cell comprising the expression vector according to claim 30 .
32. The host cell according to claim 31 , wherein said cell is a bacterial cell.
33. A method according to claim 1, substantially as hereinbefore described.
34. A polypeptide according to claim 9 or 12 , substantially as hereinbefore described.
35. An antibody according to claim 18, substantially as hereinbefore described.
```
                    sequence listing12988714
                    SEQUENCE LISTING
<110> TechnoPhage, Investigacao e Desenvolvimento em
        Biotecnologica SA
<120> Engineered Rabbit Antibody Variable Domains and Uses Thereof
<130> 14116-105002
<150> US 60/916,226
<151> 2007-05-04
<160> 210
<170> PatentIn version 3.5
<210> 1
<211> 120
<212> PRT
<213> Oryctolagus
<400> 1
Gln Gln Gln Leu Val Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu
Thr Leu Thr Ile Thr Cys Thr val Ser Gly Ile Asp Leu Ser Ser Asn
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile
    35 40 45
Gly Thr Ile Ser Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys
G7y Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile
65 70 75 80
Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ala
Leu Tyr Ala Gly Ser Thr Thr Gly Ser Pro Phe Asn Leu Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser
    115
                                    120
<210> 2
<211> 120
<212> PRT
<213> Oryctolagus
<400> 2
Gln Ser val Glu Glu Ser Arg Gly Arg Leu Val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Asn Ser Gly Tyr
    20 25 30
                                    Page 1
```

sequence 1 isting12988714

Met Glu $\underset{35}{\text { Thr }}$ Ile $\operatorname{Trp}$ Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr
 Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala
 G7y Thr Leu Val Thr Val Ser Ser
115
<210> 3
<211> 126
<212> PRT
<213> Oryctolagus
<400> 3
Gln Glu Gln Leu Met Glu Thr Glu Ser Gly Gly Gly Ala Glu Gly Gly
Leu Val Lys Pro Gly Gly Ser Leu Glu Leu Cys Cys Lys Ala Ser Gly
202530
Phe Ser $\underset{35}{\text { Leu Ser Ile Asn Tyr }} \underset{40}{\operatorname{Trp}}$ Ile Cys $\operatorname{Trp}$ Val $\underset{45}{\text { Arg Gln Ala }}$ Pro
Gly Lys Gly Leu Glu $\underset{50}{\operatorname{Trp}} \underset{55}{\text { Ile Gly }} \underset{5}{ }$


Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Lys Glu Tyr Val Tyr Ser Thr
100
Tyr Asn Phe
115 $\quad$ Trp Gly Gln Gly $\begin{array}{r}\text { Thr } \\ 120\end{array}$
<210> 4
<211> 124
<212> PRT

sequence listing12988714
105110

Trp Gly

115 Gly Thr Leu Val $\begin{aligned} & \text { Thr val Ser Ser } \\ & 120\end{aligned}$

```
<210> 6
<211> 107
<212> PRT
<213> Oryctolagus
<400> 6
```

Glu Leu Val Leu Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly
Glu Thr Val Arg Ile Arg Cys Leu Ala Ser Glu Asp Ile Tyr Ser Gly
Ile Ser $\operatorname{Trp}_{35}$ Tyr Gln Gln Lys Pro Glu Lys Pro Pro $\underset{40}{45}$ Leu Leu Ile
Ser Gly Ala Ser Asn Leu Glu Ala Gly Val Pro Pro Arg Phe Ser Gly
50


Asp Phe Gly Ala G7y Thr Asn Val G7u Ile Lys
100
<210> 7
<211> 114
<212> PRT
<213> Oryctolagus
<400> 7
Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Lys Ser Val Pro Val Gly
Asp Thr Val $\underset{20}{\text { Thr }}$ Ile Asn Cys Gln Ala Ser Glu Ser Val Ala Gly Gly
Asn Arg $\underset{35}{\text { Leu Ser }} \operatorname{Trp}$ Tyr Gln Gln Lys Pro Gly Gln $\underset{40}{45}$ Pro $\begin{gathered}\text { Lys Leu }\end{gathered}$
Leu $\underset{50}{\text { Ile }}$ Tyr Arg Ala Ser Asn Leu Ala Ser Gly $\underset{55}{\text { Val }} \underset{60}{ }$ Pro Ser Arg Phe
Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr $\underset{70}{\text { Leu }} \begin{aligned} & 75\end{aligned}$ Thr Ile Ser Asp Leu
${ }_{60}$
sequence listing12988714
Glu Cys Asp Asp Ala Ala Thr Tyr Tyr $\underset{85}{\text { Cys }} \underset{90}{ } \mathrm{Gln}$ Gly Gly Tyr $\underset{95}{\text { Asp }}$ Cys Ser Ser Ala Asp Cys Ser Ala Phe Gly Gly Gly Thr Gln Leu Thr Val $\begin{array}{r}105 \\ 100\end{array}$ Thr G7y

```
<210> 8
<211> 109
<212> PRT
<213> Oryctolagus
<400> 8
```

Glu Leu Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly
Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val $\begin{gathered}\text { Tyr Asn Asn } \\ 20\end{gathered}$

Leu Ile Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val $\underset{50}{ } \underset{50}{ } \quad$ Pro Ser Arg Phe
Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu
65

Val His Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu
100
<210> 9
<211> 109
<212> PRT
<213> oryctolagus
<400> 9
Glu Leu Val Leu
1 $\underset{5}{\text { Thr Gln Ser Pro Ser Val }} \underset{10}{ } \quad$ Ser Gly Ala Val Gly Gly
Thr val Ile $\underset{20}{\text { Ile }}$ Asn Cys Gln Thr Ser Glu ser Ile Ser $\underset{25}{\text { Asn }} \underset{30}{ }$ Trp Leu
Ala $\operatorname{Trp} \underset{35}{\operatorname{Ty}} \underset{40}{ } \mathrm{Gln} \mathrm{Gln}$ Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
Asp Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
Page 5

```
    5 0
                            5 5
                    sequence listing12988714
Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp
Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Ser Gly Ala Thr Asn
Asn Ala Phe Gly Gly Gly Thr Gln Leu Thr val Thr Gly
<210> 10
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 10
gggcccaggc ggcccagtcg gtggaggagt cctgg 35
<210> 11
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> synthetic primer
<400> 11
gggcccaggc ggcccagtcg gtgaaggagt ccgag 35
<210> 12
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> synthetic primer
<400> 12
gggcccaggc ggcccagtcg ytggaggagt ccggg
<210> 13
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 13
gggcccaggc ggcccagsag cagctgrtgg agtccgg
```

<210> 14

```
<210> 14
<211> 38
<211> 38
<212> DNA
<212> DNA
<213> Artificial Sequence
```

<213> Artificial Sequence

```

\section*{sequence listing12988714}
```

<220>
<223> Synthetic primer
<400> 14
gggcccaggc ggccgagctc gtgmtgaccc agactcca
<210> 15
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 15
gggcccaggc ggccgagctc gatmtgaccc agactcca 38
<210> 16
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 16
gggcccaggc ggccgagctc gtgatgaccc agactgaa 38
<210> 17
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 17
gggcccaggc ggccgagctc gtgctgactc agtcgccctc 40
<210> 18
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<223> synthetic primer
<400> 18
cctggccggc ctggccacta gtgactgayg gagccttagg ttgccc 46
<210> 19
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> synthetic primer
<400> 19
cctggccggc ctggcctttg atttccacat tggtgcc 37
<210> 20
sequence listing12988714

```
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 20
cctggccggc ctggcctagg atctccagct cggtccc
<210> 21
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 21
cctggccggc ctggcctttg acsaccacct cggtccc 37
<210> 22
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 22
cctggccggc ctggccgcct gtgacggtca gctgggtccc
<210> 23
<211> 25
<212> PRT
<213> Oryctolagus
<400> 23
Gln Gln Gln Leu Val Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu
Thr Leu Thr Ile Thr Cys Thr val Ser
<210> 24
<211> 24
<212> PRT
<213> Oryctolagus
<400> 24
G7n Ser val Glu Glu Ser Gly Gly Gly Leu Val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr val Ser
<210> 25
<211> 24
<212> PRT
```

```
                                    sequence listing12988714
<213> oryctolagus
<400> 25
Gln Ser Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
Leu Lys Val Ser Cys Lys Ala Ser
                                    20
<210> 26
<211> 24
<212> PRT
<213> Oryctolagus
<400> 26
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr Val Ser
<210> 27
<211> 25
<212> PRT
<213> oryctolagus
<400> 27
Gln Gln Gln Leu Met Lys Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Thr Leu Ser Cys Lys Ala Ser
<210> 28
<211> 24
<212> PRT
<213> oryctolagus
<400> 28
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly Ser
Leu Thr Pro Thr Cys Thr val Ser
<210> 29
<211> 24
<212> PRT
<213> Oryctolagus
<400> 29
Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu Thr
                                    Page 9
```

```
                                    sequence listing12988714
Leu Thr Leu Thr Cys Thr Val Ser
                                    20
<210> 30
<211> 24
<212> PRT
<213> Oryctolagus
<400> 30
Gln Ser val Glu Glu Ser Arg Gly Arg Leu val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr val Ser
<210> 31
<211> 25
<212> PRT
<213> Oryctolagus
<400> 31
Gln Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Lys Leu Ser Cys Lys Ala Ser
<210> 32
<211> 25
<212> PRT
<213> Oryctolagus
<400> 32
Gln Gln Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Lys Leu Ser Cys Lys Ala Ser
                        20 25
<210> 33
<211> 24
<212> PRT
<213> Oryctolagus
<400> 33
Gln Ser Met Lys Glu Ser Glu Gly Arg Leu val Thr Pro Gly Gly Ser
Leu Thr Leu Thr Cys Thr val Ser
<210> 34
<211> 24
<212> PRT
<213> oryctolagus
sequence 1 isting12988714
<400> 34

Leu Thr Leu Thr Cys Thr Val Ser
```

<210> 35
<211> 24
<212> PRT
<213> Oryctolagus
<400> 35

```
Gln Ser Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly ser
Leu Lys val Ser Cys Lys Ala Pro
\(\begin{array}{ll}<210> & 36 \\ <211> & 24\end{array}\)
<211> 24
<213> Oryctolagus
<400> 36
G7n Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly Ser
Leu Thr Leu Thr Cys Thr Val Ser
<210> 37
<211> 24
<212> PRT
<213> Oryctolagus
<400> 37
Gln Ser Val Glu Glu Ser Gly Gly
1
Leu Thr Leu Thr Cys Thr val Ser
<210> 38
<211> 25
<212> PRT
<213> Oryctolagus
<400> 38
\(\begin{array}{ll}\text { Gln Glu Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly } \\ 1 & \\ 10\end{array}\)
Ser Leu Thr Leu Ser Cys Lys Ala Ser
sequence listing12988714
25
```

<210> }3
<211> 24
<212> PRT
<213> Oryctolagus
<400> 39
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 40
<211> 25
<212> PRT
<213> Oryctolagus
<400> 40
Gln Gln Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Thr Leu Ser Cys Lys Ala Ser
20 25
<210> 41
<211> 24
<212> PRT
<213> Oryctolagus
<400> 41
Gln Ser val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr val Ser
<210> 42
<211> 24
<212> PRT
<213> Oryctolagus
<400> 42
Gln Ser val Glu Glu Ser Arg Gly Gly Leu val Gln Pro Gly Gly Ser
Leu Lys Val Ser Cys Lys Ala Ser
<210> 43
<211> 24
<212> PRT
<213> Oryctolagus

```
```

                                    sequence listing12988714
    <400> 43
Gln Ser Val Glu Glu Ser Arg Gly Gly Leu Phe Lys Pro Thr Asp Thr
1
Leu Thr Leu Thr Cys Thr val Ser
<210> 44
<211> 24
<212> PRT
<213> Oryctolagus
<400> 44
Gln Ser val Glu Glu Ser Gly Gly Arg Leu Ile Ser Pro Gly Gly Ser
Leu Thr Leu Thr Cys Thr Val Ser
<210> 45
<211> 24
<212> PRT
<213> oryctolagus
<400> 45
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu Thr
Leu Thr Leu Thr Cys Thr val Ser
<210> 46
<211> 24
<212> PRT
<213> Oryctolagus
<400> 46
Gln Ser Val Glu Glu Ser Arg Gly Arg Leu Val Thr Pro Gly Thr Pro
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 47
<211> 24
<212> PRT
<213> Oryctolagus
<400> 47
Gln Ser val Glu Glu Ser Arg Gly Arg Leu Val Lys Pro Asp Glu Thr
Leu Thr Leu Thr Cys Thr Val Ser
20

```
sequence listing12988714
```

```
<210> 48
<211> 24
<212> PRT
<213> Oryctolagus
<400> 48
Gln Ser val Glu Glu Ser Arg Gly Asp Leu val Lys Pro Glu Gly Ser
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 49
<211> 24
<212> PRT
<213> Oryctolagus
<400> 49
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
1
Leu Thr Leu Thr Cys Thr Ile Ser
<210> 50
<211> 24
<212> PRT
<213> Oryctolagus
<400> 50
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu val Thr Leu Gly Thr Pro
Leu Thr Leu Thr Cys Thr val Ser
<210> 51
<211> 24
<212> PRT
<213> Oryctolagus
<400> 51
Gln Ser Leu Glu Glu Ser Trp Gly Arg Leu Val Lys Pro Asp Glu Thr
Leu Thr Ile Thr Cys Thr val Ser
<210> 52
<211> 24
<212> PRT
<213> Oryctolagus
<400> 52
sequence listing12988714
```

Gln Ser val Glu Glu Ser Gly Gly Gly Leu val Gln Pro Gly Gly Ser
Leu Lys Leu Ser Cys Lys Ala Ser
<210> 53
<211> 25
<212> PRT
<213> Oryctolagus
<400> 53
Gln Glu Gln Leu val Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
Ser Leu Thr Leu Thr Cys Lys Ala Ser
20 25
<210> 54
<211> }2
<212> PRT
<213> oryctolagus
<400> 54
Gln Ser val Glu Glu Ser Gly Gly Asn Leu Val Thr Pro Gly Thr Prom
Leu Thr Leu Thr Cys Thr val Ser
20
<210> 55
<211> 25
<212> PRT
<213> Oryctolagus
<400> 55
Gln Gln Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Lys Leu Ser Cys Lys Ala Ser
<210> 56
<211> 31
<212> PRT
<213> Oryctolagus
<400> 56
Gln Glu Gln Leu Met Glu Thr Glu Ser Gly Gly Gly Ala Glu Gly Gly
Leu Val Lys Pro Gly Gly Ser Leu Glu Leu Cys Cys Lys Ala Ser
sequence listing12988714

```
<210> 57
<211> 31
<212> PRT
<213> Oryctolagus
<400> 57
Gln Glu Gln Leu Met Glu Thr Glu Ser Gly Gly Gly Ala Glu Gly Gly
Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser
<210> 58
<211> }2
<212> PRT
<213> Oryctolagus
<400> 58
Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu val Thr Pro Gly Thr Thr Pro
Leu Thr Leu Thr Cys Thr val Ser
<210> 59
<211> 24
<212> PRT
<213> Oryctolagus
<400> 59
Gln Ser val Glu Glu Ser Arg Gly Asp Leu Val Lys Pro Gly Ala Ser
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 60
<211> 24
<212> PRT
<213> Oryctolagus
<400> 60
Gln Ser val Glu Glu Ser Gly Gly Arg Leu Ile Thr Pro Gly Gly Ser
Leu Thr Leu Thr Cys Thr val Ser
<210> 61
<211> 24
<212> PRT
<213> Oryctolagus
<400> 61
```

```
        sequence listing12988714
Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
Leu Thr Leu Thr Cys Thr Ala Ser
    20
<210> 62
<211> 24
<212> PRT
<213> Oryctolagus
<400> 62
Gln Ser val Glu Glu Ser Arg Gly Arg Leu Val Thr Pro Gly Thr Prom
Leu Thr Leu Thr Cys Thr val Ser
<210> 63
<211> 27
<212> PRT
<213> Oryctolagus
<400> 63
Gln Glu Gln Leu Met Glu Thr Glu Ser Gly Gly Gly Leu Val Lys Pro
Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser
<210> 64
<211> 24
<212> PRT
<213> Oryctolagus
<400> 64
Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Ala Ser
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 65
<211> 25
<212> PRT
<213> Oryctolagus
<400> 65
Gln Gln Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly
Ser Leu Thr Leu Thr Cys Thr Ala Ser
                        20 25
```

sequence 7 isting12988714

```
<210> 66
<211> 24
<212> PRT
<213> Oryctolagus
<400> 66
Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly Ser
Leu Thr Leu Thr Cys Thr Ala Ser
<210> 67
<211> 14
<212> PRT
<213> Oryctolagus
<400> 67
T
<210> 68
<211> }1
<212> PRT
<213> Oryctolagus
<400> 68
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Tyr Ile Gly
<210> 69
<211> 14
<212> PRT
<213> Oryctolagus
<400> 69
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
<210> 70
<211> }1
<212> PRT
<213> Oryctolagus
<400> 70
Trp val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Ile Gly
<210> 71
<211> 14
<212> PRT
<213> Oryctolagus
<400> 71
Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Asp Trp Ile Gly
1 5 10
                                    Page 18
```

```
sequence listing12988714
```

```
<210> }7
<211> 14
<212> PRT
<213> Oryctolagus
<400> 72
Trp val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly
<210> 73
<211> 14
<212> PRT
<213> Oryctolagus
<400> 73
T
<210> 74
<211> }1
<212> PRT
<213> Oryctolagus
<400> 74
Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Ile Gly
<210> 75
<211> 14
<212> PRT
<213> Oryctolagus
<400> 75
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
<210> 76
<211> }1
<212> PRT
<213> Oryctolagus
<400> 76
Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Ile Gly
<210> 77
<211> }1
<212> PRT
<213> Oryctolagus
<400> 77
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
1
                    5
                        10
```

```
sequence listing12988714
```

```
<210> 78
<211> 14
<212> PRT
<213> Oryctolagus
<400> 78
Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
```

<210> 79
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 79
$\underset{1}{\text { Trp }}$ Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu $\underset{10}{ }$ Trp Ile Gly
<210> 80
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 80
Trp Phe Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Ile Gly
<210> 81
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 81
$\underset{1}{\text { Trp }}$ Phe Arg Gln Ala Pro Gly Lys Gly $\underset{10}{\operatorname{Arg}}$ Glu $\operatorname{Trp}$ Ile Gly
<210> 82
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 82
$\underset{1}{\operatorname{Trp}}$ Phe $\mathrm{Arg} \mathrm{Gln} \underset{5}{\text { Ala }}$ Pro Gly Lys Gly $\underset{10}{\text { Leu Glu Gly Ile Gly }}$
<210> 83

```
sequence listing12988714
```

```
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 83
Trp val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Ile Gly
```

<210> 84
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 84
Trp Val Arg Gln Ala Pro Gly Lys Glu Arg Glu Trp Ile Gly
<210> 85
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 85
Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Gly Ile Gly
1
<210> 86
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 86
$\underset{1}{\text { Trp Val }}$ Arg Gln $\underset{5}{\text { Ala }}$ Pro Gly Lys Gly $\underset{10}{\text { Arg Glu }}$ Trp Ile Gly
<210> 87
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 87
$\underset{1}{\operatorname{Tr} p}$ Val $A r g$ Gln $\underset{5}{\text { Ala }}$ Pro Gly Lys Gly $\underset{10}{\operatorname{Arg}} \mathrm{Glu}$ Gly Ile Gly

```
sequence listing12988714
```

```
<210> }8
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 88
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gly Ile Gly
<210> }8
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 89
Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Trp Ile Gly
1
<210> 90
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 90
Trp Phe Arg Gln Ala Pro Gly Lys Glu Leu Glu Gly Ile Gly
1 5 10
<210> 91
<211> }1
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 91
Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Gly Ile Gly
<210> 92
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> oryctolagus
<400> 92
Trp Val Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Ile Gly
                                    Page 22
```

```
sequence 1isting12988714
```

<210> 93
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Oryctolagus
<400> 93
${\underset{1}{1}}_{\operatorname{Tr} p}$ Phe Arg Gln $\underset{5}{\text { Ala }}$ Pro Gly Lys Glu $\underset{10}{\text { Arg Glu Gly }}$ Ile Gly
<210> 94
<211> 38
<212> PRT
<213> Oryctolagus
<400> 94

Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp
20 $\underset{30}{ } \quad$ Thr Ala
Thr Tyr Phe Cys Ala Arg
<210> 95
<211> 39
<212> PRT
<213> Oryctolagus
<400> 95
Tyr Ala Thr Trp Val Asn Gly Arg Phe Thr Leu Ser Arg Asp Ile Asp
Gln Ser Thr Gly Cys Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr
2520
Ala Thr ${ }_{35}^{7 y r}$ Tyr Cys Ala Arg
<210> 96
<211> 39
<212> PRT
<213> Oryctolagus
<400> 96

Thr Val Asn Leu Gln Met Glu Thr Thr Ser Leu Thr Thr Glu Asp Thr
20
25
Page 23

```
sequence listing12988714
```

```
Ala Thr Phe Phe Cys Ala Arg
<210> 97
<211> 40
<212> PRT
<213> Oryctolagus
<400> 97
Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser
Thr Thr Val Thr Leu Gln Met Glu Thr Thr Ser Leu Thr Ala Ala Asp
                        20 25 30
Thr Ala Thr Tyr Phe Cys Ala Arg
<210> 98
<211> }3
<212> PRT
<213> Oryctolagus
<400> 98
Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
Thr val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Ser
<210> 99
<211>40
<212> PRT
<213> Oryctolagus
<400> 99
Tyr Ala Ser Trp Ala Glu Gly Arg Phe Ser Ile Ser Lys Ala Ser Ser
Thr Thr Val Thr Leu Gln Met Glu Thr Thr Ser Leu Thr Ala Ala Asp
Thr Ala Thr Tyr Phe Cys Ala Arg
<210> 100
<211> }3
<212> PRT
<213> Oryctolagus
```

```
sequence listing12988714
<400> 100
Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
Thr val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
20
                        25
                            30
Tyr Phe Cys val Arg
<210> 101
<211> 40
<212> PRT
<213> Oryctolagus
<400> 101
Tyr Ala Ser Trp Pro Gln Gly Arg Phe Thr Ile Ser val Thr Ser Ser
Thr Thr val Thr Leu Gln Met Glu Thr Thr Ser Leu Thr Ala Ala Asp
Thr Ala Thr Tyr Phe Cys Ala Lys
<210> 102
<211> }3
<212> PRT
<213> oryctolagus
<400> 102
Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Gln Thr Ser Thr
Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Arg
<210> 103
<211> 40
<212> PRT
<213> Oryctolagus
<400> 103
Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Pro Ser Ser
Thr Thr val Thr Leu Gln Met Glu Thr Thr Ser Leu Thr Ala Ala Asp
```

Thr Ala Thr Tyr Phe Cys Ala Arg
sequence listing12988714

```
<210> }10
<211> 40
<212> PRT
<213> Oryctolagus
<400> 104
```


Thr Thr Val Thr Leu Gln Met Glu Thr Thr Ser Leu Thr Ala Ala Asp
Thr Ala Thr Tyr Phe Cys Ala Arg
<210> 105
<211> 37
<212> PRT
<213> Oryctolagus
<400> 105
Tyr Ala Ser $\operatorname{Trp} \underset{5}{\text { Ala }}$ Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
10
Thr Val Asp Leu Lys Ile Thr Ser $\underset{20}{\text { Pro }} \underset{25}{ }$ Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Arg
<210> 106
<211> 37
<212> PRT
<213> oryctolagus
<400> 106
Tyr Pro Ser Trp Val Asp Gly Arg Phe Thr
1
Thr val Asp Leu Lys Ile Thr Ser $\underset{20}{\operatorname{~Pro}} \underset{25}{ }$ Thr Thr Glu Asp Thr Ala Thr
Tyr Phe cys Ala Arg
<210> 107
<211> 39
<212> PRT
<213> Oryctolagus
<400> 107

Tyr Ala Asp Trp Val Thr Gly Arg Phe Thr Ile Ser Ser His Asn Ala Page 26

sequence 1 isting12988714

```
<210> }11
<211> 37
<212> PRT
<213> Oryctolagus
<400> }11
```



Tyr Phe cys Ala Arg
<210> 112
<211> 37
<212> PRT
<213> Oryctolagus
<400> 112

Thr Met Asp Leu Lys Ile Thr Ser $\underset{20}{\operatorname{pro}}$ Thr Thr Glu Asp $\underset{30}{\text { Thr Ala }}$ Thr
Tyr Phe cys Gly Arg
<210> 113
<211> 39
<212> PRT
<213> oryctolagus
<400> 113
Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Arg Asn Ala
G7n Asn Thr Leu Tyr Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr
2025
30
Ala Thr ${ }_{35}{ }_{35}$ Phe cys Ala Arg
<210> 114
<211> 39
<212> PRT
<213> Oryctolagus
<400> 114
Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala

```
                                    sequence listing12988714
Gln Asn Thr Val Asp Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr
                                    20 25
Ala Thr \(\underset{35}{\text { Tyr }}\) Phe Cys A7a Arg
<210> 115
<211> }3
<212> PRT
<213> Oryctolagus
<400> 115
Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ser Ser Lys Thr Ser Thr
Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Arg
<210> 116
<211> }3
<212> PRT
<213> Oryctolagus
<400> 116
Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
Thr val Asp Leu Glu Ile Ala Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys val Arg
<210> 117
<211> 38
<212> PRT
<213> Oryctolagus
<400> 117
Tyr Ala Ser Trp Ala Glu Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser
Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala
Thr Tyr Phe Cys Ala Arg
<210> 118
<211> 37
<212> PRT
```

```
                                    sequence listing12988714
<213> oryctolagus
<400> 118
Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr
Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Arg
<210> }11
<211> 38
<212> PRT
<213> Oryctolagus
<400> 119
Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser
Thr Thr Val Asp Leu Glu Met Thr Ser Leu Thr Thr Glu Asp Thr Ala
                                    20 25
                                    30
Thr Tyr Phe Cys Ala Arg
<210> 120
<211> }3
<212> PRT
<213> Oryctolagus
<400> 120
Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser
Thr Thr val Glu Leu Lys Met Thr Gly Leu Thr Thr Glu Asp Thr Ala
Thr Tyr Phe Cys Ala Arg
            35
<210> 121
<211> }3
<212> PRT
<213> Oryctolagus
<400> 121
Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Ser His Asn Ala
Gln Asn Thr Leu Tyr Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr
sequence listing12988714
```

Ala Thr Tyr Phe Cys Ala Arg
<210> 122
<211> 37
<212> PRT
<213> Oryctolagus
<400> 122
Tyr Ala Asn Trp Ala Arg Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr
Thr Val Asp Leu Glu Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe cys Gly Arg
<210> 123
<211> }3
<212> PRT
<213> oryctolagus
<400> 123
Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr
Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr
20
25
30
Tyr Phe cys Ile Arg
<210> 124
<211> }3
<212> PRT
<213> Oryctolagus
<400> 124
Tyr Ala Arg Trp Ala Lys Asp Arg val Thr Ile Ser Lys Thr Ser Thr
Thr val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr
Tyr Phe Cys Ala Arg
<210> 125
<211> 37
<212> PRT
<213> Oryctolagus
<400> 125
sequence listing12988714
Tyr Ala Asn $\operatorname{Trp} \underset{5}{\text { Ala }}$ Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
10 Thr val Asp $\underset{20}{\text { Leu Glu Ile Ile Ser }} \underset{25}{\underset{25}{\text { Pro }}}$ Thr Lys Glu Asp $\underset{30}{\text { Thr Ala }}$ Thr Tyr Phe Cys Ala Thr
$\begin{array}{ll}<210> & 126 \\ <211> & 37\end{array}$
<212> PRT
<213> Oryctolagus
<400> 126



Tyr Phe cys val Arg
<210> 127
<211> 37
<212> PRT
<213> Oryctolagus
<400> 127



Tyr Phe Cys Ala Arg
<210> 128
<211> 37
<212> PRT
<213> oryctolagus
<400> 128



Tyr Phe cys Ala ser

```
sequence listing12988714
```

```
<210> 129
<211> }3
<212> PRT
<213> Oryctolagus
<400> 129
```



Tyr Phe cys Ala Arg
<210> 130
<211> 37
<212> PRT
<213> Oryctolagus
<400> 130


Tyr Phe cys Ala Arg
<210> 131
<211> 37
<212> PRT
<213> oryctolagus
<400> 131


Tyr Phe Cys Ala Arg
<210> 132
<211> 38
<212> PRT
<213> Oryctolagus
<400> 132
Tyr Ala Thr $\operatorname{Trp}$ Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser
1510 15
Page 33

```
sequence listing12988714
```

Thr Thr Val $\underset{20}{\text { Asp }}$ Leu Lys Met Thr $\underset{25}{\operatorname{Ser}}$ Leu Thr Thr Glu Asp Thr Ala
Thr Tyr $\underset{35}{\text { Phe Cys Thr Arg }}$
<210> 133
<211> 37
<212> PRT
<213> oryctolagus
<400> 133

Thr val Asp Leu Lys Met Thr Ser $\underset{20}{\operatorname{pro}} \underset{25}{ }$ Thr Thr Glu Asp $\underset{30}{\text { Thr Ala }}$ Thr
Tyr Phe cys ile Arg
<210> 134
<211> 37
<212> PRT
<213> oryctolagus
<400> 134


Tyr Phe Cys Ala Arg
<210> 135
<211> 37
<212> PRT
<213> oryctolagus
<400> 135

Thr Val Asp Leu Lys Met Thr Ser $\underset{20}{\operatorname{pro}}$ Thr Thr Glu Asp Met Ala $\underset{30}{ }$ Thr
Tyr Phe Cys Ala Arg
<210> 136

```
sequence listing12988714
```

```
<211> }3
<212> PRT
<213> Oryctolagus
<400> 136
Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr
Thr Val Asp Leu Lys Ile Thr Ser Pro Ile Thr Glu Asp Thr Ala Thr
Tyr Phe cys Ile Arg
<210> 137
<211> 39
<212> PRT
<213> Oryctolagus
<400> 137
Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala
Gln Asn Thr Val Asp Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Thr
    20 25 30
Ala Thr Tyr Phe Cys Ala Arg
<210> 138
<211> }3
<212> PRT
<213> Oryctolagus
<400> 138
Tyr Ala Asn Trp Val Asn Gly Arg Phe Thr Ile Ser Leu Asp Asn Ala
Gln Asn Thr val Phe Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr
```

Ala Thr ${ }_{35}^{\text {Tyr }}$ Phe Cys Ala Arg
<210> 139
<211> 11
<212> PRT
<213> oryctolagus
<400> 139
Trp Gly Gln Gly ${ }_{1}{ }_{5}^{\text {Thr }}$ Leu Val Thr Val Ser Ser
10
<210> 140

## sequence $1 i s t i n g 12988714$

```
<211> 11
<212> PRT
<213> Oryctolagus
```

<400> 140
Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
1050
<210> 141
<211> 11
<212> PRT
<213> oryctolagus
<400> 141
$\underset{1}{\operatorname{Trp}} \mathrm{Gly}$ G7n Gly $\underset{5}{\text { Ile }}$ Leu Val Thr Val Ser Ser
10
<210> 142
<211> 11
<212> PRT
<213> Oryctolagus
<400> 142
Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser
<210> 143
<211> 11
<212> PRT
<213> Oryctolagus
<400> 143
Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser
150
<210> 144
<211> 11
<212> PRT
<213> oryctolagus
<400> 144
Trp Gly Gln Gly
1 ${ }_{5}^{\text {Thr }}$ Leu Val Thr Ala Ser Ser
<210> 145
<211> 11
<212> PRT
<213> Oryctolagus
<400> 145
Trp Gly Pro Gly $\underset{5}{\text { Thr }}$ Leu Val Ala val Ser Ser
10
<210> 146
<211> 11
<212> PRT

```
<213> oryctolagus
<400> 146
Trp Gly Gln Gly Thr Arg Val Thr Val Ser Ser
1 5 10
<210> 147
<211> 11
<212> PRT
<213> Oryctolagus
<400> 147
Trp Gly Pro Gly Thr Leu Val Thr Gly Ser Ser
<210> 148
<211> 11
<212> PRT
<213> Oryctolagus
<400> 148
Trp Gly Gln Gly Ser Leu Val Thr Ile Ser Ser
<210> 149
<211> 11
<212> PRT
<213> oryctolagus
<400> 149
Arg Gly Gln Gly Ser Leu Val Thr Ile Ser Ser
1 5 10
<210> 150
<211> 23
<212> PRT
<213> Oryctolagus
<400> 150
G7u Leu Val Leu Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser val Gly
G7u Thr val Arg Ile Arg Cys
<210> 151
<211> 23
<212> PRT
<213> Oryctolagus
<400> 151
Glu Leu Asp Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro val Gly
Gly Thr Val Thr Ile Lys Cys
sequence 1 isting12988714
```

<210> 152
<211> 23
<212> PRT
<213> Oryctolagus
<400> 152
Glu Leu Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala val Gly
Gly Thr val Thr Ile Lys Cys
20
<210> 153
<211> 23
<212> PRT
<213> Oryctolagus
<400> 153
Glu Leu Asp Leu Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly
Gly Thr val Thr Ile Lys Cys
<210> 154
<211> 23
<212> PRT
<213> Oryctolagus
<400> 154
Glu Leu Val Leu Thr Gln Thr Pro Ser Ser Ala Ser Glu Pro Val Gly
Gly Thr Ala Thr Ile Lys Cys
<210> 155
<211> 23
<212> PRT
<213> Oryctolagus
<400> 155
G7u Leu Val Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Ala val Gly
Gly Thr val Thr Ile Asn Cys
<210> 156
<211> 23
<212> PRT
<213> Oryctolagus

```
```

sequence listing12988714
<400> 156
Glu Leu Asp Met Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly
Gly Thr val Thr Ile Asn Cys
<210> 157
<211> 23
<212> PRT
<213> Oryctolagus
<400> 157
Glu Leu Asp Leu Thr Gln Thr Pro Ala Ser val Glu Val Ala Val Gly
Gly Thr val Thr Ile Asn Cys
<210> 158
<211> 23
<212> PRT
<213> Oryctolagus
<400> 158
Glu Leu Asp Met Thr Gln Thr Pro Ser Ser val Ser Ala Ala val Gly
G7y Thr val Thr Ile Asn Cys
<210> 159
<211> 23
<212> PRT
<213> Oryctolagus
<400> 159
Glu Leu Val Met Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly
1 5 10
G7y Thr val Thr Ile Asn Cys
<210> 160
<211> 23
<212> PRT
<213> Oryctolagus
<400> 160
Glu Leu Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
Asp Ser val Thr Ile Asn Cys

```
sequence listing12988714
```

```
<210> 161
<211> 23
<212> PRT
<213> Oryctolagus
<400> 161
G7u Leu Val Leu Thr Gln Thr Pro Ala Ser val Ser Glu Pro val Gly
Gly Thr val Thr Ile Lys Cys
<210> 162
<211> 23
<212> PRT
<213> Oryctolagus
<400> 162
Glu Leu Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly
Gly Thr val Thr Ile Ser Cys
<210> 163
<211> 23
<212> PRT
<213> Oryctolagus
<400> 163
Glu Leu Val Met Thr Gln Thr Glu Ser Pro Val Ser Ala Pro Val Gly
1 5 10
Gly Thr val Thr Ile Lys Cys
<210> 164
<211> 23
<212> PRT
<213> Oryctolagus
<400> 164
Glu Leu Val Leu Thr Gln Thr Pro Ser Ser Lys Ser Val Pro val Gly
Glu Thr val Thr Ile Asn Cys
<210> 165
<211> 23
<212> PRT
<213> Oryctolagus
<400> 165
```

                                    sequence listing12988714
    Glu Leu Asp Met Thr Gln Thr Pro Ser Ser Lys Ser val Pro Val arg
Gly Thr Val Ser Ile Ser Cys
20
<210> 166
<211> 23
<212> PRT
<213> Oryctolagus
<400> 166
Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Lys Ser Val Pro Val Gly
1 5 10
Asp Thr Val Thr Ile Asn Cys
20
<210> 167
<211> 23
<212> PRT
<213> oryctolagus
<400> 167
Glu Leu Asp Leu Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Val Gly
G7u Thr val Arg Ile Arg Cys
<210> 168
<211> 23
<212> PRT
<213> Oryctolagus
<400> 168
G7u Leu Asp Leu Thr Gln Thr Pro Ala Ser val Glu Ala Ala val Gly
G7y Thr val Thr Ile Lys Cys
<210> 169
<211> 23
<212> PRT
<213> Oryctolagus
<400> 169
G7u Leu Val Met Thr Gln Thr Pro Ser Pro val Ser Ala Ala Val Gly
Gly Thr val Thr Ile Ser Cys

```
sequence listing12988714
```

<210> 170
<211> 23
<212> PRT
<213> Oryctolagus
<400> }17
Glu Leu Val Leu Thr Gln Thr Pro Ser Ser Lys Ser Val Pro Val Gly
Asp Thr Val Ile Ile Asn Cys
<210> 171
<211> 22
<212> PRT
<213> oryctolagus
<400> 171
G7u Leu Val Leu Thr Gln Ser Pro Ser Val Ser Gly Ala Val Gly Gly
Thr val Ile
<210> 172
<211> 23
<212> PRT
<213> Oryctolagus
<400> 172
Glu Leu Val Leu Thr Gln Thr Pro Ser Ser Val Glu Ala Ala val Gly
Gly Thr val Thr Ile Lys Cys
<210> 173
<211> 23
<212> PRT
<213> Oryctolagus
<400> 173
Glu Leu Val Leu Thr Gln Thr Pro Ala Ser Val Glu Ala Ala val Gly
1 5 10
Gly Thr val Thr Ile Lys cys
<210> 174
<211> 15
<212> PRT
<213> Oryctolagus
<400> 174

```
```

                sequence listing12988714
    Trp Tyr Gln Gln Lys Pro Glu Lys Pro Pro Thr Leu Leu Ile Ser
1 5 10
<210> 175
<211> 15
<212> PRT
<213> Oryctolagus
<400> 175
Trp Tyr G7n G7n Lys Pro Gly G7n Pro Pro Lys Leu Leu Ile Tyr
<210> 176
<211> 15
<212> PRT
<213> oryctolagus
<400> 176
Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Arg Leu Ile Tyr
<210> 177
<211> 15
<212> PRT
<213> oryctolagus
<400> 177
Trp Tyr Gln Leu Lys Pro Gly G7n Pro Pro Lys Leu Leu Ile Tyr
<210> 178
<211> 15
<212> PRT
<213> Oryctolagus
<400> 178
Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Pro Leu Ile Tyr
<210> 179
<211> 15
<212> PRT
<213> Oryctolagus
<400> 179
Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
<210> 180
<211> 15
<212> PRT
<213> oryctolagus
<400> 180
Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Thr Leu Leu Ile Ser
1 5 10
Page 43

```
```

sequence listing12988714

```
```

<210> 181
<211> 15
<212> PRT
<213> Oryctolagus
<400> 181

```
\(\underset{1}{\operatorname{Trp}}\) Tyr G7n G7n Lys Pro Gly G7n Arg Pro Lys Leu Leu Ile Tyr \(\underset{10}{15}\)
<210> 182
<211> 15
<212> PRT
<213> oryctolagus
<400> 182
Trp Tyr Gln Gln Lys Ala Gly Lys Pro Pro Thr Leu Leu Ile Tyr
<210> 183
<211> 32
<212> PRT
<213> oryctolagus
<400> 183
Gly
1

<210> 184
<211> 32
<212> PRT
<213> Oryctolagus
<400> 184
Gly Val Ser Ser \(\underset{5}{\text { Arg }}\) She Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr
10
Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
20
<210> 185
<211> 32
<212> PRT
<213> Oryctolagus
<400> 185
\(\underset{1}{\text { Gly Val }}\) Ser Ser \(\underset{5}{\operatorname{Arg}}\) Phe Lys Gly Ser \(\underset{10}{\text { Arg Ser Gly }}\) Thr Glu Tyr Thr
Leu Thr Ile Ser Asp Leu Glu Cys Ala
20
sequence listing12988714
```

<210> 186
<211> 32
<212> PRT
<213> Oryctolagus
<400> 186
Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr
Leu Thr Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
<210> }18
<211> }3
<212> PRT
<213> Oryctolagus
<400> 187
Gly Val Pro Ser Ar Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr
Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys
<210> }18
<211> }3
<212> PRT
<213> Oryctolagus
<400> 188

```

```

Leu Thr Ile Ser Gly Met Lys Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
<210> 189
<211> 32
<212> PRT
<213> Oryctolagus
<400> 189

```

```

Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr cys
<210> 190
<211> }3
<212> PRT
<213> Oryctolagus
<400> 190

```
```

                sequence listing12988714
    Gly Val Pro Ser fr frg Phe Lys Gly Ser Gly Ser Gly Thr Glu Tyr Thr
Leu Thr Ile Ser Gly val Glu Cys Asp Asp Ala Ala Thr Tyr Tyr cys
<210> 191
<211> 32
<212> PRT
<213> Oryctolagus
<400> 191
Gly Val Pro Pro
Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
<210> }19
<211> 32
<212> PRT
<213> Oryctolagus
<400> 192

```

```

Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
<210> 193
<211> 32
<212> PRT
<213> Oryctolagus
<400> 193
Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr
Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
<210> }19
<211> }3
<212> PRT
<213> Oryctolagus
<400> 194

```


```

sequence listing12988714

```
```

<210> 195
<211> }3
<212> PRT
<213> Oryctolagus
<400> 195

```
\(\underset{1}{\text { Gly Val Pro Ser }} \underset{5}{\operatorname{Arg}}\) Phe Lys Gly Ser Gly Ser Gly Thr Gln \(\underset{10}{\text { Phe }}\) Thr
Leu Thr Ile Ser Asp Val Val Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
20
<210> 196
<211> 32
<212> PRT
<213> Oryctolagus
<400> 196
Gly Val Pro Ser
1 \(\underset{5}{\operatorname{Arg}}\) Phe Lys Gly Ser Gly Ser Gly Thr Asp \(\underset{10}{ }\) Phe Thr
Leu Thr Ile Ser Ser Val Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
20
<210> 197
<211> 32
<212> PRT
<213> Oryctolagus
<400> 197
Gly Val Pro Ser \(\underset{5}{\text { Arg }}\) Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr
Leu Thr Ile Ser Asp Leu Glu Cys \(\underset{20}{\operatorname{Asp}} \underset{25}{ }\) Asp Ala Ala Thr Tyr Tyr Cys
<210> 198
<211> 32
<212> PRT
<213> Oryctolagus
<400> 198

Leu Thr Ile Gly Gly Val Gln Ala Glu Asp Ala Ala Thr \(\underset{20}{ } \underset{30}{ } \quad\) Tyr
<210> 199
<211> 32
<212> PRT
<213> Oryctolagus
<400> 199
Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr
                                    Page 47
```

Leu Thr Ile Ser Asp Val Gln Cys \underset{20}{25}

```
```

<210> 200
<211> 32
<212> PRT
<213> Oryctolagus
<400> 200

```
Gly Val
1
Leu Thr Ile Asn Asp Leu Glu Cys \(\underset{20}{\operatorname{Asp}} \underset{25}{ }\) Asp Ala Ala Thr Tyr Tyr cys
<210> 201
<211> 32
<212> PRT
<213> oryctolagus
<400> 201
\(\underset{1}{\text { Gly }}\) Val Pro Ser \(\underset{5}{\operatorname{Arg}}\) Phe Lys Gly Ser Gly Ser Gly Thr Gln \(\underset{10}{\text { Phe }}\) Thr
Leu Thr Ile Ser Asp Val Val Cys Asp Asp Ala Ala Thr Tyr Gly Cys
    20
                                    25
<210> 202
<211> 32
<212> PRT
<213> Oryctolagus
<400> 202
Gly Val Pro Ser
1 \(\underset{5}{\operatorname{Arg}}\) Phe Lys Gly Ser Gly Ser Gly \(\underset{10}{ }\) Thr Gln \(\underset{15}{\text { Phe }}\) Thr
Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys
20
<210> 203
<211> 32
<212> PRT
<213> Oryctolagus
<400> 203
Gly Val Pro Ser
1 \(\underset{5}{\operatorname{Arg}}\) Phe Ser Gly Ser Gly Ser Gly \(\underset{10}{ }\) Thr Glu \({ }_{15}\) Phe Thr
Leu Thr Ile Asn Asp Leu Asp Cys \(\underset{20}{\operatorname{Asp}} \underset{25}{ }\) Asp Ala Ala Thr Tyr Tyr cys
<210> 204
```

sequence listing12988714

```
```

<211> }3
<212> PRT
<213> oryctolagus
<400> 204
Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr
1 5 10
Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys
<210> 205
<211> 32
<212> PRT
<213> Oryctolagus
<400> 205
Gly Val Ser Ser \underset{ f}{Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr}
Leu Thr Ile Ser Gly Val Gln Cys Ala Asp Ala Ala Thr Tyr Tyr Cys
<210> 206
<211> 10
<212> PRT
<213> Oryctolagus
<400> 206
Phe Gly Ala Gly Thr Asn val Glu Ile Lys
<210> 207
<211> 10
<212> PRT
<213> Oryctolagus
<400> 207
Phe Gly Gly Gly Thr Glu Val Val Val Lys
<210> 208
<211> 10
<212> PRT
<213> Oryctolagus
<400> 208
Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu
<210> 209
<211> 11
<212> PRT
<213> Oryctolagus
<400> 209
sequence listing12988714
Phe Gly Gly Gly $\underset{5}{\text { Thr Gln Leu Thr Val Thr Gly }}$ Th
${ }_{5}$
<210> 210
<211> 12
<212> PRT
<213> Oryctolagus
<400> 210
Phe Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu
150

